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5’/3’   5 / 3 prime 
Bcl2  b-cell lymphoma 2 
bFGF  basic fibroblast growth factor 
bp   base pairs 
C/EBP CCAAT/enhancer binding protein alpha  
CAM  chick choroallantoic membrane 
CD   cluster of differentiation 
ce-G1L  competing endogenous long galectin-1 
ceRNA  competing endogenous RNA 
CRD   carbohydrate recognition domain 
C-terminal  carboxy-terminal 
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ECM   extracellular matrix 
EGF   epidermal growth factor  
ERK   extracellular signal-regulated kinase 
GAL-1L  galectin-1 long transcript variant  
GAL-1S  galectin-1 short transcript variant 
gd   gestation day 
HBV  hepatitis B virus 
HDAC3  histone deacetylase 3 
hgs   hepatocyte growth factor substrate 
HIF-1 hypoxia inducible factor 1 alpha 
H-ras   Harvey rat sarcoma virus protein 
IFN   interferon gamma 
IL-1   interleukin 1 beta 
IL-4   interleukin 4 
IL-5   interleukin 5 
Inr   initiator 
kDa   kilo Dalton, predicted molecular mass 
LGALS1  lectin, galactoside-binding, soluble 1 gene 
LGALS9  lectin, galactoside-binding, soluble 9 gene 
m7G   7-methylguanosine 
MAPK  mitogen activated protein kinase 
miRNA  micro-RNA 
MMP   matrix-metallo proteinase 
mRNA  messenger RNA 
NF-B  nuclear factor kappa-light-chain-enhancer of activated B cells 
NK cells  natural killer cells 
NSCLC  non-small cell lung cancer 
nt   nucleotides 
N-terminal  amino-terminal 
PBMC  peripheral blood mononuclear cell 
PI3K   phosphatidylinositol 3 kinase 
pri-miRNA  primary miRNA 
qPCR   quantitative real-time polymerase chain reaction 
RAF1   rapidly accelerated fibrosarcoma protein 1 
RNA   ribonucleic acid 
SCID   severe combined immune deficient 
Sp1   specificity protein 1 
Tc cells  cytotoxic CD8+ T cells 
TGF   transforming growth factor beta 
Th1 cells  type 1 helper CD4+ T cells 
Tim-3   t cell immunoglobulin mucin-3 
TNF-  tumor necrosis factor alpha 
Treg cells  regulatory T cells 
TSH   thyroid stimulating hormone 
UTR   untranslated region 
VEGF   vascular endothelial growth factor 
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Introduction 
The human vasculature has a nutritive function, i.e. through the blood vessels oxygen and nutrients 
are transported to our organs 1. In addition, blood vessels are important for processes like organ 
morphogenesis in the embryo 2. In the developing embryo, blood vessels are generated from 
endothelial precursor cells, which initially engage in a process called vasculogenesis resulting in 
the formation of a primitive vascular plexus 3. Subsequently additional vessels sprout from pre-
existing capillaries, a process termed angiogenesis. Through pruning of redundant vessels a mature 
vascular network is formed, in which larger vessels ramify into smaller ones. Finally, mural cells, 
i.e. pericytes and smooth muscle cells, surround nascent vessels and provide strength and the 
ability to regulate vessel perfusion - a process named arteriogenesis 4.  
In adults, the total length of the vascular system is estimated to be around 80000 kilometers. 
These blood vessels are in general quiescent and angiogenesis only occurs during wound healing 
and in the cycling ovary or the placenta during pregnancy 1. However, a trigger like hypoxia can 
rapidly result in the activation of endothelial cells and start the angiogenesis cascade. Upon 
stimulation with angiogenic growth factors, like VEGF, endothelial cells will secrete proteases 
that degrade the surrounding extracellular matrix (ECM). This will allow the endothelial cells to 
 
 
Figure 1. Tumor angiogenesis. The angiogeneic cascade is depicted in a chronological order from left to right. Once 
tumors grow beyond a diffusion-limited size, tumor cells will start to secrete angiogenic growth factors like VEGF 
due a decrease in local oxygen tension. Upon stimulation with these growth factors endothelial cells will secrete 
enzymes like MMPs that degrade the basal lamina and ECM. This allows for the migration of endothelial tip cells 
towards the source of the growth factors, which will in addition instruct neighboring endothelial cells to proliferate 
and form tube-like structures. During the angiogenic cascade, the tip cells at the forefront of these outgrowing tubes 
will mediate the fusion of two tubes, resulting in the formation of a closed blood vessel and blood flow. Finally, mural 
cells, i.e. pericytes, will cover these newly formed vessels, ensuring their stability (Figure adapted from Kleibeuker 
EA et al. 2012). 
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proliferate and migrate towards the source of the angiogenic stimulus, ultimately resulting in the 
formation of a new blood vessel. The relative uncommonness of angiogenesis in physiological 
settings is greatly contrasted by the finding that a deregulation of angiogenesis has been implicated 
in more than 70 disorders. In some of these, such as ischaemic heart disease, angiogenesis is 
insufficient. In many other cases angiogenesis is excessively turned on. Amongst these are ocular 
and inflammatory disorders, obesity, diabetes, AIDS, endometriosis and cancer 1. In fact, 
angiogenesis is one of the hallmarks of cancer and a promising target for anti-cancer therapy 
5(figure 1). Thus, identifying factors that modulate and mediate tumor angiogenesis is of great 
interest. We recently identified endothelial galectin-1 as a key player during tumor angiogenesis 6 
and proceeded to assess which galectins are expressed in quiescent cells and how their expression 
changes upon endothelial cell activation 7. This identified galectins as potential regulators of tumor 
angiogenesis. 
 
Galectins 
The galectin family 
Galectins are a family of proteins characterized by a conserved domain that enables them to bind 
to -galactoside-containing carbohydrate chains on glycoproteins and glycolipids 8. This domain 
was named the carbohydrate recognition domain (CRD) and consist of 135 amino acids of which 
7 constitute the actual binding pocket 9. Fifteen mammalian galectins have been identified so far 
(figure 2).  
 
 
Figure 2. Mammalian galectins. Fifteen 
mammalian galectin family members have been 
identified so far of which 11 have human 
orthologues. Based on the type and number of 
domains present in a single amino acid chain, 
these are subdivided into protype galectins which 
contain one CRD domain, tandem-repeat galectins 
which contain 2 CRD domains linked by a linker 
region and chimera galectins which contain one 
CRD domain and an atypical non-lectin domain. 
The slightly different color of the two CRDs of 
tandem-repeat galectins indicates they have 
different specificity and affinity for carbohydrate 
chains.  
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All galectins have either one or two CRDs within a single polypeptide chain and based on 
their domain organization they are divided into three different subfamilies: prototype, tandem-
repeat and chimera galectins. Prototype galectins contain one CRD while tandem-repeat 
galectins contain two CRDs linked by a linker domain. Galectin-3 contains one CRD and a non-
lectin amino-terminal region and was designated as a chimera galectin 10. The fine specificity for 
carbohydrates differs between the CRDs of galectin family members and equally between the N- 
and C-terminal CRDs of tandem-repeat galectins 11,12. Also, most galectins oligomerize, i.e. they 
are either bivalent or multivalent with regard to their carbohydrate binding activities 13. Prototype 
galectins can dimerize. Tandem-repeat galectins are at least bivalent and they can also form 
higher order oligomers 14. Finally, multiple galectin-3 proteins can oligomerize and form 
pentamers 15.  
 
Galectin functions 
Galectins are often found outside of the cell despite their lack of a classical secretion signal. The 
precise mechanism by which galectins externalize is not clear yet but intact carbohydrate-binding 
activity is required 13 and molecular players mediating the secretion of individual galectins have 
been identified, like MMPs and calpain-4 16-19. Galectins can exert a wide range of functions 
outside of the cell where they cross-link glycoconjugates both on the cell membrane and in the 
ECM. Consequently, galectins mediate cell-cell and cell-ECM interactions as well as the formation 
of lattices and the activation of signaling complexes on the cell membrane (figure 3). For example, 
galectin-3 and galectin-9 have been shown to modulate homotypic cell adhesion of various cell  
 
 
Figure 3. Galectin localization and 
function. Galectins are found both inside 
the cell, both in the nucleus and in the 
cytoplasm and extracellular. 
Intracellularly, galectins modulate 
processes independently of their 
carbohydrate binding capacity, like pre-
mRNA splicing and signaling pathways. 
Outside of the cell, galectins can cross-
link glycoproteins and glycolipids via 
their CRDs, which allows them to mediate 
homo- and heterotypic cell adhesion as 
well as adhesion of cells to the ECM. In 
addition galectins can mediate the 
formation of lattices of receptors on the 
cell membrane, resulting in the activation 
or inhibition of signaling pathways 
associated with these receptors. 
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types 20,21, galectin-1 and galectin-9 control the migration of immune cells like T cells through the 
ECM and across the endothelium 22-24 and they induce signaling pathways leading to apoptosis in 
T cells 25,26 or activation of endothelial cells 27,28. Galectins are also found intracellularly and they 
have been implicated in various processes inside the cell, both in the cytoplasm and in the nucleus 
29. For example galectin-1 and galectin-3 have been implicated in pre-mRNA splicing 30,31 and 
galectin-3, galectin-7 and galectin-12 have been shown to regulate apoptosis inside the cell, acting 
either pro-apoptotic or anti-apoptotic 29. Galectins exert these functions independent of their 
carbohydrate binding capacity. 
Considering that single galectin family members can modulate a wide range of cellular 
processes simultaneously, both intra- and extra-cellularly, it is not surprising that they are 
important for several physiological processes. For example, galectin-1 has been implicated in 
olfactory development 32 and in maintenance of tolerance at the feto-maternal interface 33. On the 
other hand, loss of control over immune cell proliferation and activation by several galectins has 
been implicated in various diseases of the immune system like rheumatoid arthritis 34,35 and 
encephalomyelitis 36,37. Moreover, therapeutic intervention by administration of galectins has 
beneficial effects in mouse models for many immunological diseases like rheumatoid arthritis 38,39, 
encephalomyelitis 36, hepatitis 40, inflammatory bowel disease 41,42, autoimmune diabetes 43 and 
graft-versus-host disease 44,45.  
 
Galectins in cancer 
Besides their involvement in different pathologies as described above, several galectins have been 
shown to play a role in cancer 46. Thus far, altered expression of three family members is frequently 
associated with tumor progression and disease outcome, i.e. galectin-1, galectin-3, and galectin-9. 
 
Galectin-1  
Galectin-1 is the first galectin family member cloned in humans 47. The gene encoding galectin-1, 
LGALS1 (HGNC: 6561), contains 4 exons and is located on chromosome 22q13.1. Galectin-1 
(14.7 kDa) is a prototype galectin that occurs as a monomer as well as a non-covalent homodimer 
under reducing conditions 48 via dimerization of 2 galectin-1 proteins at their hydrophobic cores 
49. At low concentrations however, galectin-1 is predominantly monomeric 50 and still able to bind 
to carbohydrate chains via its CRD, although with a lower affinity 51. A number of studies suggest 
additional levels of complexity in galectin-1 protein structure. Galectin-1 can be oxidized and it 
this form it lacks carbohydrate binding activity and remains a monomer 52,53. 
Altered galectin-1 expression levels have been found in different cancer types 46,48. For 
example, galectin-1 expression is increased in colon carcinoma 54, pancreatic cancer 55, gliomas 
56,57 and non-small-cell lung cancer 58. in renal cell carcinoma 59,60 and head and neck squamous 
cell carcinoma 61-63 galectin-1 expression appears to depend on histological grade or type, 
respectively. In addition, galectin-1 is a diagnostic or prognostic marker for a number of cancer, 
like colon carcinoma 54 and head and neck squamous cell carcinoma 64. In general, increased 
galectin-1 expression is associated with a more malignant phenotype and poorer outcome. 
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A number of extracellular factors and their associated signaling pathways that modulate 
galectin-1 expression have been found 48. For example, galectin-1 expression increases in breast 
cancer cells upon stimulation of these cells with EGF 65 and TGF 66. In addition estrogen, 
progesterone, TSH and RA all modulate galectin-1 levels in various cell types 48. Also, endothelial 
cell activation results in an increase in galectin-1 expression 7. At the genetic level, the methylation 
status of the LGALS1 promotor has been implicated in controlling galectin-1 transcription. 
Hypermethylation results in a decreased expression of in colon cancer cells 67, while demethylation 
correlates with galectin-1 levels when comparing different tissues 68,69. In fact, distinct promotor 
elements, i.e. a Sp1 site and Inr and TATA core promotor elements, have been identified that drive 
the transcription of different galectin-1 transcripts 70,71. Transcription factors that control galectin-
1 transcription have recently been found. Intronic binding of NF-B to LGALS1 results in an 
increased transcription in T cells 72,73 and C/EBP and HIF- 1have been shown to act 
synergistically to increase galectin-1 expression in acute myloid leukemic cells 74. 
 
Galectin-3 
The gene encoding galectin-3, LGALS3 (HGNC: 6563) lies on chromosome 14q22.3, contains 6 
exons and was first discovered as a macrophage surface antigen 75. This galectin is the sole member 
of the chimera galectin subfamily as it has both a CRD and an atypical glycine-proline rich N-
terminal domain of roughly 120 amino acids 76. Upon extracellular ligand binding, this domain 
allows for the formation of galectin-3 homo-pentamers, which greatly increases its valency 77. 
Also,  phosphorylation of specific serines within the N-terminal domain appears to be required for 
galectin-3 secretion 78. The carbohydrate-binding specificity of galectin-3 is well characterized and 
is different from that of other galectin family members 8,79. This is reflected in galectin-3 function. 
For example, galectin-1 and galectin-3 bind to distinct surface glycoproteins to induce T cell death 
80.  
 The expression level of galectin-3 in cancer appears to depend on the cancer type 81. For 
example, increased expression has been shown for melanoma 82, liver carcinoma 83,  renal 
carcinoma 84,85 thyroid cancer 76 and tumors of the central nervous system 86. Conversely, 
decreased expression of galectin-3 has been reported in leukemia 87 and various tumors of 
epithelial origin 88-90. The finding that epithelial tumor cells show both an increased and a 
decreased galectin-3 expression compared to their physiological counterparts  could also reflect a 
dynamic regulation of galectin-3 expression depending on the subtype and cancer stage, as has 
been shown for breast cancer 91. Moreover, the change in galectin-3 expression can differ between 
subcellular compartments. For example in squamous cell carcinoma nuclear galectin-3 levels are 
decreased while cytoplasmic levels are increased when comparing tumor cells to normal cells 92. 
Since it often correlates with tumor aggressiveness, galectin-3 expression also has prognostic value 
in several cancer types, as has been shown for colorectal cancer 93, renal carcinoma 84, melanoma 
94, squamous cell carcinoma 92 and nasopharyngeal carcinoma 95.  
Similar to galectin-1, several factors that modulate galectin-3 expression have been found. 
For example, IL-4, IL-7, VEGF and bFGF have been implicated as inducers of galectin-3 
expression 96-98. The effect that specific growth factors have on galectin-3 expression can also 
depend on the cell type as shown for EGF, as it decreases galectin-3 expression in liver cells 99 and 
increases galectin-3 expression in Sertoli cells 100. Conversely, TNF- decreases galectin-3 
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expression in fibroblasts 101. Inside the cell, transcription factors like NF-kB 102, jun 103, runx1 and 
runx2 104, as well as the signaling pathways that regulate the activity of these transcripton factors 
have been implicated in the regulation of galectin-3 expression.  
 
Galectin-9 
Galectin-9 is a tandem-repeat galectin that was cloned in 1997 by 3 independent groups working 
in different research fields 105-107. The gene encoding galectin-9, LGALS9 (HGNC: 6570), is 
located on chromosome 17q11.2 and consists of 11 exons. The galectin-9 transcript is subject to 
extensive post-transcriptional splicing, a phenomenon that has also been observed for another 
tandem-repeat galectin, i.e. galectin-8 108, which results in the generation of mature mRNAs that 
vary in the inclusion of exons 5 and 6. Both exons encode for the linker region of galectin-9 and 
deletion of exons 5 and 6 results in a shorter linker region. Unfortunately, only few functional 
studies take the existence of these isoforms into account. As mentioned before, the specificity for 
carbohydrates varies between the N-terminal and C-terminal CRDs of tandem-repeat galectins 8 
and galectin-9 is no exception to this 109,110. In addition, galectin-9 can form oligomers via its linker 
region which increases its valency for glycoconjugates 14 and reports indicate that hetero-
oligomers of galectin-9 together with galectin-3 and galectin-8 can be formed 111.  
Similar to galectin-1 and galectin-3, changes in galectin-9 expression have been associated 
with tumor progression. In fact, galectin-9 was initially cloned as a tumor antigen in Hodgkin’s 
lymphoma 106. Now, ample data show that galectin-9 expression levels vary when comparing 
tumor tissue to normal tissue. In general, there appears to be an inverse correlation galectin-9 
expression and tumor progression. This is the case for breast 112,113, lung 113, melanoma 113,114, renal 
113, head and neck squamous cell carcinoma 115 and prostate cancer 113. The exceptions to this are 
colon carcinoma 116 and leukemia 113, in which galectin-9 levels appear to increase compared to 
normal tissues. The prognostic value of galectin-9 expression is emerging, as demonstrated for 
breast cancer, where loss of galectin-9 predicts distant metastasis better than lymph node status 
and increased galectin-9 expression correlates in increased disease free survival 21,112. Similar 
results were obtained for melanoma 114 and cervical squamous cell carcinoma 117. Unfortunately 
these studies did not take the existence of galectin-9 isoforms into account. 
The regulation of galectin-9 expression is less well understood than that of galectin-1 and 
galectin-3. IFN has been shown to induce galectin-9 expression in fibroblasts 118 and endothelial 
cells 119, which was dependent on HDAC3 in the latter case 120. In addition, IL-1 121 and IL-5 122 
have been shown to increase galectin-9 expression in astrocytes and eosinophils respectively. 
Overall galectin-9 expression decreases upon activation of endothelial cells 7. However, the 
regulation of individual splice variants was not assessed in this study. At this point the pathways 
involved in modulating galectin-9 expression and the promotor structure and transcription factors 
controlling LGALS9 transcription remain to be elucidated. In addition, the factors that control 
galectin-9 isoform expression are still to be found.  
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Functions of galectins in tumor progression 
As mentioned, tumor progression is often associated with changes in the expression of galectin-1, 
-3, and -9. Consequently, these galectins are now implicated in several aspects of tumorigenesis, 
underlining their potential as therapeutic targets (figure 4).  
 
Tumor cell transformation and survival 
Tumor cell transformation, i.e. an increased proliferative potential and motility, and an increased 
survival potential combined with evasion of apoptotic queues are thought to be hallmarks of cancer 
that occur early during tumorigenesis 5. The most extensively studied function of galectins in the 
context of tumor progression is the regulation of apoptosis 123,124. Both galectin-1 and galectin-9 
can induce apoptosis when added exogenously to tumor cells 46. In fact, both have this effect on 
malignant immune cells, which is not surprising considering both galectins have immune-
suppressive properties 11. For example, galectin-1 induces apoptosis in anaplastic large cell 
lymphoma and Hodgkin´s lymphoma 125 while galectin-9 has been shown to induce apoptosis in 
various leukemia cell lines 126,127 and myeloma cells 128. Studies now show it is feasible to treat 
these cancers with recombinant galectin-9 129, as has been demonstrated in models for leukemia 
126 and myeloma 128. Contrary to galectin-1 and galectin-9, galectin-3 influences apoptosis mainly 
inside the cell. Galectin-3 has anti-apoptotic activity in several tumor cell types 29 and a number 
of mechanisms underlying this function of galectin-3 have been proposed. For example, the anti-
apoptotic activity appears to depend on phosphorylation of the N-terminal domain 130 and 
phosphorylated galectin-3 upregulates the MAPK pathway, which is implicated in the regulation 
of apoptosis 131. Galectin-3 has considerably sequence similarity with a well characterized anti-
apoptotic protein, i.e. bcl2 132, and recruitment of bcl2 to mitochondria via galectin-3 has been 
suggested as a possible mechanism by which galectin-3 exerts anti-apoptotic activity 46. Also, 
blocking changes in mitochondrial membrane potential 133 and interaction with synexin and 
inhibition of cytochrome c release 134 underly the anti-apoptotic activity of galectin-3. 
Interestingly, the anti-apoptotic effect of galectin-3 seems to depend on the subcellular localization 
of galectin-3, as cytosolic galectin-3 has a protective effect while nuclear galectin-3 has been 
implicated in the induction of apoptosis of prostate cancer cells 135. Finally, it is important to note 
that galectin-3 also regulates the susceptibility of tumor cells to apoptosis induced by 
chemotherapeutics 131,136. 
 Galectin-1 and galectin-3 have been implicated in tumor cell transformation, as inhibition 
of their expression suppresses the transformed phenotype of glioma cells 137 and breast carcinoma 
cells 138 and thyroid carcinoma cells 139 respectively. Both galectins likely exert this function 
through modulation of ras signaling. Ras oncoproteins are implicated in the transformation to a 
malignant phenotype in many tumor types and efficient signaling via the ras pathway requires 
these proteins to be anchored to the plasma membrane 140. Paz et al. demonstrated that galectin-1 
binding to H-ras is required for the membrane anchorage of the latter 141, which in turn results in 
the activation of downstream signaling molecules like RAF1 and ERK 142. On the other hand, 
galectin-3 appears to preferentially bind to K-ras, which in turn results in the activation of RAF1 
and PI3K 143. 
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Metastasis 
Outside of the cell galectins can modulate the adhesion of cells to the ECM as well as homo- and 
heterotypic cell-cell adhesion via cross-linking of carbohydrate chains on ECM components and 
membrane proteins 77. In order for tumor cells to metastasize changes in cell adhesion are 
necessary, i.e. a loss of tissue integrity and increased migratory and invasive capacities as well as 
adhesion to endothelial cells or basal membrane proteins at distal sites. Aside this, tumor 
angiogenesis and evasion of the immune system are often also necessary for tumor cells to 
metastasize. Galectin-1, galectin-3 and galectin-9 have all been implicated in tumor cell adhesion 
and their effects appear to be cell type specific, i.e. dependent on which glycoconjugates are 
expressed on the tumor cell. For example, while the addition of recombinant galectin-1 to most 
tumor cells inhibits the adhesion of these cells to ECM proteins 144,145, the result is opposite when 
added to ovarian 146 or prostate cancer cell lines 147. In addition extracellular galectin-1 has been 
shown to increase the motility of astrocyte tumor cells 56. Taken together these data point towards 
a role for galectin-1 in loss of tissue integrity and increased motility of tumor cells, which 
corresponds with the increased intratumoral levels of galectin-1 observed in most cancer types. 
Similar results have been obtained for galectin-3 144,148, as it inhibits the adhesion of tumor cells to 
extracellular matrix proteins. In vivo data further supports a pro-metastatic role for galectin-3. For 
example, galectin-3 has been implicated in homotypic adhesion of metastasizing tumor cells like 
breast and prostate carcinoma cells since it clusters at sites of cell-cell contacts in tumor cell 
aggregates at the sites of attachment to the endothelium 149. In addition, liver metastases of human 
adenocarcinomas are inhibited in SCID mice upon treatment of these mice with anti-galectin-3 
antibody 150. Of note, galectin-3 could also promote metastasis by desensitizing metastasizing cells 
to apoptosis. Conversely, galectin-9 appears to ensure tissue integrity in models for melanoma 114 
and breast cancer 21. In fact, in the latter study a correlation between decreased galectin-9 levels 
increased metastasis was found. Interestingly, this effect of galectin-9 appears to depend on the 
relative abundance of galectin-9 splice variants since overexpression of the most abundant splice 
variant, i.e. gal-95, indeed increases adhesion of tumor cells to ECM components 115, while 
overexpression of gal-9FL or gal-95/6 has the opposite effect 21.  
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Figure 4. Proposed and known roles of galectin-1, galectin-3 and galectin-9 in tumor biology. Galectin-1, 
galectin-3 and galectin-9 exert a multi-level role in tumor biology, which makes them attractive candidates to attack 
tumors on several fronts simultaneously. Blue: galectin-1. Orange: galectin-3. Green: galectin-9. “+” indicates there 
are studies supporting this role for the galectin corresponding to this color. “?” indicates it is not known yet whether 
this galectin modulates this process. Of note: the amount of studies supporting these roles for galectin-9 is often 
limited.  
 
 On a molecular level, galectin-1 has been shown to recognize ECM components like 
vitronectin 151, osteopontin 152, fibronectin 153 and laminin 154 . The latter has also been identified 
as a binding partner of galectin-3 155. An important family of signaling plasma membrane receptors 
involved in binding these ECM components is integrins 156. Galectin-1 binds to the 1 integrin 
subunit 157 and as a result to integrin-11 158, integrin-71 159 and integrin-51 160. In fact, 
integrin-11 has also been identified as a receptor for galectin-3 161, as well as integrin-3162, 
integrin-2163 and integrin-3 164. Thus, it is likely that galectins affect cellular adhesion and 
migration via modulation of the interactions between these membrane receptors and ECM 
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components. So far there are only a limited number of reports available in which galectin-9 binding 
partners were found and one study did imply galectin-9 binding to integrin-41 165. 
 
Tumor immune escape 
As tumor cells progress towards a more malignant phenotype, an increasing amount of tumor 
antigens will be presented by these cells. In addition, once these cells disseminate through the 
vascular system they will readily be recognized and cleared by the immune system. To avoid this, 
tumors often hijack physiological immune-suppressive pathways. As mentioned, both galectin-1 
and galectin-9 have well documented immune-suppressive functions 11, for example by inducing 
apoptosis of activated T cells 25,26. Several studies have now shown galectin-1 indeed enables 
tumors to escape from immune surveillance 166,167. In fact, Rubinstein et al. have shown in a murine 
melanoma model that blocking galectin-1 function in tumor tissue results in a reduced tumor size, 
due to the generation of a potent tumor specific T-cell mediated response and as a result an 
enhanced rejection of the tumor mass. Alternatively, galectin-1 could hamper the anti-tumor 
immune response by suppressing the secretion of pro-inflammatory cytokines 168 or blocking the 
recruitment of neutrophils 169.  
 Similar to galectin-1, exogenous galectin-3 also induces apoptosis of T-cells 170 and 
prevents T cell activation 171. However, other studies show galectin-3 can also induce the activation 
of various immune cell types. Galectin-3 is a chemo-attractant for monocytes, macrophages 172, 
attracts and activates neutrophils 173,174 and induces the degranulation of mast cells 175. In addition, 
cytosolar galectin-3 prevents apoptosis of several immune cell types 46. Galectin-3 deficient mice 
show reduced immune responses in models of peritoneal 176 and airway inflammation 177. The role 
of galectin-3 in tumor immune escape has not been addressed yet and would be an interesting 
subject for future studies.  
Galectin-9 modulates the activity and survival of several types of immune cells as well 178. 
However, similar to galectin-3, a role for galectin-9 in tumor immune escape remains largely 
unexplored at this point although several findings point towards such a role. Epstein-Bar-virus 
infected nasopharyngeal carcinoma cells are thought to escape immune surveillance by secreting 
vesicles containing galectin-9 179. Several additional findings further suggest a role for galectin-9 
in tumor immune escape. Galectin-9 is a potent inducer of Tc and Th1 cell apoptosis via binding to 
Tim-3 on these cells 26,180. Also, galectin-9 is a chemoattractant for eosinophils 181, which are 
predominantly associated with anti-tumor activity and a good prognosis 182. In addition galectin-9 
has been shown to skew the differentiation of progenitor cells towards immune-suppressive 
subsets, i.e. Tregs 
39. At first sight an immune-suppressive function of galectin-9 seems hard to 
reconcile with decreased overall levels of galectin-9 as observed in most tumor cell types compared 
to their physiological counterpart. This might simply be explained by galectin-9 not exerting an 
immune-suppressive role and a pro-metastatic role concomitantly in these tumors or an alternative 
mechanism might be at play. A decrease in tumor cell galectin-9 levels with a simultaneous 
increase of galectin-9 levels in stromal cells might offer an elegant mechanism permitting 
detachment and metastasis of tumor cells while maintaining an immune-suppressive tumor micro-
environment. 
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Tumor angiogenesis 
Once tumors grow beyond an oxygen-diffusion limited size of a few mm3 the need for an adequate 
blood supply arises, i.e. the angiogenic switch occurs 5,183(figure 1). Different strategies can be 
employed by tumors to become vascularized like vessel intussusception, vessel co-option and 
vasculogenic mimicry. However, the most common way of tumor vascularization is sprouting 
angiogenesis, i.e. the generation of de novo blood vessels out of pre-existing capillaries and many 
growth factors and mechanisms underlying this process have been identified 1,184.  
Galectin-3 was the first galectin family member implicated in tumor angiogenesis 185. A 
racial disparity in the occurrence of a polymorphism within LGALS3 is related to breast cancer 
incidence in Asian and Caucasian women. Interestingly, this polymorphism determines the 
susceptibility of galectin-3 to cleavage by MMPs and the resulting galectin-3 form induces 
angiogenesis and mediates tumor progression more potently compared to the non-cleaved form 
186. In 2006, we showed that endothelial galectin-1 is the receptor for the drug anti-angiogenesis 
drug anginex, which prevents adequate tumor vascularization and as a result hampers tumor 
growth 6. In addition, galectin-1 expression is increased in response to hypoxia 64,74,187 and tumor 
cell-derived galectin-1 can activate endothelial cells and supplement the galectin-1 pool of these 
cells 28. We found that quiescent endothelial cells mainly express galectin-1, galectin-3, galectin-
8 and galectin-9, and that the change in expression levels of these galectins was the most 
pronounced for galectin-1 and galectin-9 7. While galectin-1 levels increase in tumor endothelial 
cells compared to quiescent cells, galectin-9 mRNA levels decrease upon endothelial cell 
activation. It should be noted that in these experiments total galectin-9 levels were assessed and 
no distinction was made between individual splice variants. In addition, it is not clear yet what role 
endothelial galectin-9 exerts in tumor biology.  
 
 
Aim and outline of this thesis 
Aberrant angiogenesis has been implicated in a large amount of diseases, most notably in cancer. 
Galectin-1, galectin-3, galectin-8 and galectin-9 are the predominant galectins expressed in 
endothelial cells and upon endothelial cell activation galectin-1 levels greatly increase while 
galectin-9 mRNA levels decrease. Endothelial galectin-1 has been implicated in tumor immune 
escape and tumor angiogenesis. On the other hand, no studies are available assessing the function 
of endothelial galectin-9 in tumor biology. Also, it remains largely unexplored which functions 
alternative transcripts of galectin-1 and galectin-9 have. The expression level of both galectins has 
been shown to have prognostic merit in various diseases. From an anti-cancer therapy standpoint, 
endothelial targets have several advantages, including easy accessibility and a lower chance of 
therapy resistance.  
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The aim of this thesis is twofold. Firstly, we set out to determine the complete galectin-1 and 
galectin-9 expression profile in cancer. Secondly, we aim to explore the function of alternative 
endothelial galectin transcripts in tumor biology and angiogenesis.  
 
To obtain a more complete insight in the relevance of galectin expression levels in cancer, we first 
performed extensive galectin expression profiling in NSCLC (chapter 2). This study confirmed 
the importance of galectin-1 as a prognostic marker. More importantly, it also identified galectin-
95 as a prognostic marker and indicated the relevance to distinguish between the different 
galectin9 splice variants. This was further illustrated by analysis of galectin-9 splice variant 
expression in normal and pathological pregnancy (chapter 3). We found that the expression levels 
of individual galectin-9 splice variants indeed varies between these settings and that galectin-9 
might serve as a marker for adverse pregnancy outcome. All these findings led us to further explore 
galectin-9 expression in endothelial cells during tumor angiogenesis. As described in chapter 4, 
extensive galectin-9 expression analysis resulted in the identification of atypical galectin-9 splice 
variants in endothelial cells. Subsequent functional analyses revealed that its function mainly 
pertains to modulation of the immune system. Our data indicate that a marked increase in 
endothelial galectin-9 protein levels in tumors might account for a potent suppression of the 
immune system by these tumors by inducing apoptosis in Tc and Th1 cells and not in Tregs. Also, 
we exhaustively detected which galectin-9 splice variants are expressed in endothelial cells and 
found one novel splice variant, i.e. galectin-95/6/10.  Our findings are placed in context with all 
relevant literature concerning the role of galectin-9 in tumor biology in chapter 5. This shows that 
the best studied property of galectin-9 is the modulation of tumor cell adhesion and survival. 
Furthermore, we propose a hypothesis reconciling the decrease in tumor galectin-9 levels reported 
in most studies with tumor immune escape via endothelial galectin-9. 
Based on the identification of novel galectin-9 transcripts in endothelial cells we then 
focused on galectin-1 expression since an alternative murine galectin-1 transcript has been 
reported once in literature. We verified the existence of 2 alternative galectin-1 transcripts in 
human endothelial cells, which vary in the length of the 5’UTR (chapter 6). RNA folding analysis 
indicated that the longest galectin-1 transcript allows for the formation of a stable loop. Our data 
indicate the presence of a processing site downstream of the loop structure. Finally, preliminary 
experiments suggest that this processed 5’UTR of the long galectin-1 transcript might scavenge 
miRNA-296, a miRNA which targets several proteins involved in endothelial cell biology. Since 
miRNAs have emerged as regulators of complex biological processes, we finally reviewed all 
literature on miRNA expression in endothelial cells, comprehensively combining the data of 
several genome-wide profiling studies (chapter 7). 
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Abstract 
Background: Approximately 30-40% of the patients with early stage non-small cell lung cancer 
(NSCLC) will present with recurrent disease within two years of resection. We performed 
extensive galectin expression profiling in early stage NSCLC patients to identify markers of poor 
prognosis.  
Methods: Galectin expression profiling was performed by qPCR on tumor tissue from patients 
(n=93) with stage I-IIIa NSCLC who underwent curative resection. Galectin-1 and galectin-9 
expression was further analyzed using immunohistochemistry on a subset (n=45) of patients. 
Results: Galectin expression in NSCLC is confined to galectin-1,-3,-4,-7,-8, and -9. Overall 
survival was shorter in patients that express galectin-1 above median levels, i.e. 21.9 (15.3-58.9) 
vs. 56.3 (37.7-66.9) months (p=0.022) as well as in patients that express galectin-9∆5 below the 
median, i.e. 18.3 (12.7-59.3) vs. 58.9 (39.3-65.8) months (p=0.007). Low galectin-9∆5 expression 
was also prognostic for disease free survival, i.e. 13.9 (8.4-42.3) vs. 58.1 (23.8-65.1) months 
(p=0.005). Galectin-1 and galectin-9 staining of showed differences in frequency and localisation 
of protein expression.  
Conclusion: These data confirm the prognostic value of galectin-1 in NSCLC and identify galectin-
9∆5 as a novel potent prognostic marker in early stage NSCLC. These findings can be used to 
identify those patients that might benefit most from adjuvant chemotherapy. 
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Introduction 
In non-small cell lung cancer (NSCLC), clinicopathological staging according to the TNM 
classification is still the main delimiter to classify patients with a distinct outcome. Unfortunately, 
of the patients diagnosed with early stage disease almost 30% to 40% will present tumour 
recurrence within two years after surgical resection1. Since it has been shown that adjuvant 
chemotherapy can improve the survival of patients with resected stage II-IIIa NSCLC, 
identification of early stage patients with poor survival is clinically relevant1.  
Galectins are a protein family of which the members are defined by the presence of a 
conserved carbohydrate recognition domain with beta-galactoside binding affinity2. Thus far, 
fifteen galectins have been identified, eleven of which are also expressed in different human cells 
and tissues3. They exert many different functions, with regulation and fine-tuning of the immune 
system being the best studied. Consequently, deregulation of galectin expression is frequently 
associated with an inadequate immune response giving rise to different pathologies, including 
cancer4,5. In addition, galectins have been found to mediate tumour cell metastasis6-8 and to induce 
and maintain tumour angiogenesis which further adds to cancer progression9-13. All this has 
resulted in the recognition of galectins as prognostic markers in different cancer types, including 
lung cancer. For example, increased galectin-3 expression has been described as an indicator of 
poor prognosis in stage II NSCLC patients14 as well as in a patient population comprised of all 
subtypes and stages15. Similar observations were reported for galectin-1 expression14-16. More 
recently, elevated levels of galectin-1 expression were found to promote lung cancer progression 
and chemoresistance17. All these findings illustrate the prognostic potential of galectins in lung 
cancer. Unfortunately, most studies only assessed galectin-1 and/or galectin-3 expression which 
has left the prognostic value of other galectin family members unresolved. To address this, we 
performed comprehensive galectin expression profiling and determined the prognostic value of all 
known human galectins in early stage NSCLC patients. Apart from galectin-1, we identified a 
splice variant of galectin-9, i.e. gal-9∆5, as a potent prognostic marker in the earliest stages of 
NSCLC.  
 
Materials and Methods 
Patient material 
Tumour samples of 93 patients with NSCLC who underwent a anatomic resection between 1994 
and 2004 were included in this study as described before18. Only tissues with a tumour area >50%, 
as evaluated by an experienced pathologist (R-JvS), were included for further investigations. The 
study complies with the recommendations guiding physicians in biomedical research involving 
human subjects as laid down in the Declaration of Helsinki. 
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Table 1. Patient characteristics  
Total number of patients 93 
Median age in years (range) 65.6 (37.4 - 81.5) 
Sex  
Male 71 (76.3%) 
Female 22 (23.7%) 
Histology  
Adeno carcinoma 33 (35.5%) 
Squamous cell carcinoma 46 (49.5%) 
Large cell carcinoma 13 (14.0%) 
Pleiomorph carcinoma 1 (1.0%) 
Stage (TNM)  
Stage IA 11 (11.8%) 
Stage IB 45 (48.4%) 
Stage IIA 6 (6.5%) 
Stage IIB 26 (28.0%) 
Stage IIIA 5 (5.3%) 
Smoking status  
Never 2 (2.2%) 
Former 62 (66.7%) 
Current 24 (25.8%) 
Unknown 5 (5.3%) 
Median OS in months (95% CI) 43.1 (23.0 - 59.3) 
Median DFS in months (95% CI) 28.7 (14.8 - 56.3) 
 
 
Cell cultures 
The following cell lines were used: A549 human alveolar carcinoma, H460 human large cell 
carcinoma, H1650 human bronchoalveolar carcinoma, H1975 human non-small cell lung 
carcinoma, H3255 human non-small cell lung carcinoma. All cell lines were cultured in RPMI 
(invitrogen) supplemented with 10% foetal calf serum, penicillin (50 U/mL) and streptomycin (50 
micrograms/mL). Cells were maintained at 37˚C and 5%CO2 in a humidified incubator. 
 
RNA isolation and cDNA synthesis 
Total RNA was isolated from 10x10 µm thick frozen tissue sections or from cultured cells using 
the RNeasy kit (Qiagen) according to the manufacturer’s instructions. Genomic DNA 
contamination was removed by on column DNAse treatment. cDNA synthesis was performed with 
the iScript cDNA Synthesis Kit (BioRad) using 0.5 to 1.0 micrograms of total RNA. 
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Real-time qPCR 
qPCR was performed on an iQ5 Multicolour Real-Time PCR Detection System (BioRad) or the 
CFX96 (BioRad) using the iQ SYBR Green PCR master mix (BioRad) using 400 nmol/L of the 
appropriate primers which have been described before19. To distinguish between the different 
galectin-9 splice variants the following primers were used: gal-9 FL forward 
GCAGACAAAAACCTCCCG, gal-9 FL reverse CCCAGAGCACAGGTTGATG, gal-9 ∆5 
forward ATCAGCTTCCAGCCTCCC, gal-9 ∆5 reverse CCCAGAGCACAGGTTGATG, gal-9 
∆5/6 forward CTACATCAGCTTCCAGACCCA, gal-9 ∆5/6 reverse 
CCCAGAGCACAGGTTGATG. qPCR for these splice variants was performed using Sensimix 
(Quantace) at Tm = 61˚C. All primers were synthesized by Eurogentec. 
 
Immunohistochemistry 
Immunohistochemistry was performed on paraffin embedded tissue sections according standard 
procedures using the following primary antibodies: rabbit anti-galectin-1 (1:500, Peprotech 
P210) and goat anti-galectin-9 (1:500, R&D systems). Staining were visualized using the 
StreptABComplex/HRP kit (Dako). The sections were counterstained with haematoxylin 
(Merck), dehydrated, and mounted in Depex (BDH prolabo). Blinded scoring of galectin-1 and 
galectin-9 was performed on three different compartments of the tumour, i.e. the tumour cells, 
the tumour stroma, and the tumour endothelial cells. All stainings were scored by at least two 
independent persons. For scoring of galectin-1 and galectin-9 the frequency of staining was 
determined using the following scale: 0 = no or hardly any cells positive,1 = fraction of cells 
positive, 2 = all or majority of cells positive. 
 
Statistical analysis 
The data are presented as mean values±SEM unless indicated otherwise. Survival comparisons 
were performed using Kaplan-Meier survival estimates with the Breslow test. Median mRNA 
expression levels or median IHC scores were used as cut-off value to divide the patients into a 
high expression group (above median) and low expression group (below median). The Student’s 
t-test was used to compare mRNA expression between the different histological groups as well 
as to compare IHC staining scores between different tumour compartments. Statistical 
computations were performed in SPSS20.0.0 and p-values < 0.05 were considered statistically 
significant.  
 
Results 
We performed extensive galectin gene expression analysis on tumour tissues derived from 93 
patients diagnosed with early stage NSCLC. The average age of the patients was 65.6 years (range 
37.4 - 81.5) and follow-up was at least 5 years during which 52 patients (55.9%) presented 
recurrent disease. The median overall survival was 43.1 months (95% CI 23.0 - 59.3 months) 
(Table 1). To get insight in the prognostic value of galectin expression in early stage NSCLC we 
first determined the mRNA expression levels of all known human galectins by qPCR19. This 
analysis revealed that six galectins, i.e. galectin-1,-3,-4,-7,-8, and -9 were detectable in tumour 
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tissue from NSCLC patients (Figure 1A). Because extensive splicing has been reported for 
galectin-919,20, we also determined the mRNA expression of the most common galectin-9 splice 
variants, i.e. galectin-9 full length (FL), galectin-9 with a deletion of exon 5 (∆5), and galectin-9 
with a deletion of exons 5 and 6 (∆5/6). All three variants were detectable with gal-9∆5 as the 
dominant variant (Figure 1A, inset). Protein expression of the different galectin family members  
 
Figure 1 
 
 
was confirmed by screening immunohistochemical stainings available in the human protein atlas21 
(Figure 1B). These data suggest that galectin expression in NSCLC is confined to galectin-1, -3, -
4, -7, -8, and -9. Therefore, further analyses focussed on these galectins.  
Comparison of the expression levels between the different subtypes of NSCLC did not 
reveal any significant differences except for galectin-7 which was significantly higher expressed 
in squamous cell carcinoma as compared to the other two subtypes (Figure 2A). Expression 
profiling on different lung cancer cell lines also showed comparable expression profiles which 
were again comprised of galectin-1, -3, -4, -7, -8, and -9 (Figure 2B). 
  
Figure 1. Galectin mRNA expression profile in 
tumour tissues obtained from early stage non-small 
cell lung cancer patients (A). The inset shows the 
expression of the three galectin-9 splice variants. 
B) Immunohistochemical staining of the galectins 
with detectable mRNA expression21. 
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Figure 2 
 
 
We then determined whether galectin expression was linked to patient survival. Correlation 
analysis showed that galectin-1 mRNA levels were inversely correlated with overall survival (corr. 
coef. -0.308, p = 0.003) while there was a positive correlation between overall survival and total 
galectin-9 (corr. coef. 0.245, p = 0.018) or gal-9∆5 (corr. coef. 0.225, p = 0.030). Next, we analyzed 
the overall survival in patients grouped according to the expression level of a specific galectin. 
Patients that express galectin-1 above median levels had a significant shorter overall survival, i.e. 
21.9 (15.3-58.9) vs. 56.3 (37.7-66.9) months (p = 0.022), which is in agreement with previous 
findings (Figure 3A and Table 2). The expression of galectin-3, which has also been associated 
with poor disease outcome, was not prognostic in our patient group, i.e. median overall survival 
24.0 (15.8-61.7) vs. 58.4 (32.8-62.9) months (p=0.086) (Figure 3B and Table 2). Interestingly, we 
did find a splice variant of galectin-9, i.e. gal-9∆5, to be of prognostic value. Patients with gal-9∆5 
expression levels below the median had significant shorter OS, 18.3 (12.7-59.3) vs. 58.9 (39.3-
65.8) months (p=0.007) (Figure 3C and Table 2). Moreover, the prognosis of patients with poor 
survival based on gal-9∆5 became even worse when also galectin-1 expression levels were 
included (Figure 3D). Thus, high galectin-1 expression combined with low gal-9∆5 expression is 
associated with poor OS of early stage NSCLC patients. None of the other galectins was prognostic 
for OS (Table 2). In case of disease free survival (DFS), only gal-9∆5 was prognostic (Figures 4A-
C and Table 3) and this was not further improved by addition of galectin-1 levels (Figure 4D). 
Figure 2. Galectin mRNA expression profile in 
the main subtypes of NSCLC, i.e. squamous cell 
carcinoma, adenocarcinoma, and large cell 
carcinoma (A). The inset shows the expression 
of the three galectin-9 splice variants. * p < 0.05 
vs. adenocarcinoma and large cell carcinoma. B) 
Galectin mRNA expression profile in different 
NSCLC lines. The inset shows the expression of 
the three galectin-9 splice variants. 
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Altogether, these data confirm the prognostic value of galectin-1 and identify gal-9∆5 as a novel 
potent prognostic factor in early stage NSCLC.  
 
Figure 3 
 
 
 To get more insight in the localization and distribution of galectin-1 and galectin-9 protein 
we performed immunohistochemical stainings on a representative subset of tumours (n=45). As 
was the case in the complete patient group, galectin-1 expression above median and galectin-9 
expression below median were prognostic in this subgroup (data not shown).  
  
Figure 3. Kaplan-Meier plots of 
overall survival (OS) in early 
stage NSCLC patients with low 
(Lo: below median) or high (Hi: 
above median) expression of 
galectin-1 (A), galectin-3 (B), 
and galectin-95 (C). D) 
Kaplan-Meier plot of OS in 
early stage NSCLC patients with 
low galectin-95 expression 
(below median) further grouped 
according to expression of 
galectin-1 below (Lo) or above 
(Hi) median expression. 
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Table 2. Galectin expression and overall survival (OS)  
  Median OS (95% CI) in months 
  Low expressiona High expression P 
Galectin-1 56.3 (37.7-66.9) 21.9 (15.3-58.9) 0.022 
Galectin-3  24.0 (15.8-61.7) 58.4 (32.8-62.9) 0.086 
Galectin-4  32.8 (14.7-61.7) 55.5 (21.9-66.2) 0.175 
Galectin-7 55.0 (18.4-61.9) 48.7 (16.5-64.0) 0.859 
Galectin-8 39.3 (20.8-61.7) 55.5 (16.7-65.8) 0.724 
Galectin-9 24.0 (14.7-61.9) 55.5 (32.8-61.7) 0.118 
Galectin-9FL 23.2 (15.2-61.8) 58.6 (32.8-64.6) 0.078 
Galectin-9∆5 18.3 (12.7-59.3) 58.9 (39.3-65.8) 0.007 
Galectin-
9∆5/6 
33.6 (16.5-61.9) 58.6 (25.2-65.0) 0.288 
a) Low = below median, High = above median  
 
 
 
Table 3. Galectin expression and disease free survival 
(DFS)  
  Median DFS (95% CI) in months 
  Low expressiona High expression P 
Galectin-1 45.9 (22.5-66.2) 17.8 (10.7-58.6) 0.069 
Galectin-3  14.8 (9.9-51.1) 55.4 (23.0-61.9) 0.106 
Galectin-4  20.9 (10.8-61.5) 43.2 (13.0-59.3) 0.315 
Galectin-7 26.8 (10.7-58.6) 43.1 (13.0-64.0) 0.506 
Galectin-8 26.8 (16.2-61.4) 39.6 (12.7-60.1) 0.697 
Galectin-9 14.1 (9.0-60.4) 48.9 (21.9-60.1) 0.101 
Galectin-9FL 20.9 (10.1-61.2) 56.0 (14.8-63.2) 0.088 
Galectin-9∆5 13.9 (8.4-42.3) 58.1 (23.8-65.1) 0.005 
Galectin-
9∆5/6 
23.0 (12.7-56.0) 54.7 (13.0-63.2) 0.203 
a) Low = below median, High = above median  
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Figure 4 
 
 
Galectin-1 was widely expressed in most tumour tissues. The expression in the tumour 
cells varied between tumours as well as within tumours, with some tissues showing no positive 
tumour cells while in other tissues the tumour cells were strongly positive. Most tissues showed 
positive staining in the stroma as well as in the tumour endothelial cells (Figure 5A). Galectin-9 
staining was less prominent as compared to galectin-1. In fact, positive tumour cells were 
infrequent although some tissues appeared to display a gradient with increasing galectin-9 levels 
in the tumour cells closer to the stromal tissue. Both the stroma and the tumour endothelial cells 
stained positive more frequently (Figure 5B). Subsequent statistical analysis of the staining scores 
showed that there was a significant inverse correlation between the score of galectin-1 and 
galectin-9 in the tumour cells (corr. coef. -0.348, p = 0.018). while there was a positive correlation 
between galectin-1 and galectin-9 protein score in the tumour stroma (corr. coef. 0.299, p = 0.046) 
and the tumour endothelial cells (corr. coef. 0.438, p = 0.003). However, neither the galectin-1 or 
galectin-9 protein staining scores were prognostic for patient overall survival (data not shown). 
Thus, while immunohistochemical analysis did reveal differences in localization and frequency of 
galectin staining, this was not related to patient survival. 
 
 
 
Figure 4 Kaplan-Meier plots of 
disease free survival (DFS) in 
early stage NSCLC patients with 
low (Lo: below median) or high 
(Hi: above median) expression of 
galectin-1 (A), galectin-3 (B), 
and galectin-95 (C). D) Kaplan-
Meier plot of DFS in early stage 
NSCLC patients with low 
galectin-95 expression (below 
median) further grouped 
according to expression of 
galectin-1 below (Lo) or above 
(Hi) median expression. 
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Figure 5 
 
Figure 5 Images of immunohistochemical galectin-1 stainings (A: brown) and galectin-9 stainings (B: brown) of three 
different tumors. Staining was observed in tumor cell compartment (T), stromal compartment (S) and in tumor 
endothelial cells (arrows). The inset on the left shows the isotype control staining. Scale bar = 50 micrometer. The bar 
graphs showing quantification of IHC scores for galectin-1 and galectin-9 in different tumor compartments. 
 
Discussion 
Identification of early stage NSCLC patients with a poor prognosis is important since these patients 
will likely benefit from adjuvant therapy1. Here, we determined the prognostic value of the 
expression of galectins, a family of proteins involved in different steps of tumour progression, 
including immune escape, metastasis, and angiogenesis. We found mRNA expression of galectin-
1,-3,-4,-7,-8, and -9 in human NSCLC tissues. The expression of galectin-1 and galectin-3 was 
previously reported in different types and stages of lung cancer patients14,15,22. In our study, 
galectin-1, galectin-3, and galectin-8 were the most abundantly expressed galectins while the 
expression of galectin-4, galectin-7, and galectin-9 was relatively low, both in tumour tissues and 
in a number of lung cancer cell lines. This corroborates with a study by Lahm et al. who analyzed 
the expression of multiple galectins in a broad panel of cancer cell lines. They found that NSCLC 
cell lines HS-24 and SB-3 only expressed galectin-1, galectin-3 and galectin-823.  
Changes in galectin expression have been associated with disease progression and patient 
survival in different types of cancer. Thus far, only galectin-1 and galectin-3 have been evaluated 
as prognostic markers in NSCLC. Overall, a worse prognosis is observed for patients with an 
increased expression or binding capacity of both galectins14,15. Although we did not evaluate the 
binding capacity, we did not observe increased galectin-3 expression as a prognostic factor in early 
stage NSCLC patients. This is most likely due to differences in the patient inclusion criteria since 
we only included patients with stage I-IIIA NSCLC. We did find that galectin-1 mRNA expression 
was inversely correlated with overall survival and that expression above median levels indicated 
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poor prognosis. This is in line with previous studies in lung cancer14,15 as well as in other types of 
cancer24.  
Apart from galectin-1, we also found that gal-9∆5 expression positively correlated with 
both overall survival and disease-free survival and that expression below median levels indicated 
poor prognosis. To our knowledge, this is the first study that identifies gal-9∆5 as a prognostic 
marker in NSCLC. Gal9∆5 is one of the three most frequently identified galectin-9 variants. These 
three splice variants encode galectin-9 isoforms that vary in the length of the linker region between 
the two CRD domains which affects multimer formation and valency25. Indeed, data suggest that 
galectin-9 isoforms have a diverging role in tumour cells, e.g. they differently affect the adhesion 
of these cells to the ECM and endothelial cells26. Furthermore, studies suggest that the galectin-9 
isoforms differently modulate immune cell activity27,28. Together with our current observation 
these observations stress the importance of profiling the expression of individual splice variants.  
Opposite to galectin-1, increased gal-  for 
early stage NSCLC patients. This is in line with other reports in which galectin-9 expression was 
inversely correlated with cancer progression in a number of different cancer types29,30. It has been 
shown that galectin-9 mediates homo- and heterotypic cell adhesion8,31,32 and that cancer cells with 
high galectin-9 expression can form cell clusters in contrast to low expressing cells33. 
Consequently, loss of galectin-9 expression could compromise tissue integrity allowing tumour 
cells to extravasate into circulation and metastasize. Indeed, in breast cancer galectin-9 expression 
was a better predictor of distant metastasis compared to lymph node status. Nineteen out of 21 
metastasis-positive cases were galectin-9 negative and high galectin-9 expression resulted in an 
increased cumulative disease free survival of these patients29,30. Similar observations were made 
in melanoma and cervical squamous cell carcinoma33,34. Whether a correlation between galectin-
9 expression and the occurrence of metastasis also exists in NSCLC remains to be determined.  
Given the emerging role of galectin-9 in the maintenance of tissue integrity it has been 
suggested that the administration of recombinant galectin-9 could hamper tumour metastasis. 
Indeed, this has been shown for lung metastasis of 2 different colon cancer cell lines8. Interestingly, 
a recent study using a murine LLC lung cancer model indicates that galectin-9 can also prolong 
survival via the modulation of immune cells. It was found that galectin-9 triggered a signalling 
cascade leading to the differentiation of macrophages into plasmacytoid dendritic cell-like 
macrophages, resulting in a more potent immune response35. It is not yet clear whether this also 
occurs in NSCLC. Nevertheless, the finding that an increased expression of gal-
abundant splice variant, correlates with a better prognosis for early stage NSCLC patients 
corresponds well with all these reported roles for galectin-9 in cancer progression.  
Immunohistochemical analysis did reveal differences in the frequency and localization of 
galectin-1 and galectin-9 expression. In line with previous findings in different tumours, both 
galectin-1 and galectin-9 proteins could be detected in different compartments of the tumour, 
including tumour cells, tumour stroma and tumour endothelial cells15,19,24,29,34. However, there was 
no relation between IHC scores and mRNA levels. Most likely this is related to the fact that 
immunohistochemical staining represents a more qualitative evaluation rather than a quantitative 
analysis. Thus, actual protein expression levels could not be obtained from IHC staining. 
Furthermore, no galectin-9 antibodies are available that recognize specific splice variants. 
Consequently, IHC scores had no prognostic value in our patient group. This suggest that in case 
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of early stage NSCLC patients, determining galectin mRNA levels is of more value for prognostic 
analyses as compared to immunohistochemical staining.  
In summary, using extensive galectin expression profiling confirmed the prognostic value 
of galectin-1 and identified gal-9∆5 as a novel prognostic marker in early stage NSCLC. 
Identification of such markers is important to identify patients that will benefit from adjuvant 
chemotherapy. In addition, we provide evidence for the relevance of profiling individual splice 
variants of galectin-9. It remains to be determined whether splice variant-specific profiling has a 
similar benefit in other cancer types, including those in which overall galectin-9 expression is a 
prognostic marker. 
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Abstract  
Disruption of fetal-maternal tolerance mechanisms can contribute to pregnancy complications, 
including spontaneous abortion. Galectin-9 (LGALS9), a tandem repeat lectin, associated with 
immunomodulation is expressed in the endometrium during the mid- and late-secretory phases and 
in early-pregnancy decidua. However, the role of LGALS9 during pregnancy remains poorly 
understood. We used qPCR and immunohistochemical stainings to analyze the expression of 
LGALS9 during mouse gestation as well as in human tissues obtained from normal pregnancy and 
spontaneous abortions. In mice, three Lgals9 splice variants were detected of which the expression 
was differentially regulated during gestation. Furthermore, decidual Lgals9 expression was 
deregulated in a mouse model of spontaneous abortion, whereas placental levels did not change. 
We further found that the LGALS9 D5 isoform suppresses IFNG production by decidual NK cells. 
In human patients, six Lgals9 splice variants were detected and a decrease in Lgals9 D5/10 was 
associated with spontaneous abortion. Altogether, these results show a differential regulation of 
Lgals9 isoforms expression during normal and pathological pregnancies and designate Lgals9 as 
a potential marker for adverse pregnancy outcomes. 
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Introduction 
Galectin-9 (LGALS9) belongs to the galectin protein family of which all members share affinity 
for specific β-galactoside-containing glycoproteins and glycolipids 1. LGALS9 is a tandem-repeat 
galectin, consisting of two carbohydrate binding domains (CRDs) covalently bound by a flexible 
linker peptide. Traditionally, the protein has been associated with regulation of the immune system 
during inflammation and autoimmunity 2,3. In addition, LGALS9 has been implicated in tumor 
biology 4. The receptor for LGALS9 on immune cells is hepatitis A virus cellular receptor 2 
(HAVCR2, previously known as Tim-3) 5 and several findings point towards an important role for 
LGALS9 in a negative feedback loop following immune activation, preventing an excessive 
immune response. First, LGALS9 induces apoptosis in a variety of immune effector cells and 
modulates the differentiation and maturation of immune cells. For example, it has been shown that 
interferon gamma (IFNG) producing hepatitis A virus cellular receptor 2 (HAVCR2) positive T 
helper type 1 (TH1) cells are susceptible to LGALS9 induced apoptosis 4. LGALS9 can also cause 
apoptosis in CD8+ T cells 6,7 and induce dendritic cells (DC) maturation 8. The notion that LGALS9 
is a potent immunosuppressive protein is further supported by in vivo experiments in a variety of 
mouse models. For instance, Wang et al. demonstrated that the administration of recombinant 
mouse LGALS9 suppresses rejection and improves survival of allogeneic skin grafts 9. Besides its 
effects on TH1 cells, LGALS9 is also able to induce the differentiation of regulatory T cells and 
prevent the differentiation of pro-inflammatory TH17 cells from naïve T cells, suppressing 
collagen-induced arthritis (CIA) in a dose dependent manner 10. 
Pregnancy requires well coordinated mechanisms that modulate the maternal immune 
system to tolerate the fetus bearing paternal alloantigens but at the same time protect the mother 
against infections. We have previously shown that another member of the galectin family, i.e. 
LGALS1, is involved in the regulation of feto-maternal tolerance 11. Considering the immune 
suppressive function of LGALS9, we hypothesized a regulatory role for LGALS9 at the feto-
maternal interface as well. This is supported by the observation that LGALS9 is expressed in 
human endometrial epithelial cells and its expression increases during the mid- and late-secretory 
phases and in early-pregnancy decidua 12-14. We also observed LGALS9 expression in the 
endothelial cells of the human placenta 14. In addition, bovine early gestational endometrial cells, 
late gestational trophoblasts and maternal epithelial and stromal cells express LGALS9 15.  
Analysis of LGALS9 expression is complicated by the observation that cells can express 
multiple LGALS9 isoforms 14,16 which can exert diverging functions 17,18. Thus, characterization 
of Lgals9 splice variant expression is important to gain insight in the role of this protein during 
pregnancy. In this study, we set out to analyze for the first time the expression of multiple Lgals9 
splice variants during gestation, in both normal pregnancy and spontaneous abortion. Furthermore, 
we highlight differences in the expression of Lgals9 splice variants at the feto-maternal interface. 
Our results designate the Lgals9 splice variant profile as a potential marker for adverse pregnancy 
outcome, as well as an important player at the feto-maternal interface during both normal and 
pathological pregnancies. 
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Materials and Methods 
Human tissue collection 
Spontaneous abortion samples from first trimester (6-11 weeks) pregnancies were collected at the 
Gynaecology Department, San Cecilio University Hospital (Granada, Spain). Spontaneous 
abortion was confirmed by ultrasonography and bleeding. Specimens from elective terminations 
of pregnancy (6-11 weeks) were obtained from the Clínica El Sur (Malaga, Spain) and 
Ginegranada Clinic (Granada, Spain). Decidual-placental tissue was obtained by suction curettage; 
in spontaneous abortion, curettage was carried out within 24 h after diagnosis. None of the samples 
showed any evidence of necrosis or acute inflammation. All patients provided written informed 
consent for the collection of samples and subsequent analysis. This study was approved by the 
institutional review board at the University of Granada (Spain) and Charité (Berlin, Germany).  
 
Animals 
Mice were purchased from Janvier SAS and maintained in an animal facility with a 12 h light/dark 
cycle. CBA/J females were caged with DBA/2J or Balb/c males overnight and examined for a 
vaginal plug the next morning. The presence of a plug was designated as gestation day (gd) 0.5. 
Gravid females were sacrificed on gd 7.5 and 13.5 (n=5-7/group/day analyzed). Uteri and 
placentae were removed and divided into pieces for RNA isolation followed by qPCR and 
complete implantations were frozen for immunohistochemistry. Of note, samples from gd 7.5 
contained both mesometrial (MD) and anti-mesometrial decidual (AMD) compartments, whereas 
samples on gd 13.5 included decidua basalis (DB) and mesometrial lymphoid aggregate of 
pregnancy (MLAp). Procedures that involved mice were approved by state authority and the 
Medicine University of Berlin committee on Animal Use in Research and Education. 
 
RNA Isolation and cDNA Synthesis 
Total RNA was isolated using the RNeasy®Protect Mini kit (QIAgen, Netherlands) according to 
the supplier’s protocol for frozen tissue. The concentration and purity of the RNA was analyzed 
using the BioPhotometer plus (Eppendorf AG, Germany). After DNase digestion (Invitrogen, 
Germany), cDNA synthesis was performed using random primers (Invitrogen, Germany) on 1 µg 
of RNA. Nuclease-free water was added up to a final volume of 20 µL. 
 
Real-Time PCR 
Real-time PCR was performed on the CFX96 real-time PCR Detection System (Bio-Rad) using a 
standard two-step amplification protocol (Tannealing at 61°C) followed by a melting curve analysis. 
For each reaction, 1.5 µL of cDNA was used in a total volume of 25 µL containing 1x SensiMix 
(Quantace) and 400 nmol/L of the respective forward and reverse primer. Primers were designed 
to target specifically human or mouse Lgals9 splice variants (Table 1, Fig. S1). All primers were 
synthesized by Eurogentec (Liège, Belgium).  
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Table 1. Primers used to specifically detect Lgals9 splice variants in murine and human tissue.  
Lgals9 Mouse 
Splice 
variant 
Forward Reverse 
ALL CTTTCTACACCCCCATTCCA CTCGTAGCATCTGGCAAG 
FL GCAAACAGAAAACTCAGA TCCACAGCGAAGGTTGATA 
D5 ATCACCTTCCAG][ACTCAG TCCACAGCGAAGGTTGATA 
D6 GCAAACAGAAA][GCTCAAACT TCCACAGCGAAGGTTGATA 
DD10 GCAAACAGAAAACTCAGA TTCACATATGATCCACAC][CTCG 
D5/6 CTTTATCACCTTCCAG][GCTCA TCCACAGCGAAGGTTGATA 
D5/10 ATCACCTTCCAG][ACTCAG TTCACATATGATCCACAC][CTCG 
D6/10 GCAAACAGAAA][GCTCAAACT TTCACATATGATCCACAC][CTCG 
D5/6/10 CTTTATCACCTTCCAG][GCTCA TTCACATATGATCCACAC][CTCG 
Lgals9 Human 
Splice 
variant 
Forward Reverse 
ALL CTTTCATCACCACCATTCTG CTCTGAGCACTGGGCAGG 
FL GCAGACAAAAACCTCCCG CCCAGAGCACAGGTTGATG 
D5 ATCAGCTTCCAG][CCTCCC CCCAGAGCACAGGTTGATG 
D6 GCAGACAAAAA][ACCCAGACA CCCAGAGCACAGGTTGATG 
D10 GCAGACAAAAACCTCCCG TTCACACAAGATCCACAC][CTCT 
D5/6 CTACATCAGCTTCCAG][ACCCA CCCAGAGCACAGGTTGATG 
D5/10 ATCAGCTTCCAG][CCTCCC TTCACACAAGATCCACAC][CTCT 
D6/10 GCAGACAAAAA][ACCCAGACA TTCACACAAGATCCACAC][CTCT 
D5/6/10 CTACATCAGCTTCCAG][ACCCA TTCACACAAGATCCACAC][CTCT 
 
][ indicates the exon boundaries in case of intron/exon spanning primers. 
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Supplementary figure 1. Galectin-9 splice variants. 
 
 
LGALS9 immunohistochemistry 
After deparaffinization and rehydration, serial human and mouse paraffin-embedded tissue 
sections (4 µm) were washed in TBS, followed by blocking of endogenous peroxidase through 
incubation with 3% H2O2 in methanol for 30 minutes at room temperature. After incubation with 
2% normal serum for 20 minutes, primary antibody against LGALS9 (1:100, sc-19292, Santa Cruz 
Biotechnology) was incubated overnight at 4°C. The slides were then washed and incubated with 
donkey anti-goat PO-conjugated secondary Ab (1:200, Jackson ImmunoResearch, 705-035-147) 
for 1 hour at room temperature (RT). The signal was detected using liquid DAB+Substrate 
Chromogen System (DAKO, K3467) at RT. After washing, nuclei were counterstained with 0.1% 
Mayer’s hematoxylin followed by a standard dehydration procedure and mounting in Vitro-Clud 
medium (R. Langenbrinck, Germany). Negative controls with irrelevant IgG showed no specific 
immuno-reactivity. LGALS9+ cells in mouse samples were enumerated in the central and lateral 
regions of the MD and AMD (gd 7.5) or DB and MLAp (gd 13.5) on three o more 
sections/implantation site from both NP and SA groups. In addition, LGALS9 stained human 
samples were analyzed using the Image-J software, the number of positive pixels per area was 
measured digitally, indicating the level of expression for LGALS9 staining. The software identifies 
and measures positive cells by setting a threshold. After predefining the threshold of a LGALS9 
positive cell, an automatically running function was performed.  
 
DBA lectin/LGALS9 dual staining 
Uterine tissue sections from gd 13.5 were stained following our standard protocol 11. Briefly, slides 
were washed 3 times in TBS for 5 min, blocked with 2% normal serum for 20 min and incubated 
overnight at 4°C with the following primary antibody LGALS9 (1:100, sc-19292, Santa Cruz 
Biotechnology). Negative control was established by replacing the primary Ab with irrelevant IgG. 
After washing, LGALS9 stained sections were incubated 1 h at room temperature (RT) with FITC-
conjugated secondary antibodies (1:200, 703-096-147, Jackson ImmunoResearch). Biotinylated 
conjugated Dolichos biflorus agglutinin (DBA) lectin (1/2000, L6533, Sigma Aldrich) [19] was 
incubated overnight at 4°C followed by Rhodamine (TRITC)-Avidin D (1:200, A-2002, Vector 
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Laboratories) for 1 hour at RT. Nuclei in all sections were counterstained by incubating 5 min in 
DAPI solution, followed by washing and mounting in Immumount medium (Shandon). Sections 
were analyzed using a confocal laser scanning microscope (cLSM 510, Carl Zeiss).  
 
Decidual NK cell purification and cell culture 
Uteri were collected, washed with sterile PBS, carefully cut into small pieces, collected in tubes 
containing sterile HBSS and digested for 20 min at 37°C under slight agitation in HBSS with 200 
U/ml hyaluronidase (H3506, Sigma, Germany), 1 mg/ml collagenase (type C-2139, Sigma), 0.2 
mg/ml DNase I (1284932, Boehringer Mannheim GmbH, Germany) and 1 mg/ml BSA/fraction V 
(A9418, Sigma). Thereafter, the isolated cells were collected in a fresh tube through a 40 µm net 
(Becton Dickinson, San Francisco, USA) and washed with RPMI 1640-10% FBS. The procedure 
was repeated twice, with sterile HBSS medium containing no cocktail of enzymes. Cells were 
resuspended and centrifuged at 1500 g for 10 min at RT. Trypan blue exclusion revealed that cell 
viability was about 95%. Then we isolated the KLRB1C (previously known as NK1.1) positive 
cell fraction by magnetic cell sorting. For collection of cells expressing KLRB1C to use in cell 
culture, uterine suspensions were incubated (30 min, 4°C) with biotinylated mouse anti-mouse 
KLRB1C (clone PK136, BD Bioscience) diluted 1:100 in labeling buffer (PBS supplemented with 
2mM EDTA. After washing, cells were incubated (15 min, 4°C) with Streptavidin MicroBeads 
(130-048-101) and processed using magnetic cell sorting (MACS) to collect KLRB1C+ cells. 
Examination by FACS® revealed that >95% of selected cells by miniMACS expressed KLRB1C. 
Cells were placed at a density of 2x105cells/well in the presence of recombinant LGALS9 D5 (50, 
100nM, R&D Systems), lactose (10mM, Sigma Aldrich), IL15 (50ng/ml, R&D systems) or media 
and incubated for 48h. Cultures were performed at 37°C in a 5% CO2 atmosphere in RPMI 1640 
supplemented with antibiotic (50U/ml penicillin and 50 µg/ml streptomycin), 2g/L sodium 
bicarbonate, 2mM L-glutamine, 1mM pyruvate and 10% fetal bovine serum (FBS).  
 
Cytometric bead array (CBA) analysis of secreted IFNG  
Supernatants from 48h cell culture were harvested and stored at -80°C until cytokine testing was 
performed. IFNG were detected using the mouse inflammation cytokine cytometric bead array kit 
(BD Biosciences, Germany). Briefly, 50 µl of each sample was mixed with 50 µl of mixed capture 
beads and 50 µl of the mouse inflammation PE detection reagent consisting of PE-conjugated anti-
mouse IFNG. The samples were incubated at room temperature for 2 h in the dark. After incubation 
with the PE detection reagent, the samples were washed once and resuspended in 300 µl of wash 
buffer. Data were acquired on the FACS Calibur (BD Biosciences, Germany) and analyzed using 
FCAP Array TM software (BD Biosciences, Germany). Standard curve was generated for IFNG 
using the cytokine standard provided by the kit. The range of IFNG detection was 20–5000 pg/ml. 
 
Statistical Analysis 
Real time PCR data are shown as mean values ± SD. The Mann-Whitney rank sum test was used 
to calculate statistically significant differences in mRNA expression. P values <0.05 were 
considered statistically significant, and all calculations were performed using the SPSS 12.0.1. 
Software (SPSS Inc., Gorinchem, the Netherlands). 
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Figure 1. LGALS9 expression in normal 
and pathological mouse pregnancies. (A) 
Real time PCR of Lgals9 ALL was performed 
in decidual tissue on gd 7.5 and 13.5 in normal 
pregnancy (NP; CBA/J x Balb/c; n=5/day 
analyzed) and spontaneous abortion (SA; 
CBA/J x DBA/2J; n=5/day analyzed) mouse 
models. V= virgin female; non pregnant 
uterus. Data are shown as mean values ± SD. 
* denotes p<0.05 as analyzed by Mann-
Whitney rank sum. (B) Localization of 
LGALS9 at the feto-maternal interface of NP 
and SA mice as identified by 
immunohistochemistry at gd 7.5. Left: 
Schematic diagram of a mouse implantation 
site at gd 7.5. Right: Upper panels show 
representative stainings in the mesometrial 
decidua (MD), lower panels in anti-
mesometrial decidua (AMD). EC = 
embryonic cavity, VZ = vascular zone. Scale 
bar = 50 µm. The number of LGALS9+ 
cells/mm2 on gd 7.5 as analysed by light 
microscopy using 400X magni-fication. No 
significant differences were observed. Data 
are shown as mean values ± SD of five to 
seven animals/group. (C) Left: Schematic 
diagram of a mouse placenta and decidua at gd 
13.5. Right: LGALS9 localization in deciduas 
of NP and SA mice at gd 13.5 as identified by 
immunohistochemistry. Upper panels show 
representative images of LGALS9 staining in 
the mesometrial lymphoid aggregate of 
pregnancy (MLAp) and lower panels in the 
decidua basalis (DB). SpA= spiral arteries, 
ML= maternal lacunas. Scale bar = 50 µm. 
The number of LGALS9+ cells/mm2 in the 
decidua was analyzed by light microscopy 
using 400X magnification. Data are shown as 
mean values ± SD of five to six 
animals/group. * denotes p<0.05 as analyzed 
by one way ANOVA.  
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Results 
 
Normal pregnancy and spontaneous abortion mouse models are characterized by distinct decidual 
Lgals9 splice variant profiles  
To characterize LGALS9 during pregnancy, we analyzed the LGALS9 expression at the 
feto-maternal interface in two mouse models. The mating of CBA/J female mice with Balb/c males 
analysed in the present study defines a normal pregnancy (NP), while DBA/2J-mated CBA/J 
females are considered a mouse model for spontaneous abortion (SA), in which the abortion rate 
(10-15%) is increased when compared to normal pregnancy (2%) 19. First we compared decidual 
total Lgals9 mRNA levels by qPCR between gestation day (gd) 7.5 (peri-implantation period) and 
gd 13.5 (placentation period completed). This showed that, decidual total Lgals9 mRNA 
expression increased from gd 7.5 to 13.5 during NP and SA models, but this increase was only 
statistically significant during NP (Fig. 1A). We observed no statistically significant differences 
between the normal and pathological pregnancies at gd 7.5, although there was a trend towards 
increased Lgals9 expression in SA decidual tissues. As pregnancy progressed to gd 13.5 the Lgals9 
mRNA levels in deciduas from SA mice significantly increased compared to those observed in NP 
mice.  
 
Figure 2. Profile of 
Lgals9 splice variants 
in normal and 
pathological 
pregnancy. (A) Lgals9 
splice variants were 
determined by real time 
PCR. In the murine 
uterus, the FL, D5, and 
D5/6 splice variants were 
detected, whereas the 
D6, D5/10, D6/10, 
D5/6/10, and D10 splice 
variants were not 
detectable. Quantitative 
PCR of Lgals9 splice 
variants was performed 
in gd 7.5 and gd 13.5 
decidual tissues of NP, 
SA mice and in the non-
pregnant uterus. Data are 
expressed as mRNA 
expression (2-DCt). The 
(B) FL, (C) D5, and D5/6 
(D) splice variants were 
analyzed. ND = not 
detected. In all figures, 
data are shown as mean 
values ± SD of five to 
seven animals/group. * 
denotes p<0.05 as 
analyzed by Mann-
Whitney rank sum test.  
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Next, we investigated total LGALS9 protein levels at the murine feto-maternal interface 
on gd 7.5 and gd 13.5 using immunohistochemistry. During early gestation, i.e. on gd 7.5, 
LGALS9 was observed in the vascular zone, mesometrial (MD) and anti-mesometrial decidua 
(AMD). Interestingly, while LGALS9 in the MD was localized predominantly within the cell 
nucleus, it was restricted to the cytoplasm of cells in the AMD and vascular zone (Fig. 1B, left 
panels). The implantation sites of the SA females exhibited the same localization and pattern of 
LGALS9 expression (Fig. 1B; right panels) and the number of positive cells were comparable in 
both models (Fig. 1B). In advanced gestation, i.e. on gd 13.5, we detected cytoplasmic LGALS9 
expression in endothelial cells and NK cells in the mesometrial lymphoid aggregate of pregnancy 
(MLAp) (Fig. 1C, upper panel). Additionally, endothelial cells of the spiral arteries and other 
maternal blood vessels (maternal lacunas) in the decidua basalis (DB) exhibited a pronounced 
cytoplasmic immuno-reactivity for LGALS9 (Fig. 1C, lower panel). The total number of LGALS9 
expressing cells in both MLAp and DB was significantly elevated in SA compared to NP mice 
(Fig. 1C).  
Knowing that LGALS9 can be expressed as multiple isoforms, we next analyzed the 
presence of Lgals9 splice variants in the mouse uterus and decidua. Since Lgals9 splicing in 
humans appears to be confined to exons 5, 6, and 10, we analyzed all potential combinations in 
the mouse samples (deleted exon (D) 5, D6, D10, D5/6, D5/10, D6/10 and D5/6/10) as well as the 
full length (FL) variant. This revealed that the FL, D5, and D5/6 splice variants were expressed at 
detectable levels in the murine uterus while the D6, D5/10, D6/10, D5/6/10, and D10 splice 
variants could not be detected (Fig. 2A). For further analysis we focused on the detectable variants. 
Lgals9 FL significantly increased in both NP and SA deciduas from gd 7.5 to gd 13.5 (Fig. 2B). 
Expression of the predominant splice variant, i.e. Lgals9 D5, remained unchanged during normal 
pregnancy, while it was increased in SA mice from gd 7.5 to gd 13.5, respectively (Fig. 2C). When 
comparing the groups to NP mice at gd 13.5, we observed that Lgals9 D5 was increased in SA 
deciduas. The expression of Lgals9 D5/6 mRNA did not change significantly in the deciduas of 
NP and SA mice as pregnancy progressed. In addition, Lgals9 D5/6 expression was augmented in 
SA deciduas on gd 13.5 when compared to the NP model (Fig. 2D). In contrast, no differences 
were found in placental Lgals9 mRNA levels of the splice variants between the NP and SA mice 
(Fig. 3). 
 
LGALS9 D5 down-regulated the IFNG production by decidual NK cells 
As the predominant splice variant Lgals9 D5 was up-regulated in SA during the peri-implatation 
period (gd 7.5), we wanted to analyze the effect of the LGALS9 D5 isoform on IFNG production 
by NK cells. Therefore, ex vivo experiments were done to clarify whether LGALS9 D5 is involved 
in the regulation of IFNG production by NK cells. When decidual NK cells were treated with 
LGALS9 D5 100nM for 48 h, IFNG secretion was down-regulated (Fig. 4A), indicating that 
LGALS9 D5 suppressed IFNG production by NK cells. Furthermore, we found that LGALS9 D5 
suppressed IFNG secretion in a dose dependent manner (Fig 4A). Such LGALS9 D5 mediated 
suppression was significantly inhibited by lactose, indicating that LGALS9 D5 mediated 
suppression was carbohydrate-dependent (Fig. 4A). Knowing that IFNG production by NK cells 
is important for maturation of the maternal vasculature and remodeling of the spiral arteries; we 
next evaluated the expression of LGALS9 on NK cells later during gestation (gd 13.5) in the NP 
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and SA models. As shown in Fig. 4B, a greater proportion of the NK cells (DBA Lectin + cells) 
in the MLAp and DB expressed LGALS9 in the SA model compared with NP tissues.     
 
 
Figure 3. Profile of Lgals9 splice variants in placenta tissues.  (A) The total Lgals9 level in NP and SA placentas 
was determined by real time PCR at gd 13.5. The levels did not differ between the groups. (B) FL, (C) D5 and (D) 
D5/6 splice variant analyses did not show any differences between NP and SA placentas. Data are shown as mean 
values (mRNA expression 2-DCt) ± SD of five to six animals/group and were analyzed by Mann-Whitney rank sum 
test. (E) Immunohistochemistry was used to identify LGALS9 expressing cells within the placenta at gd 13.5. Left: 
Schematic diagram of murine placenta and decidua at gd 13.5. Upper panels on the right show representative images 
of the junction zone (JZ). The lower panels represent images of the labyrinth (Lab) compartments of the placenta. 
Scale bar = 125 µm.  
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Lgals9 D5/10 expression is decreased during human spontaneous abortion  
To assess LGALS9 expression during human pregnancies, first we analyzed Lgals9 levels of 
freshly isolated first trimester samples from healthy pregnant women undergoing elective 
termination of pregnancy and spontaneous abortion patients by real time PCR. It should be noted 
that these samples contained both the decidual and placental compartments. Total Lgals9 ALL 
expression levels in SA tissues were similar to NP tissues (Fig. 5A). Next, we assessed LGALS9 
protein expression at the feto-maternal interface by immunohistochemistry. Decidual cells showed 
a strong LGALS9 expression in the cytoplasm and nucleus during normal pregnancy (Fig. 5B, left 
upper panel). Interestingly, the LGALS9 expression in the placental compartment, comprising 
stromal and cytotrophoblast cells (CTB), was lower than in the decidua (Fig. 5B, left lower panel). 
The protein was mostly localized to the cytoplasm of stromal cells, although some cells showed 
an additional nuclear staining. LGALS9 expression in CTBs was cytoplasmic, while the signal 
was absent from syncytiotrophoblasts (SynCTB). When comparing NP to SA deciduas, we did not 
observe any differences (Fig. 5B-C). Comparable to NP samples, the CTBs of SA placentas 
samples expressed LGALS9 in their cytoplasm. The localization of LGALS9 protein did not differ 
between both groups, but LGALS9 expression was significantly reduced in the stroma of SA 
patients compared to NP placentas (Fig. 5B-C).  
Figure 4. Effect of LGALS9 
D5 on IFNG production by 
decidual NK cells. (A) 
LGALS9 D5 suppressed IFNG 
production by NK cells in a 
dose dependent manner (**, 
denotes p<0.01 as analyzed by 
ANOVA followed by Turkey’s 
test). Further, suppression of 
IFNG production by LGALS9 
D5 (100 nM) was inhibited by 
lactose (10 mM, p<0.05). Data 
represent mean ± SEM from 
triplicates of two independent 
experiments. (B) 
Colocalization of 
LGALS9/DBA lectin was 
assessed on sections from gd 
13.5 (scale bar= 100 µm) of 
normal pregnancy (NP; n=5) 
and spontaneous abortion (SA; 
n=5) by immunofluorescence. 
Abbreviations: MLAp= 
mesometrial lymphoid 
aggregate of pregnancy and 
DB= decidua basalis. Scale bar 
= 100 µm. 
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In order to characterize the Lgals9 splice variants expression in normal and spontaneous 
abortion during early gestation, we analyzed the FL, D5, D5/6, D5/10, D5/6/10, and D6 Lgals9 
splice variants, with FL and D5 being the predominant splice variants. When comparing Lgals9 
splice variant levels in NP and SA samples, we observed that Lgals9 D5/10 was the only splice 
variant with significantly decreased expression in the SA group (Fig. 5D).  
 
  
 
Figure 5. Lgals9 splice variants profile 
during human pregnancy. (A) The total 
Lgals9 ALL levels did not differ between 
NP and SA patients. Fresh first trimester 
samples (n=18, decidua + placenta) from 
normal pregnancy (NP) and spontaneous 
abortion (SA; n=22) patients were isolated 
and Lgals9 levels were measured by real 
time PCR. (B) Localization of LGALS9 
was assessed in first trimester deciduas 
(scale bar= 100 µm) of normal pregnancy 
(NP; n=18) and spontaneous abortion (SA; 
n=22) patients by immunohistochemistry. 
Abbreviations: S=stroma, 
CTB=cytotrophoblasts, SynCTB= 
syncytiotrophoblasts. (C) Quantification of 
LGALS9 staning using Image J. Graphics 
represent pixels/standarized area in the 
decidua or placenta. (D) mRNA expression 
levels of Lgals9 splice variants. The 
difference between the NP and SA samples 
was significant for the Δ5/10 splice variant. 
Data are shown as mean values ± SD. * 
denotes p<0.05, as analyzed by Mann-
Whitney rank sum test. 
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Discussion 
During pregnancy, a fine regulation of the maternal immune system induces tolerance of paternally 
derived antigens carried by the embryo. Nevertheless, a competitive immune system is able to 
protect the mother from infections. As a first step in exploring the role played by LGALS9 in this 
process, we characterized the expression of LGALS9 in mice and humans during normal 
pregnancy and compared this with the expression during pathological pregnancy, i.e. spontaneous 
abortion. Since human studies during the first trimester are limited to elective interruptions and 
spontaneous abortions, we took advantage of mouse models which represent normal and 
pathological pregnancies. Balb/c-mated CBA/J female mice analysed in the present study undergo 
normal gestations, while mating with DBA/2Jmales constitutes a mouse model for SA, in which 
the abortion rate (10-15%) is increased when compared to normal pregnancy (2%) 19.  
Using real time PCR we showed a gestation-related increase of Lgals9 ALL in the decidua 
of normal pregnancy mice suggesting that Lgals9 accompanies the course of a successful 
pregnancy. In this context, it is known that soon after implantation (i.e. gd 5.5) there is a shift from 
TH1 to TH2 cytokines at the fetal-maternal interface, which helps in the maintenance of pregnancy 
20-22. Interestingly, LGALS9 is able to limit TH1 immunity, activate tolerogenic dendritic cells 
(DC) and induce immuno-regulatory mechanisms 5,8-10, which can explain the increase of LGALS9 
during the course of normal pregnancy. However, we did not observe the up-regulation of Lgals9 
ALL in the spontaneous abortion mouse model (CBA/J x DBA/2J) from gd 7.5 to 13.5; confirming 
that a less defined TH1 and TH2 milieu characterizes this model. For instance it has been shown 
that paternal antigens in the CBA/J x DBA/2J mouse model fail to induce the switch to TH2 
cytokines after implantation 19 and as a consequence an increase of embryo death is observed in 
this mating combination 23. Thus, the notion that LGALS9 could participate in the limitation of 
TH1  cytokines 5 during the shift to a TH2 milieu is further supported by the impaired decidual 
Lgals9 response in SA implantations.  
Our results showed similar trends of Lgals9 placenta expression between the NP and SA 
models. Although healthy embryo-placenta units coexist with resorption sites (necrotic and 
hemorragic tissue derived from a non-healthy placenta-embryo unit) on gd 13.5, we only included 
healthy implantation sites in our study. Taking this into consideration, our data suggests that 
Lgals9 expression is similar in healthy placenta units from both mouse models. However, we 
cannot exclude the possibilty that at the beginning of the abortion process (around gd 8.5 to 10.5) 
Lgals9 expression could be dysregulaled since Lgals9 expression on decidual tissue is sensitive to 
the number of healthy embryos carried. In addition, Lgals9 mRNA levels in the placenta are higher 
than the decidua, suggesting that Lgals9 could be important for placental development.  
When studying Lgals9 expression it is important to note the several splice variants 
described to date, which differ in the inclusion of exons 5, 6 and 10 in the mature mRNA transcript. 
These splice variants can have diverging functions. For example, Lgals9 FL is a more potent 
eosinophil chemoattractant compared to Lgals9 D5 17 and is more susceptible to thrombin cleavage 
24. In addition, ectopic expression of Lgals9 FL decreases E-selectin expression in LoVo colon 
carcinoma cells whereas Lgals9 D5 and Lgals9 D5/6 increase the expression of E-selectin 18. 
Alternative Lgals9 splicing is also relevant in the context of immune system modulation, as the 
linker length, encoded by exons 5 and 6, has been shown to influence the apoptotic effect of 
LGALS9 on T cells 25 and the N- and C-terminal CRD contribute differentially to this process 26. 
At the murine feto-maternal interface, we detected the expression of Lgals9 FL, Lgals9 D5 and 
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Lgals9 D5/6, with Lgals9 D5 being the predominant splice variant. The relative amounts of each 
splice variant are consistent with those found in most other tissues [16]. In line with this, Lgals9 
D5 levels in the different mouse models closely resemble those we observed when assessing 
overall Lgals9 levels. Of interest, the increase from gd 7.5 to gd 13.5 in overall Lgals9 levels 
during normal pregnancy seem to be mainly due to an increase of Lgals9 FL, since a large increase 
in expression of this splice variant is found, contrary to Lgals9 D5. Conversely, Lgals9 D5/6 levels 
actually appear to decrease in normal pregnancy from gd 7.5 to gd 13.5, further supporting the 
relevance of assessing the expression of individual Lgals9 splice variants. Unfortunatly, no 
antibodies are available at this time to distinguish between these variants and developing such a 
tool would be of great value to study the actual functional contribution of each Lgals9 splice variant 
during pregnancy.  
Localization of overall LGALS9 protein at gd 7.5 was found at both the MD and AMD. Of 
note, in the MD LGALS9 is localized predominantly in the nucleus, while in the AMD it is in the 
cytoplasm and on the cell surface suggesting a differential role of this lectin during early gestation. 
For instance, during decidualization, stromal cells differentiate into decidual cells, but only stromal 
cells from the AMD undergo endoreduplication and become polyploid giant cells in order to 
increase their biosynthetic capacity and thus support embryonic growth 27. The cytoplasmatic 
localization of LGALS9 in stromal cells from the AMD could be important for cell differentiation, 
since LGALS9 was reported to influence immune cell differentiation 28. In addition, the role of 
this lectin in reducing cell adhesion by preventing cell binding to ligands on the vascular 
endothelium and extracellular matrix 29-31 could be also relevant for the AMD, in which deposition 
of collagen decreases less rapidly than in the MD pole during normal pregnancy, preventing 
trophoblast invasion and migration 32.  
We previously reported that the expression of LGALS9 in human umbilical vein 
endothelial cells is decreased while the membrane-bound portion of LGALS9 is increased upon 
cell activation 14. These findings suggest that the LGALS9 level may influence stromal cell 
differentiation and vascular processes in the MD. Indeed, LGALS9 expression was mainly found 
in the granules of NK cells within the MD pole, implying that this lectin may influence their 
functions during pregnancy. Here we provided evidence for the role of LGALS9 D5 in suppressing 
IFNG secretion  by NK cells. Since IFNG producing NK cells are known to be crucial for decidual 
artery remodelling into spiral arteries 33, it is tempting to speculate that LGALS9/HAVCR2 
signaling could be involved in these processes. During mid-gestation, the maternal spiral arteries 
expand in order to increase blood flow to the placental bed 34 and mature NK cells facilitate dilation 
of spiral arteries 35. Our results showed that the number of LGALS9 expressing NK cells are 
increased in SA compared to NP model, sugesting that accumulation of mature NK cells in the 
MLAp could be a compensatory mechanism triggered in SA to sustain placental function. Indeed, 
DBA mated CBA/J females showed some features of preeclampsia, in which complement 
activation increased tissue factor expression causing dysregulation of angiogenic factors 36.  
Finally, we profiled Lgals9 splice variant expression in first trimester (6-11 weeks) human 
samples. We did not observe any significant changes in expression of the most dominant splice 
variants when comparing NP to SA samples, which could be due to the fact that both the placental 
and decidual compartments were analyzed, instead of separately as was done with the mouse 
samples. Whether Lgals9 levels change significantly in the decidua and placenta during human 
pregnancy remains to be determined. However, we did observe a significant decrease of  Lgals9 
D5/10 mRNA in samples from spontaneous abortion patients. Just as Lgals9 D5/6/10 and  Lgals9 
Chapter 3 
 
64 
D6, Lgals9 D5/10 was not detected in mouse samples. In fact, Lgals9 splice variants lacking exon 
10 might be human specific 37. At this time, there are no studies yet reporting on the functional 
role of Lgals9 splice variants lacking exon 10, although initial results show these splice variants 
are not secreted and presumably act solely intracellularly 37. Thus, it is tempting to speculate 
Lgals9 D5/10 may play an important role in ensuring succesful pregnancy, as a decrease of Lgals9 
D5/10 was associated with spontaneous abortion. 
Previous studies reported on the expression of LGALS9 during the window of implantation 
and in normal human early decidua 12,13. We provide splice variant-specific profiling at the feto-
maternal interface in both murine and human samples of normal pregnancy and spontaneous 
abortion. The relevance of detecting specific Lgals9 splice variants is supported by the diverging 
expression patterns and changes in expression we observed. Moreover, we show Lgals9 splice 
variant expression changes significantly in the decidua of spontaneous abortion models compared 
to normal pregnancy, providing the first line of evidence linking this disorder to dysregulated 
Lgals9 expression. As such, it would be interesting to analyse the dinamics  of Lgals9 expression 
at the maternal-fetal interface and determine whether it could indeed function as a diagnosis marker 
for fetal loss in larger patient groups.  
 
. 
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Abstract 
We previously reported that endothelial cells express galectin-9 and that its expression is regulated 
upon endothelial cell activation. However, the function of galectin-9 in the endothelium remained 
unclear. Here, we show that galectin-9 levels are increased on the tumor endothelium and that 
endothelial cells express 5 galectin-9 splice variants, of which one novel variant: gal-9Δ5/6/10. 
Furthermore, we show that endothelial cells secrete galectin-9 and our data suggest that exogenous 
galectin-9 predominantly has an immune-suppressive role in tumor biology, rather than a role in 
tumor angiogenesis.  
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Introduction 
Galectins are a family of sugar binding proteins characterized by the presence of one or two 
conserved carbohydrate recognition domains (CRDs) 1,2. These CRDs have a high affinity for beta-
galactoside containing carbohydrate chains present on glycoconjugates. Three subgroups of 
galectins have been described; prototype galectins, which consist of one CRD that can form 
homodimers, tandem-repeat galectins, in which 2 CRDs are joined by a linker domain, and 
chimaera galectins which have a single CRD  linked to an atypical N-terminal domain 2. Aside 
from their sugar binding activity, galectins also engage in direct protein-protein interactions 3. 
These two modes of interaction allow galectins to contribute to several aspects of tumor growth 
and agressiveness 4. For example, galectins have been shown to contribute to tumor cell 
transformation, e.g. by enabling H-ras signal transduction 5. Galectins also promote tumor immune 
escape, by inducing an immuno-regulatory signature in T cells 6,7. In addition, several galectin 
family members have been implicated in tumor cell invasion and metastasis 8-12. Consequently, 
altered galectin expression in tumors is frequently associated with poor patient survival 13-17. We 
recently identified a galectin-9 splice variant lacking exon 5, i.e. gal-9∆5, as a prognostic marker 
in non-small cell lung cancer. The overall survival of patients with decreased gal-9∆5 expression 
was significantly shorter as compared to those with higher expression levels. Subsequent 
immunohistochemical staining identified high galectin-9 protein expression in the tumor 
endothelial cells. Interestingly, increased endothelial expression of galectin-1, galectin-3 and 
galectin-8 have previously been associated with enhanced angiogenic activity in tumors 18-22. For 
example, tumor derived galectin-1 can activate endothelial cells and can complement the 
endothelial galectin-1 pool thereby facilitating tumor angiogenesis 23-25. Likewise, the tandem 
repeat galectin-8 was shown to promote endothelial cell function in vitro as well as angiogenesis 
in vivo19. Pro-angiogenic activity has also been attributed to galectin-3 21,26 further illustrating the 
important role of galectins in tumor progression.  
Thus far, the role of galectin-9 in angiogenesis is unresolved. Galectin-9 has been mainly 
studied in the context of immune-modulation27. For example, galectin-9 is a secreted 
chemoattractant for eosinophils 28 and a potent inducer of apoptosis in activated Th1 cells 
29. In 
recent years, the clinical benefit of interfering with these galectin-9 actions in certain pathological 
settings is emerging 30-34. To get more insight in the function of galectin-9 in endothelial cell 
biology and angiogenesis we studied the expression of galectin-9 splice variants in endothelial 
cells. We found that endothelial cells  express 5 different splice variants, one of which has not been 
described before, i.e. gal-9Δ5/6/10. Furthermore, we show that gal-9Δ5 is secreted by endothelial 
cells and modulates endothelial cell function in vitro and angiogenesis in vivo. Finally, we 
demonstrate that endothelial gal-9Δ5 preferentially inducs apoptosis of cytotoxic T cells.   
 
 
 
 
Chapter 4 
 
70 
Materials and methods 
Isolation of primary cells and cell culture 
Primary human umbilical vein endothelial cells (HUVECs) were isolated as described previously 
35. Quiescent HUVEC were directly harvested from the umbilical cord without further culturing. 
Activation of HUVEC was achieved by culturing the cells for at least three days in culture medium 
supplemented with 20% human serum. This has already been shown to induce sufficient EC 
activation causing alterations in galectin expression 35. HUVEC and immortalized human 
microvascular endothelial cells (HMEC-1) were cultured at 37°C/5% CO2 in RPMI (Gibco) 
containing 10% fetal calf serum (Invitrogen) and 10% human serum supplemented with L-
glutamin (Invitrogen) and penicillin/streptomycin (Invitrogen).  
 
RNA isolation, cDNA synthesis and real-time PCR 
RNA was isolated using the RNeasy kit (QIAgen) accoding to the supplier’s protocol. Isolations 
were subjected to on-column DNaseI digestion (QIAgen). The purity and concentration of the 
RNA samples was determined by spectrophotometry (ND-1000, Nanodrop technologies). cDNA 
synthesis was performed on 500 ng total RNA using the iScript cDNA synthesis kit (BioRad) 
according to the supplier’s protocol. Real time PCR was performed on the CFX96 real time PCR 
detection system (BioRad). In short, 1.5 µL of cDNA was used in a total reaction volume of 25 
µL containing 1x SensiMix (Quantace) and 400 nmol/L of galectin-9 splice variant specific 
primers (Supplementary Table 1). A standard 2-step amplification protocol was used with Tm = 
61°C followed by a melting curve analysis. Measurements were performed on at least 3 different 
HUVEC isolations or in triplicate for cell lines. To compare expression levels between different 
conditions, the ΔΔCt method was used as described previously 35. 
 
Supplementary Table 1. Galectin-9 splice variant-specific primers 
Gal-9 variant Forward (5' - 3') Reverse (5' - 3') 
ALL CTTTCATCACCACCATTCTG CTCTGAGCACTGGGCAGG 
FL GCAGACAAAAACCTCCCG CCCAGAGCACAGGTTGATG 
∆5 ATCAGCTTCCAGCCTCCC CCCAGAGCACAGGTTGATG 
∆5/6 CTACATCAGCTTCCAGACCCA CCCAGAGCACAGGTTGATG 
∆5/10 ATCAGCTTCCAGCCTCCC TTCACACAAGATCCACACCTCT 
∆5/6/10 CTACATCAGCTTCCAGACCCA TTCACACAAGATCCACACCTCT 
∆6 GCAGACAAAAAACCCAGACA CCCAGAGCACAGGTTGATG 
∆6/10 GCAGACAAAAAACCCAGACA TTCACACAAGATCCACACCTCT 
∆10 GCAGACAAAAACCTCCCG TTCACACAAGATCCACACCTCT 
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Cloning of galectin-9 splice variants 
Endothelial galectin-9 splice variants were cloned from HUVEC cDNA into the pCR2.1 TOPO 
vector using the TOPO TA cloning kit (Invitrogen). Galectin-9 flanking primers were used for the 
cloning PCR (forward primer: 5’- ATGGCCTTCAGCGGTTCC; reverse primer 5’-
CTATGTCTGCACATGGGTCAG). Ligation products were transformed into OneShot TOP10 E. 
Coli (Invitrogen) and grown overnight on LB plates containing ampicillin. Positive clones were 
selected by insert PCR with M13 primers. Midipreps were performed with the QiaPrep Spin 
Midiprep Kit (Qiagen), according to the supplier’s protocol. To obtain eukaryotic expression all 
galectin-9 splice variants were directionally cloned into pcDNA3.1 using HindIII/XhoI digestion 
and subsequent ligation with T4 DNA Ligase (New England Biolabs). Successful cloning was 
confirmed by restriction enzyme digestion and sequence analysis performed by BaseClear (Leiden, 
the Netherlands).  
 
Transfection and recombinant gal-95 
For gain of function experiments, HMEC were seeded in 96-well plates coated with 0.2% 
gelatin/PBS at a density of 1.5x104 cells/well. The next day, the subconfluent cells were transfected 
with the appropriate constructs using lipofectamine LTX and PLUS reagent (Invitrogen) according 
to the supplier’s protocol. 72 hours following transfection, functional assays, i.e. migration and 
proliferation, were performed. To assess the secretion of galectin-9 splice variants by endothelial 
cells, transfected HMEC were grown for 48 hours in culture medium after which the cells were 
washed with PBS and continued to grow in serum-free medium. After 24 hours, the serum-free 
medium was collected for western blot analysis.  
 
Protein isolation and near-infrared Western Blotting 
For Western blot analysis, cells were lysed in the culture plates using cell lysis buffer (Cell 
Signaling) supplemented with protease inhibitors according to the supplier’s protocol. Protein 
concentrations were determined using the BCA protein assay (Pierce). Subsequently, 30 µg of 
protein was suspended in Laemlli sample buffer (Biorad) supplemented with 1:20 β-mercapto-
ethanol. Samples were boiled for 5 minutes and immediately separated by gel electrophoresis on 
a 15% polyacrylamide gel and transferred onto PVDF membranes (Millipore) following standard 
protocols. Membranes were blocked with Oddyssey blocking buffer (LI-COR Biosciences) for 1 
hour and incubated overnight at 4°C with goat anti-galectin-9 antibody (1:500, R&D systems), 
which recognizes the N-terminal part of gal-9. Equal loading of the gels was confirmed by α-actin 
detection using mouse anti-α-actin (1:10000, MP Biomedicals). The membranes were washed 
three times with PBS/0.1% tween and subsequently incubated with the appropriate secondary 
IRDye antibodies (IRDye 800 anti-goat and IRDye 800 anti-mouse, LI-COR Biosciences) for 1 
hour at room temperature. Finally, membranes were washed two times with PBS/0.1% tween and 
rinsed with PBS. Images were obtained by scanning the membranes with the Odyssey infrared 
imaging system (LI-COR Biosciences). 
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Immunohistochemistry 
Galectin-9 immunohistochemistry was performed on tissue-micro arrays of 4 different cancer 
types (Super Bio Chips); kidney (CL), liver (CSA), lung (CCA) and breast (CBA) according to 
the supplier’s protocol. Each array contains 50 tumor sections and 9 matched control sections, i.e. 
sections made from adjacent non-malignant tissue. As a primary antibody, we used a polyclonal 
goat anti-human galectin-9 antibody (1:500, R&D systems). Galectin-9 was visualized by DAB 
staining of a polyclonal HRP-conjugated rabbit-anti-goat secondary antibody (DAKO 1:500). 
Blind scoring was performed by two independent observers who first assessed the overall staining 
intensity on a single array. Next, we used a 3-step scoring scale to score individual sections: 0 for 
absent or very low staining, 1 for moderate staining and 2 for strong staining. Scoring was 
performed for both tumor cells (their non-malignant counterparts) and endothelial cells.  
 
In vitro proliferation and migration assays 
To assess endothelial cell proliferation and migration, HMEC were transfected with galectin-9 
splice variants and used in functional assays 72 hours post transfection. Alternatively, HUVECs 
were incubated with a concentration range of exogenous recombinant gal-9D5 (R&D systems) for 
48 hours (proliferation) or during the scratch assay (migration). The CellTiter-Glo assay (Promega) 
was used to assess the proliferation rate of endothelial cells. In short, cells in a 96 well plate were 
washed and incubated with 100 ml CellTiter-Glo reagent for 10 minutes on a shaker. Next, 
luminescence levels were determined on a microplate reader (Tecan). Endothelial cell migration 
was assessed by creating a scratch in a confluent layer of endothelial cells, followed by monitoring 
of its closure. Images of each scratch were automatically acquired at t = 0 and t = 8 hours with a 
1.4 Mb GiGE color camera (Hitachi) on a DMI3000B microscope equipped with an automated 
xyz-stage (Leica) using Universal Grab software (version6.3, DCIlabs). Scratch area was 
determined using Scratch Assay software (version6.2, DCIlabs). All experiment were performed 
in triplicate and within each experiment there were three replicates of all treatment conditions.  
 
Chick chorioallantoic membrane assay 
Fertilized chicken eggs (Het Anker, the Netherlands) were incubated and rotated at a relative air 
humidity of 65% and a temperature of 37.6°C in a hatching incubator with an automatic rotator 
for 3 days. On embryonic day 3 (EDD3), a small opening of approximately 3 mm in diameter was 
made in the eggshell at the top of the egg and sealed with tape. The eggs were then incubated for 
3 days with the opening facing upwards. On EDD6, the eggs were opened further to allow easier 
access to the chorioallantoic membrane. For the topical application of recombinant gal-9D5, 
polyethylene rings were deposited on the CAM. From embryonic EDD6 to EDD9, recombinant 
gal-9D5 was applied daily within the polyethylene rings. Finally, on EDD10, pictures of the 
chorioallentoic membrane were taken using an Optech LFZ stereo microscope (Optech) after 
injection of approximately 1 mL contrast agent (zinc oxide in pure vegetable oil) under the 
chorioallantoic membrane and the ring. Quantification of different vascular parameters was 
obtained using HetCAM software (Peira, Belgium). At least 8 eggs per condition were used.  
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Magnetic activated cell sorting of PBMCs and flow cytometry 
Peripheral blood mononuclear cells (PBMCs) were isolated by density centrifugation 
(Lymphoprep, Nycomed AS) from buffy coats obtained from healthy blood donors and cultured 
in Yssel medium (IMDM, Bio Whittaker supplemented with 1% human serum, penicillin (100 
U/ml), streptomycin (100 mg/ml), linoleic acid (2 g/ml), oleic acid (2 g /ml), ethanolamine (2 
g/ml), insuline (5 g/ml) and transferrine (30 g/ml). After isolation, PBMCs were sorted by 
magenetic-activated cell sorting (MACS, miltenyi biotec) into CD4-, CD4+ and CD4+/CD25+ 
fractions. Next, the cells in each fraction were activated overnight by aCD3/aCD28 exposure. The 
activated fractions were subsequently incubated for 24 hours with different concentrations of 
recombinant gal-9D5 after which apoptosis was assessed by flow cytometry using the Apoptest 
kit by staining with AnnexinV-FITC according to the supplier’s protocol (VPS diagnostics, the 
Netherlands). Successful sorting was confirmed by immunophenotyping the lymphocyte-gated 
fractions with monoclonal antibodies directed against CD4, CD25 and CD8 respectively. In 
addition, Tim-3 expression in each fraction was assessed by staining with a monoclonal antibody. 
Flow cytometry was performed on a Calibur flow cytometer (BD biosciences) and data was 
analyzed with the CellQuest Pro software (BD biosciences). All experiments were performed in 
triplicate with PBMCs from independent blood donors.  
 
Statistical analyses 
All data are presented as mean +/- sem unless indicated otherwise. For testing, the Mann-
Whitney rank sum test was used. P-values < 0.05 were considered statistically significant and all 
statistical analyses were performed using SPSS (SPSS Inc., Gorinchem, the Netherlands). 
 
Results 
Galectin-9 protein levels are increased on the tumor endothelium of solid tumors 
We recently identified decreased expression of a galectin-9 splice variant lacking exon 5 (gal-9∆5) 
as a marker of poor prognosis in patients with early stage non-small cell lung cancer. Interestingly, 
immunohistochemical analysis of galectin-9 protein expression showed increased levels in tumor 
endothelial cells as compared to tumor cells. To confirm this finding we performed galectin-9 
staining on tissue sections from 4 types of solid tumors and their normal counterparts, i.e. lung, 
liver, breast, kidney. Interestingly, all four tumor types displayed increased galectin-9 protein 
levels in the tumor endothelial cells as compared to the normal endothelium (Figure 1A). 
Subsequent scoring indicated that endothelial galectin-9 staining in most tumors was significantly 
increased compared to normal endothelium (Figure 1B). Tumor cell expression did not change as 
compared to normal epithelium, except for kidney (Figure 1C). Thus, endothelial cells show 
elevated galectin-9 protein levels in a tumor microenvironment pointing towards a role for 
galectin-9 in tumor angiogenesis. 
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Figure 1. Galectin-9 protein expression on the tumor endothelium. (A) Immunohistochemical staining of galectin-
9 on normal and tumor tissues. Insets show endothelial staining. (B) Quantification of galectin-9 staining in endothelial 
cells. (C) Quantification of galectin-9 staining in epithelial cells. 
 
Endothelial cells express five galectin-9 splice variants. 
To get more insight in the function of galectin-9 in endothelial biology we first aimed to determine 
galectin-9 expression in endothelial cells. Since the galectin-9 transcript is subject to extensive 
splicing we set out to identify characterize all galectin-9 splice variants in endothelial cells. To that 
end, a PCR was performed on HUVEC cDNA with primers flanking the open reading frame of 
the full length galectin-9 transcript, i.e. the transcript containing all 11 exons (Gal-9FL). The PCR 
products were cloned into the pCR2.1 T/A cloning vector and clones were screened for different 
insert lengths by insert PCR and restriction enzyme digestion (Supplementary Figure 1). This 
approach identified 5 different galectin-9 splice variants which were further characterized by 
sequence analysis. This identified three transcripts that have already been described, i.e. gal-9FL 
(Full length, containing all 11 exons), gal-9Δ5 (lacking exon 5) and gal-9Δ5/6 (lacking exons 5 
and 6). In the two additional splice variants the splicing of exon 5 or exons 5/6 was accompanied 
by splicing of exon 10 resulting in gal-9Δ5/10 and gal-9Δ5/6/10, respectively. Exclusion of exon 
10 from the mature transcript caused a frame-shift, resulting in a premature stop codon in exon 11 
and a truncated C-terminal CRD (Figure 2A and Supplementary Figure 1).  
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Figure 2. Galectin-9 mRNA expression in endothelial cells. (A) Visual representation of endothelial galectin-9 
splice variants and protein isoforms. Gal-9FL, gal-95 and gal-95/6 vary in their linker length. Gal-95/10 and Gal-
95/6/10 vary in their linker length and have a truncated C-terminal CRD. (B) Galectin-9 mRNA expression levels in 
quiescent HUVEC assassed by qPCR. (C) Change in galectin-9 expression upon HUVEC activation relative to 
expression in quiescent cells. Total galectin-9 indicates detection of all galectin-9 splice variants concomitantly. 
Galectin-1 expression was used as a positive control.  
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Supplementary 
Figure 1. (A) Flanking 
PCR on galectin-9 in 
HUVEC endothelial 
cells. (B) Galectin-9 
insert PCR. (C) 
Aligned amino acid 
sequence of the 5 
endothelial galectin-9 
splice variants. The 
shift in the open 
reading frame caused 
by splicing of exon 10 
is shown in grey. (D) 
A detailed illustration 
of the frame-shift and 
the subsequent 
premature stop codon 
(TGA) causing a 
truncation of the 
second carbohydrate 
recognition domain.  
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To confirm that the cloned variants indeed compromise the entire endothelial repertoire of 
galectin-9 splice variants, real-time PCR was performed on HUVEC cDNA with splice-variant 
specific primers (Supplementary Table 1). All primer combinations were analyzed for specificity 
and sensitivity (Supplementary Figure 2). In accordance with the cloning data, the real-time PCR 
analysis indicated that galectin-9 expression in endothelial cells is restricted to 5 transcripts, i.e. 
gal-9FL, gal-9Δ5, gal-9Δ5/6, gal-9Δ5/10, and gal-9Δ5/6/10 (Figure 2B). None of the other 
potential splice variants varying in exons 5, 6 and 10 were expressed at detectable levels. Real-
time PCR also indicated that gal-9Δ5 is the most abundantly expressed splice variant in quiescent 
endothelial cells. Gal-9Δ5/6/10 expression was the lowest while the remaining three splice variants 
were expressed at comparable levels. To evaluate splicing of other exons we also performed an in 
silico analysis to search for consensus splicing donor/acceptor sites within the galectin-9 transcript 
and for predicted alternative transcripts. As expected, consensus splicing sites were only found for 
all known exons (Supplementary Table 2). In addition, both the ASPic and SpliceNest 
databases36,37 predicted alternative splicing of only exons 5, 6 and 10 in sufficiently long protein- 
coding transcripts of galectin-9. Altogether, these data suggest that alternative splicing of galectin-
9 transcript is restricted to exons 5, 6 and 10. 
 
 
 
Supplementary Figure 2. 
Galectin-9 primer sensitivity 
and specificity. (A) Galectin-
9 primer design. Thin lines 
represent exons spanned by the 
specific primer. (B) 
Representative dilution series 
with primers targeting specific 
galectin-9 splice variants as 
determined by real-time PCR. 
(C) Analysis of primer 
specificity by real-time PCR. 
Each panel shows the signals 
generated with all primers on 
the individual splice variants 
of galectin-9. While the 'ALL' 
primers amplify each splice 
variant, all the other primers 
are specific for a single splice 
variant. 
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Supplementary Table 2. Splicing donor-acceptor sites in the galectin-9 transcript 
 Length donor branch acceptor 
  GU GU A/G A C/U AG 
intron 1 6958 GU CUGAC (-32) AG 
intron 2 2217 GU CTAAT (-258) AG 
intron 3 1464 GU CTGAC (-315) AG 
intron 4 1176 GU CTAAC (-125) AG 
intron 5 1693 GU CUGAC (-22) AG 
intron 6 511 GU CTAAC (-184) AG 
intron 7 635 GU CTAAC (-158) AG 
intron 8 441 GU CUGAC (-26) AG 
intron 9 151 GU CTGAT (-68) AG 
intron 10 1403 GU CTGAT (-121) AG 
    (bp upstream from 3' flanking exon) 
 
 
Table 1. Galectin-9 expression in human cell lines of different origin. 
Source Cell line FL D5 D5/6 D5/10 D5/6/10 
Endothelium HUVEC + ++ + + + 
 EC-RF24 - ++ + + + 
 HMEC - ++ - + + 
Colon HCT116 - - - - - 
 HT29 ++ + + + + 
 Colo205 ++ + + + + 
 Colo320 ++ + - - + 
 LS174T ++ - - - - 
 Caco2 - - - - - 
Blood Jurkat ++ + - + + 
Liver HepG2 - - - - - 
Breast MCF7 - - - - - 
 MD231 - ++ - - - 
Skin MUM2B - - - - - 
 MUM2C - - - - - 
 C8161 - - - - - 
 C81-61 - ++ - + + 
Kidney HEK293T - - - - - 
Miscellaneous Fibroblasts - ++ - - + 
 HeLa + + ++ - + 
 EW7 - - - - - 
 A2780 - - - - - 
+ = splice variant detected, - = splice variant not detected, ++ = dominant splice variant. 
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Since most of the studies that reported on galectin-9 expression in cells and tissues of 
different origin did either not discriminate between different splice variants or determined the 
expression of only a few variants we determined the complete galectin-9 splice variant expression 
profile in a panel of human cell lines of different origin. These data show that the expression and 
relative abundance of galectin-9 splice variants varies between these cell lines, suggesting 
diverging activities in cell biology (Table 1).   
 
Galectin-9 splice variant mRNA expression is altered following endothelial cell activation 
To determine whether the expression of individual splice variants was differentially affected by 
endothelial cell activation, we assessed the expression in quiescent and activated HUVEC by real-
time PCR. In line with previous findings we observed that endothelial cell activation in vitro results 
in a significant decrease of overall galectin-9 mRNA expression levels (Figure 2C). This was 
predominantly caused by a decrease in gal-9Δ5 levels, the most abundantly expressed splice 
variant. Compared to the overall galectin-9 expression, the relative mRNA expression levels of the 
splice variants lacking exon 6, i.e. gal-9Δ5/6 and gal-9Δ5/6/10, increased upon endothelial cell 
activation (Figure 2C).  
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Figure 3. Galectin-9 splice variant overexpression in HMEC. (A) Galectin-9 pcDNA3.1 expression constructs. 
White arrows indicate start codons, black arrows indicate stop codons. (B) Galectin -9 protein expression in HMEC 
upon overexpression of galectin-9 splice variants. (C) Relative HMEC proliferation following overexpression of 
galectin-9 splice variants. (D) Relative inhibition of HMEC migration following overexpression of galectin-9 splice 
variants. 
 
Endogenous galectin-9 stimulates proliferation and inhibits migration of endothelial cells. 
The observation that tumor endothelial cells in vivo have elevated galectin-9 levels while 
endothelial cell activation in vitro is accompanied by a decreased expression urged us to  
 
Figure 4. Effect of exogenous galectin-95 on endothelial cell proliferation and migration. (A) Galectin-9 protein 
levels in the supernatant of HMEC transfected with galectin-9 splice variant constructs. Blank: only transfection 
vehicle was used. Mock: empty vector. (B)(D) Relative proliferation rate of HMEC and HUVEC upon treatment with 
recombinant gal-95. (C)(E) Relative inhibition of HMEC and HUVEC migration upon treatment with recombinant 
gal-95. 
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investigate the role of galectin-9 in angiogenesis. To that end, we cloned and expressed the specific 
galectin-9 splice variants in human microvascular endothelial cells (HMEC), which have a low 
levels of endogenous galectin-9 mRNA (Figure 3A+B). Subsequent functional analyses revealed 
a modest increase in endothelial cell proliferation which reached statistical significance for gal-
9Δ5 while here was no effect on migration (Figure 3C + 3D). Next, we determined whether 
exogenous application of galectin-9 could modulate endothelial cell function, similar as described 
for other galectins 19,21,25. First, we established whether endothelial cells can secrete galectin-9 in 
the supernatant. Western blot analysis of supernatants collected from HMEC transfected with 
different galectin-9 variants indicated that secretion at detectable levels is restricted to gal-9Δ5 and 
gal-9Δ5/6 (Figure 4A). Since gal-9Δ5 is the dominant endothelial splice variant which is also 
available as a recombinant protein, we further focused on the effects of this variant. First, we 
performed a proliferation assay using different galectin-9Δ5 concentrations. Similar to the 
experiments with increased endogenous expression we observed that exposure of HMEC to 
galectin-9Δ5 did not affect proliferation, except for a high concentration of 500 nM (Figure 4B). 
The same was observed for HMEC migration in the presence of galectin-9Δ5 (Figure 4C). On the 
other hand, in primary isolated human umbilical vein endothelial cells, we did observe effects on 
cell proliferation and migration at lower galectin-9Δ5 concentrations (Figures 4D + 4E). Given 
these cell-type dependent effects in vitro we finally determined the effects of exogenous galectin-
9Δ5 in vivo using the chick chorioallantioc membrane (CAM) assay. Here, application of 
exogenous gal-9Δ5 also appeared to induce only a modest angiostatic effect at higher 
concentrations (Figure 5). Altogether, these data indicate that galectin-9 has moderate effects on 
endothelial cell function and angiogenesis. 
 
 
Figure 5. Effect of exogenous galecitin-9 on in vivo angiogenesis in the CAM model. Top panels show 
representative images of CAMs after treatment with different gal-95 concentrations. Lower panels show the 
quantification of vessel length, branch points and end points as determined with the HetCAM software.  
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Endothelial galectin-9 preferentially induces apoptosis of CD8+ T cells  
Since the effects of galectin-9 on endothelial cell biology appear modest and galectin-9 has several 
well documented effects on immune cells we hypothesized that increased endothelial galectin-9 
might predominantly acts as an immuno-modulator. To address this, we first confirmed that gal-
9Δ5 hampers immune cell survival. Exposing PBMCs for 24 hours to gal-9Δ5 induced a 
concentration dependent induction of apoptosis with approximately 80% cell death at a 
concentration of 500 nM (Figure 6A). Considerable effects were observed already at 
concentrations that did not affect endothelial cell function. Next, we questioned whether the 
induction of cell death varied between different subsets of T cells, i.e. CD8+ cytotoxic T cells, 
CD4+ T helper cells, and CD4+/CD25+ T regulatory cells. Since the effects of galectin-9 on T-
cells are mediated via Tim-3, we first assessed the expression of this receptor on different T cell 
populations. FACS analysis indicated that approximately 12.7±3.4% of CD8+ cells expressed 
Tim-3. This percentage increased to 27.0±14.3% after activation (Figure 6B). Both the CD4+ and 
CD4+/CD25+ cell populations presented lower percentages of Tim-3+ cells, respectively 
4.1±0.4% and 2.8±0.4%. Furthermore, activation did increase the percentage of Tim-3+ cells in 
these populations but only up to the levels observed in unstimulated CD8+ cells (Figure 6B). 
Consequently, CD8+ cells were more susceptible to galectin-9Δ5 induced apoptosis as compared 
to CD4+ T cells or CD4+/CD25+ T cells (Figure 6C). These data suggest that increased galectin-
9 in the tumor endothelium could promote the selection of immune-suppressive T cell populations. 
 
Discussion 
We have previously shown that endothelial cells predominantly express galectin-1, -3, -8 and -9 
35. While galectin-1, -3, and -8 have been linked to endothelial cell biology and angiogenesis 
19,21,24,25, little was known regarding the function of galectin-9 in endothelial cells. First, we 
determined the expression of galectin-9 on the endothelial cells of normal and cancerous tissue of 
4 different organs. In all tissues examined, i.e. kidney, liver, lung and breast, galectin-9 protein 
levels were higher on tumor endothelial cells compared to normal endothelium. In addition we 
show that epithelial galectin-9 levels do not show the same pattern. In liver, lung and breast tumors 
epithelial galectin levels stay constant compared to controls. Conversely, galectin-9 levels decrease 
significantly in the epithelium of kidney tumors. The latter is in accordance with an anti-metastatic 
role for galectin-9 as has been reported in various tumor types like breast cancer11, cervical 
squamous cell carcinoma38 and melanoma39. However, we could not confirm the finding by Irie et 
al. that galectin-9 levels are significantly decreased in breast cancer. This apparent inconsistency 
will have to be addressed in future studies.  
 To gain insight into the role of galectin-9 in endothelial cells we set out to clone galectin-
9 from these cells. Here, we report on the expression of 5 galectin-9 splice variants in quiescent 
endothelial cells at different levels. To our knowledge, this is the first comprehensive study in 
which the expression of all splice variants of galectin-9 is assessed within a single cell type. 
Alternative splicing of galectin-9 has been reported in cells and tissues of different origin. Three 
main variants have been described in which splicing appears to be confined to the exons encoding 
the linker between the two CRDs, i.e. exon 5 and 6 27,40,41. Endothelial expression of these 3 
galectin-9 splice variants was first reported by Spitzenberger et al. 40 and later confirmed by others 
35,42. The most abundantly expressed variant in quiescent endothelial cells, i.e. gal-9Δ5, is also the 
most frequently reported in literature. Full length galectin-9 and gal-9Δ5/6 appear to be expressed  
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at lower levels. Although limited, initial studies suggest a diverging function for galectin-9 splice 
variants differing in linker length. For example, while ectopic expression of gal-9FL decreases E-
selectin expression in LoVo colon carcinoma cells, gal-95 and gal-95/6 overexpression 
increases the expression of E-selectin in these cells and as a result increases their adhesion to 
endothelial cells 39. In addition, gal-9FL is a more potent eosinophil chemoattractant compared to 
gal-9Δ5 43. Of the two other variants, gal-9Δ5/10 is expressed at almost equal levels as compared 
to gal-9Δ5/6. Thus far, expression of gal-9Δ5/10 has only been reported by Lipkowitz in cells of 
non-endothelial origin, i.e. colon epithelial cells and peripheral blood lymphocytes 44. The latter 
study also described a galectin-9 variant which only lacks exon 10. Although we could confirm 
the existence of this variant in other cell types (unpublished observation), we did not detect it in 
endothelial cells. We did however identify a novel variant, i.e. gal-9Δ5/6/10, which to our 
knowledge has not been described before. Further expression profiling of the galectin-9 splice 
Figure 6. Effect of exogenous galectin-9 
on immune cell survival. (A) Induction of 
apoptosis in total PBMCs upon treatment 
with increasing concentrations of gal-95. 
(B) Percentage of Tim-3 positive cells in 
CD8+, CD4+ and CD4+/CD25+ immune 
cell populations before and after 
aCD3/CD28 activation. (C) Induction of 
apoptosis in CD8+, CD4+ and 
CD4+/CD25+ immune cell populations 
after treatment with 0.8nM and 20nM 
recombinant gal-95. 
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variants in a panel of cell lines revealed that the splicing is cell type specific, which is in agreement 
with a previous study 45. In addition, these profiling data together with the in silico data provided 
by splicing prediction algorithms suggest that the splicing of galectin-9 is confined to exons 5, 6, 
and 10. The splicing factors that control this process, as well as the upstream signaling cascades 
that direct this still need to be resolved. 
The identification of two variants that lack exon 10 was intriguing. Unlike exons 5 and 6, 
this exon encodes part of the C-terminal CRD of galectin-9. Exclusion of exon 10 results in a 
frame-shift and premature stop-codon in exon 11 which gives rise to a truncated C-terminal CRD. 
While a similar splicing event has been observed for gal-8, another tandem-repeat galectin 46 it is 
still unknown what the functional consequence of this truncation is. It also remains to be 
determined whether such a truncation results in a “class-switch” from a tandem-repeat galectin to 
a prototype galectin and whether galectin-9 variants lacking exon 10 dimerize. Given the 
functional importance of bivalent carbohydrate binding by galectins, the loss of the second CRD 
might generate a dominant negative protein. It is also possible that the truncated galectin-9 
interacts with other intracellular proteins since this is usually independent of carbohydrate binding.   
 Next, we examined the effect of endothelial activation on galectin-9 splice variant 
expression levels. We have previously reported a decrease in overall galectin-9 mRNA expression 
after endothelial cell activation 35 and could confirm that finding in this study. Here we show this 
is due to a decrease in gal-95, the dominant splice variant in endothelial cells. In addition, 
contrary to the other splice variants of galectin-9, the relative abundance of gal-9Δ5/6 and gal-
9Δ5/6/10 mRNA appears to increase upon endothelial cell activation. In silico analysis revealed 
the presence of a myristoylation site within exon 6 which potentially confers a co-translational 
modification that has been associated with signal transduction and membrane targeting 47. Whether 
gal-9Δ5/6 and gal-9Δ5/6/10 indeed have a different cellular distribution compared to the other 
splice variants remains to be determined. Also, the functional relevance of the differential change 
in expression of splice variants remains unclear. The decrease of galectin-9 mRNA levels upon 
endothelial cell activation appears to contradict with our finding that galectin-9 protein levels are 
significantly increased on the tumor endothelium of solid tumors. This is likely due the presence 
of a complex tumor microenvironment in tumors with specific growth factors, cytokines and other 
environmental queues that are not present in the in vitro setting. For example, IFN- has been 
shown to induce galectin-9 expression in endothelial cells 42 and is now also implicated as a pro-
tumorigenic factor 48. Alternatively, this finding reflects an increased translation efficiency in the 
tumor endothelium, possibly of the splice variants whose mRNA expression is increased upon 
endothelial cell activation, i.e. gal-9Δ5/6 and gal-9Δ5/6/10. Finally, galectin-9 on the tumor 
endothelium could have been secreted by other cells and consequently taken up by endothelial 
cells to modulate their activity, as we have recently shown a similar mechanism for galectin-1 25. 
In this context and for functional assays, future studies will greatly benefit from the generation of 
antibodies that allow for a specific detection of galectin-9 splice variants.   
 The finding that galectin-9 levels are high on the tumor endothelium prompted us to 
investigate its role in tumor angiogenesis. When overexpressed in HMEC, we found that all 
galectin-9 splice variants seem to increase the proliferation rate slightly. However, this effect was 
only significant for gal-9Δ5. Conversely, no effect on the migration rate of these transfected cells 
could be observed. Interestingly, galectin-9 is found both intra- and extracellularly and secretion 
of galectin-9 has been reported for several cell types like T cells 43 and fibroblasts 49. Here, we 
confirm that HMEC secrete gal-9Δ5 and gal-9Δ5/6 into the supernatant upon overexpression of 
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these splice variants. Galectins lack a classical secretion signal and the precise mechanism by 
which galectin-9 is secreted is unclear at this point, although specific matrix metalloproteinases 
and protein kinase C appear to be involved 43. Also, it is not clear why these 2 splice variants are 
secreted while others are not. Of note, Lipkowitz et al. previously found that splice variants lacking 
exon 10 are not translocated to the cell membrane, suggesting an intracellular role for these variants 
50. Since gal-9Δ5 is the most abundant endothelial galectin-9 splice variants and because it is 
available as a recombinant protein we assessed the role of this variant in angiogenesis when applied 
exogenously. As for the proliferation and migration of the HMEC cell line the effect of exogenous 
galectin-9 was similar to that of the overexpression approach, i.e. we could not observe a change 
in the activity of these cells except at a high concentration of 500nM. Conversely, we did observe 
a clear effect on the proliferation and migration of primary HUVEC cells. At all concentrations 
tested, the proliferation rate of HUVEC was drastically decreased. As for migration the effect of 
exogenous galectin-9 appeared to be biphasic: at lower concentrations we observed stimulation of 
HUVEC migration while a high concentration we observed an inhibition. Interestingly we recently 
reported a similar biphasic effect for another endothelial galectin that is highly expressed on the 
tumor endothelial, i.e. galectin-1 25. Finally we assessed the effect of exogenous galectin-9 on in 
vivo angiogenesis in the CAM model. Here, we found that exogenous gal-9Δ5 application results 
in a trend towards an inhibition of angiogenesis at the higher concentrations, i.e. 100nM and 
500nM. However, this effect is limited and only significant for the number of vessel end points. 
At 20 nM exogenous gal-9Δ5 does not appear to interfere with an efficient angiogenic response, 
in fact it shows a trend towards an increased vessel length, which suggests that gal-9Δ5 mainly 
acts through modulation of endothelial cell migration. Thus, although galectin-9 is found inside 
the cell there is very limited knowledge about the function of galectin-9 in this context. So far, 
only NF-IL6 has been identified as an intracellular binding partner of galectin-9 51. In addition, it 
is not clear yet whether the subcellular localization of galectin-9 differs between different splice 
variants.  
 Galectin-9 has a well-documented role in the modulation of the activity and the survival of 
immune cells 52. In fact, galectin-9 was first discovered as an eosinophil chemoattractant 28 and 
subsequent studies demonstrated it induces apoptosis potently in Th1 cells 
29  and in Tc cells 
53 via 
its receptor Tim-3. Because the role of galectin-9 in angiogenesis appears to be limited, we 
explored whether exogenous gal-9Δ5 could mediate tumor immune escape by inducing cell death 
in tumor-attacking immune cells specifically. First, we confirmed gal-9Δ5 induces cell death in 
PBMCs at concentrations considerably lower than those that hamper angiogenesis (IC50: 20 nM). 
Next, we confirmed that the receptor for gal-9Δ5, Tim-3, is expressed in the cell populations we 
examined, i.e. CD8+ Tc cells, CD4+ Th cells and CD4+/CD25+ Tregs. In fact, the percentage of 
Tim-3+ cells increased in all populations following aCD3/aCD28 activation and the fraction of 
Tim-3+ cells was highest in the CD8+ cells. When assessing the induction of apoptosis in these 
different immune cell types, we found that gal-9Δ5 preferentially induces cell death of Tc cells, 
while Tregs are largely unaffected. This is likely due to the higher fraction of Tim-3+ cells in the Tc 
population. However, it should be noted that Tim-3 independent signaling of galectin-9 has been 
reported 54. Since Tregs suppress immune function and Tc cells are prone to target tumor cells, 
endothelial gal-9Δ5 could contribute to tumor immune escape by inducing apoptosis in immune-
competent cells while leaving immune-suppressive cell populations unaffected.  
 Taken together, our data suggest endothelial galectin-9 is mainly involved in tumor 
immune escape rather than tumor angiogenesis. This hypothesis will have to be further tested in 
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future studies, for example it will be interesting to compare immune cell infiltration near galectin-
9 positive and galectin-9 negative blood vessels. Considering overall galectin-9 levels appear to 
decrease upon transformation to malignancy in several cancer types 11,38,39,45, galectin-9 seems to 
exert a multifaceted role in tumor biology similar to galectin-1 and galectin-3 4. This property 
makes galectins interesting targets for therapy since interfering with galectin function could 
potentially hamper tumor progression via different mechanisms concomitantly. We identified a 
novel splice variants of galectin-9 in endothelial cells, i.e. gal-9Δ5/6/10. Although we recently 
demonstrated the relevance of galectin-9 splice variant detection 55 their function remains largely 
unclear. The generation of antibodies that allow for the specific detection of galectin-9 splice 
variants will allow to further explore their roles.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Galectin-9 splice variant expression in the tumor endothelium 
 
87 
References 
1 Barondes, S. H. et al. Galectins: a family of animal beta-galactoside-binding lectins. Cell 76, 597-598, 
(1994). 
2 Leffler, H., Carlsson, S., Hedlund, M., Qian, Y. & Poirier, F. Introduction to galectins. Glycoconj J 19, 433-
440, (2004). 
3 Liu, F. T., Patterson, R. J. & Wang, J. L. Intracellular functions of galectins. Biochim Biophys Acta 1572, 263-
273, (2002). 
4 Liu, F. T. & Rabinovich, G. A. Galectins as modulators of tumour progression. Nat Rev Cancer 5, 29-41, 
(2005). 
5 Paz, A., Haklai, R., Elad-Sfadia, G., Ballan, E. & Kloog, Y. Galectin-1 binds oncogenic H-Ras to mediate Ras 
membrane anchorage and cell transformation. Oncogene 20, 7486-7493, (2001). 
6 Rabinovich, G. A. & Croci, D. O. Regulatory circuits mediated by lectin-glycan interactions in autoimmunity 
and cancer. Immunity 36, 322-335, (2012). 
7 Ilarregui, J. M., Bianco, G. A., Toscano, M. A. & Rabinovich, G. A. The coming of age of galectins as 
immunomodulatory agents: impact of these carbohydrate binding proteins in T cell physiology and 
chronic inflammatory disorders. Ann Rheum Dis 64 Suppl 4, iv96-103, (2005). 
8 Dalotto-Moreno, T. et al. Targeting galectin-1 overcomes breast cancer-associated immunosuppression 
and prevents metastatic disease. Cancer Res 73, 1107-1117, (2013). 
9 Ito, K. & Ralph, S. J. Inhibiting galectin-1 reduces murine lung metastasis with increased CD4(+) and CD8 
(+) T cells and reduced cancer cell adherence. Clin Exp Metastasis 29, 561-572, (2012). 
10 Barrow, H. et al. Serum galectin-2, -4, and -8 are greatly increased in colon and breast cancer patients and 
promote cancer cell adhesion to blood vascular endothelium. Clin Cancer Res 17, 7035-7046, (2011). 
11 Irie, A. et al. Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer. Clin Cancer 
Res 11, 2962-2968, (2005). 
12 Zick, Y. et al. Role of galectin-8 as a modulator of cell adhesion and cell growth. Glycoconj J 19, 517-526, 
(2004). 
13 van den Brule, F., Califice, S. & Castronovo, V. Expression of galectins in cancer: a critical review. Glycoconj 
J 19, 537-542, (2004). 
14 Kim, H.-J. et al. High galectin-1 expression correlates with poor prognosis and is involved in epithelial 
ovarian cancer proliferation and invasion. Eur J Cancer 48, 1914-1921, (2012). 
15 Le Mercier, M., Fortin, S., Mathieu, V., Kiss, R. & Lefranc, F. Galectins and gliomas. Brain Pathol 20, 17-27, 
(2010). 
16 Saussez, S., Camby, I., Toubeau, G. & Kiss, R. Galectins as modulators of tumor progression in head and 
neck squamous cell carcinomas. Head Neck 29, 874-884, (2007). 
17 Yamauchi, A. et al. Galectin-9, a novel prognostic factor with antimetastatic potential in breast cancer. 
Breast J 12, S196-200, (2006). 
18 D'Haene, N. et al. Endothelial hyperplasia and endothelial galectin-3 expression are prognostic factors in 
primary central nervous system lymphomas. Br J Haematol 140, 402-410, (2008). 
19 Cardenas Delgado, V. M. et al. Modulation of endothelial cell migration and angiogenesis: a novel function 
for the "tandem-repeat" lectin galectin-8. Faseb J 25, 242-254, (2011). 
20 Thijssen, V. L., Poirier, F., Baum, L. G. & Griffioen, A. W. Galectins in the tumor endothelium; opportunities 
for combined cancer therapy. Blood 110, 2819-2827, (2007). 
21 Nangia-Makker, P. et al. Galectin-3 Induces Endothelial Cell Morphogenesis and Angiogenesis. Am J Pathol 
156, 899-909, (2000). 
22 Croci, D. O. et al. Disrupting galectin-1 interactions with N-glycans suppresses hypoxia-driven angiogenesis 
and tumorigenesis in Kaposi's sarcoma. J Exp Med 209, 1985-2000, (2012). 
23 Hsieh, S. H. et al. Galectin-1, a novel ligand of neuropilin-1, activates VEGFR-2 signaling and modulates the 
migration of vascular endothelial cells. Oncogene 27, 3746-3753, (2008). 
24 Thijssen, V. L. et al. Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis 
therapy. Proc Natl Acad Sci U S A 103, 15975-15980, (2006). 
Chapter 4 
 
88 
25 Thijssen, V. L. et al. Tumor cells secrete galectin-1 to enhance endothelial cell activity. Cancer Res 70, 
6216-6224, (2010). 
26 Markowska, A. I., Liu, F. T. & Panjwani, N. Galectin-3 is an important mediator of VEGF- and bFGF-
mediated angiogenic response. J Exp Med 207, 1981-1993, (2010). 
27 Hirashima, M. et al. Galectin-9 in physiological and pathological conditions. Glycoconj J 19, 593-600, 
(2004). 
28 Matsumoto, R. et al. Human ecalectin, a variant of human galectin-9, is a novel eosinophil 
chemoattractant produced by T lymphocytes. J Biol Chem 273, 16976-16984, (1998). 
29 Zhu, C. et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 6, 
1245-1252, (2005). 
30 Chou, F.-C., Shieh, S.-J. & Sytwu, H.-K. Attenuation of Th1 response through galectin-9 and T-cell Ig mucin 
3 interaction inhibits autoimmune diabetes in NOD mice. Eur J Immunol 39, 2403-2411, (2009). 
31 Chou, F.-C. et al. Overexpression of Galectin-9 in Islets Prolongs Grafts Survival via Downregulation of Th1 
Responses. Cell Transplant, (2012). 
32 Vega-Carrascal, I. et al. Dysregulation of TIM-3-galectin-9 pathway in the cystic fibrosis airways. J Immunol 
186, 2897-2909, (2011). 
33 Katoh, S. et al. Involvement of galectin-9 in lung eosinophilia in patients with eosinophilic pneumonia. Int 
Arch Allergy Immunol 153, 294-302, (2010). 
34 Matsumoto, N. et al. A Possible Role of Galectin-9 in the Pulmonary Fibrosis of Patients with Interstitial 
Pneumonia. Lung, (2013). 
35 Thijssen, V. L., Hulsmans, S. & Griffioen, A. W. The galectin profile of the endothelium; altered expression 
and localization in activated and tumor endothelial cells. Am J Pathol 172, 545-553, (2008). 
36 Martelli, P. L. et al. ASPicDB: a database of annotated transcript and protein variants generated by 
alternative splicing. Nucleic Acids Res 39, D80-85, (2011). 
37 Krause, A., Haas, S. A., Coward, E. & Vingron, M. SYSTERS, GeneNest, SpliceNest: exploring sequence 
space from genome to protein. Nucleic Acids Res 30, 299-300, (2002). 
38 Liang, M. et al. Galectin-9 expression links to malignant potential of cervical squamous cell carcinoma. J 
Cancer Res Clin Oncol 134, 899-907, (2008). 
39 Kageshita, T. et al. Possible role of galectin-9 in cell aggregation and apoptosis of human melanoma cell 
lines and its clinical significance. Int J Cancer 99, 809-816, (2002). 
40 Spitzenberger, F., Graessler, J. & Schroeder, H. E. Molecular and functional characterization of galectin 9 
mRNA isoforms in porcine and human cells and tissues. Biochimie 83, 851-862, (2001). 
41 Zhang, F. et al. Different roles of galectin-9 isoforms in modulating E-selectin expression and adhesion 
function in LoVo colon carcinoma cells. Mol Biol Rep 36, 823-830, (2009). 
42 Imaizumi, T. et al. Interferon-{gamma} stimulates the expression of galectin-9 in cultured human 
endothelial cells. J Leukoc Biol 72, 486-491, (2002). 
43 Chabot, S. et al. Regulation of galectin-9 expression and release in Jurkat T cell line cells. Glycobiology 12, 
111-118, (2002). 
44 Lipkowitz, M. S., Leal-Pinto, E., Rappoport, J. Z., Najfeld, V. & Abramson, R. G. Functional reconstitution, 
membrane targeting, genomic structure, and chromosomal localization of a human urate transporter. J 
Clin Invest 107, 1103-1115, (2001). 
45 Lahm, H. et al. Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR 
and its implications for diagnostic and therapeutic procedures. J Cancer Res Clin Oncol 127, 375-386, 
(2001). 
46 Bidon-Wagner, N. & Le Pennec, J. P. Human galectin-8 isoforms and cancer. Glycoconj J 19, 557-563, 
(2004). 
47 Resh, M. D. Fatty acylation of proteins: new insights into membrane targeting of myristoylated and 
palmitoylated proteins. Biochim Biophys Acta 1451, 1-16, (1999). 
48 Zaidi, M. R. & Merlino, G. The two faces of interferon-gamma in cancer. Clin Cancer Res 17, 6118-6124, 
(2011). 
49 Asakura, H. et al. Selective eosinophil adhesion to fibroblast via IFN-gamma-induced galectin-9. J Immunol 
169, 5912-5918, (2002). 
Galectin-9 splice variant expression in the tumor endothelium 
 
89 
50 Lipkowitz, M. S., Leal-Pinto, E., Cohen, B. E. & Abramson, R. G. Galectin 9 is the sugar-regulated urate 
transporter/channel UAT. Glycoconj J 19, 491-498, (2004). 
51 Matsuura, A. et al. Intracellular galectin-9 activates inflammatory cytokines in monocytes. Genes Cells 14, 
511-521, (2009). 
52 Rabinovich, G. A. & Toscano, M. A. Turning 'sweet' on immunity: galectin-glycan interactions in immune 
tolerance and inflammation. Nat Rev Immunol 9, 338-352, (2009). 
53 Wang, F. et al. The Tim-3 ligand galectin-9 negatively regulates CD8+ alloreactive T cell and prolongs 
survival of skin graft. Cell Immunol 250, 68-74, (2007). 
54 Su, E. W., Bi, S. & Kane, L. P. Galectin-9 regulates T helper cell function independently of Tim-3. 
Glycobiology 21, 1258-1265, (2011). 
55 Heusschen, R. et al. Profiling Lgals9 splice variant expression at the fetal-maternal interface: implications 
in normal and pathological human pregnancy. Biol Reprod 88, 22, (2013). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4 
 
90 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Chapter 5 
 
Galectin-9 in tumor biology: A jack of multiple 
trades 
 
Roy Heusschen, Arjan W Griffioen and Victor L Thijssen 
 
Biochimica et Biophysica Acta Reviews Cancer 2013. 1836: 177-85 
 
 
 
 
 
 
 
 
Chapter 5 
 
92 
Abstract 
Galectin family members have been shown to exert multiple roles in the context of tumor biology. 
Several recent findings support a similar multi-faceted role for galectin-9. Galectin-9 expression 
is frequently altered in cancer as compared to normal tissues. In addition, an increasing amount of 
evidence suggests that galectin-9 is involved in several aspects of tumor progression, including 
tumor cell adhesion and survival, immune escape and angiogenesis. Also, galectin-9 shows 
potential as a prognostic marker and a therapeutic target for several malignancies. In this review 
we summarize both the established and the emerging roles of galectin-9 in tumor biology and 
discuss the potential application of galectin-9 in anti-cancer therapy. 
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Introduction 
Galectins are characterized by -galactoside binding affinity and the presence of an evolutionary 
conserved sequence: the carbohydrate recognition domain1,2 (CRD). To date, 15 mammalian 
galectins have been identified which can be subdivided into 3 groups. Galectin-3, which contains 
a proline-glycine rich N-terminal tail fused to a CRD, is classified as a chimeric galectin. All other 
galectin family members either contain one CRD, i.e. prototype galectins, or 2 CRDs which are 
linked by a linker domain, i.e. tandem-repeat galectins. Galectins decode and interpret the glycome 
code by binding to specific carbohydrate moieties on glycoconjugates. Since galectins can di- or 
multimerize, their interaction with carbohydrates enables them to cluster and cross-link 
multivalent glycoconjugates, resulting in a large degree of diversity in terms of specificity, affinity 
and valency for carbohydrates within the galectin family3-5. This allows galectins that are present 
in the extracellular environment to influence cell-cell and cell-matrix interactions and to modulate 
signaling pathways by regulating receptor lattice formation on the cell membrane. The 
carbohydrate binding activity is also required for secretion of galectins since they lack a classical 
secretion signal5,6.  
 Next to their extracellular localization and function, galectins are also found intracellularly, 
both in the cytoplasm and the nucleus. There, they have been implicated in processes like signal 
transduction and mRNA splicing which are mainly carbohydrate independent2,7,8. The widespread 
localization of galectins implicates that they exert a large variety of functional roles. Indeed, 
galectins have been shown to participate in physiological processes including brain 
development9,10, angiogenesis11-13, T cell homeostasis4,5,14 and feto-maternal tolerance15,16. In 
addition, galectins have been associated with different pathologies, most notably with cancer7. In 
fact, galectins contribute to different key events during tumorigenesis. For example, galectins can 
mediate tumor cell transformation by interacting with oncogenic ras7,17,18 and affect tumor cell 
survival19,20. Galectins have also been described to modulate homo- and heterotypic adhesion of 
tumor cells thereby mediating tumor metastasis7,21,22. Finally, different galectin family members 
have been implicated in tumor immune escape23,24 and tumor angiogenesis11,13,19. In recent years, 
an increasing amount of data suggests a similar multi-faceted role for galectin-9 in tumor biology. 
Here, we summarize the established and hypothesized roles of galectin-9 in tumor biology, and 
discuss its potential as a therapeutic target for cancer treatment.  
 
Galectin-9: gene, protein, and binding partners 
The cDNA of galectin-9, a tandem-repeat galectin, was cloned in 1997 by 3 independent groups 
working in different research areas25-27. The galectin-9 gene, i.e. LGALS9 (HGNC:6570), is 
located on chromosome 17q11.2 and consists of 11 exons encoding a 355 amino acid long protein 
of approximately 39.5 kD. In humans, two additional LGALS9-like genes have been described, 
LGALS9B (HGNC:24842) and LGALS9C (HGNC:33874)2, which are both located on 
chromosome 17p11.2 close to LGALS9 which is indicative of gene duplication (Figure 1A). Both 
have a good exon-intron structure but whether these genes are transcriptionally active is still under 
debate. Matsushita et al. claim, based on in silico comparison of cloned galectin-9 sequences, that 
all transcripts found are derived from a single gene, i.e. LGALS928. On the other hand, other groups 
reported that LGALS9B and LGALS9C are transcriptionally active and protein-coding29-31. Given 
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the high percentage of similarity between the galectin-9 derived proteins (Figure 1B) it remains 
elusive whether they can exert different cellular functions.  
A feature that has been shown to affect galectin-9 protein function is posttranscriptional 
splicing, a phenomenon which has also been described for galectin-8, another tandem-repeat 
galectin32-34. In the case of galectin-9, splice variants vary in the exclusion of exons 5, 6 and 10 
from the full length (FL) mRNA transcript. Three splice variants are frequently described in the 
literature, i.e. gal-9FL (or gal-9L), gal-9∆5 (or gal-9M, ecalectin) and gal-9∆5/6 (or gal-9S)35. In 
addition, several groups now reported splice variants lacking exon 10, i.e. gal-9∆10, gal-9∆5/10 
and gal-9∆5/6/1016,36. Exclusion of exon 10 from the mature mRNA transcript generates a 
frameshift and premature stopcodon within exon 11, resulting in a truncation of the C-terminal 
CRD and a prototype-like galectin (Figure 1C). The function of such a truncated galectin-9 is still 
unresolved. Exclusion of exon 5, alone or in combination with exon 6, results in length variations 
of the linker domain between the two CRDs. This linker domain influences the rotational freedom 
of both CRDs and mediates higher-order multimer formation thereby increasing gal-9 valency37,38. 
As a result, splice variants varying in linker length likely have different specificities and/or 
affinities for glycoconjugates. Splicing also appears to affect the cellular localization of galectin-
9. The protein has been found extracellularly as well as intracellularly, both in the nucleus and in 
the cytoplasm39,40 (Figure 1D). Interestingly, splice variants lacking exon 10 do not seem to be 
secreted41, suggesting an intracellular role for these proteins. While this function has not been 
identified yet, most intracellular galectins act through direct protein-protein interactions. It is thus 
likely that this is also the case for the intracellular galectin-9 isoforms. Different from the ∆10 
isoform, secretion of other galectin-9 isoforms has been confirmed for various cell types, including 
T lymphocytes35 and fibroblasts42. Although the precise mechanism by which galectin-9 is secreted 
is still not known, matrix-metalloproteinases (MMPs) and protein kinase C (PKC) appear to be 
involved35. Extracellularly, galectin-9 can regulate cell adhesion and lattice formation of 
glycoconjugates via its CRDs (Figure 1D).  
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Figure 1. Galectin-9 splice variants and protein localization. (A) Location of galectin-9 (LGALS9) and galectin-9-
like (LGALS9B and LGALS9C) genes on chromosome 17. (B) Homology of LGALS9, LGALS9B and LGALS9C 
proteins. Grey boxes depict differences with LGALS9. Sequences encoding the CRDs and linker region have green 
and blue bars above them respectively. (C) Galectin-9 (LGALS9) gene structure and confirmed splice variants. Boxes 
represent exons (white: untranslated region, green: coding region, orange: frameshift in the coding region). So far, 6 
splice variants have been identified that vary in the exlusion of exons 5, 6 and 10. As a result, linker length and the C-
terminal CRD varies between splice variants. Gal-9FL: galectin-9 full length. (D) Protein localization of galectin-9. 
Galectin-9 can be found both intra- and extracellularly. Extracellularly galectin-9 can multimerize and is involved in 
adhesion of cells to the extracellular matrix and hetero- and homotypic cell adhesion via binding to varying 
carbohydrate epitopes (colored red, yellow and blue). In addition, galectin-9 can likely regulate receptor lattice 
formation and domain organization on the cell membrane. Galectin-9 is also found intracellularly, although it’s mode 
of action there is not clear yet.  
 
 
The ligand binding is well regulated and dynamic. As already mentioned, variations in the linker 
length can affect valency. Furthermore, the specificity and affinity of the N- and C-terminal CRDs 
for specific glycoconjugates vary43,44. This readily affects the affinity for different binding 
partners. So far, a limited number of galectin-9 binding partners have been identified and verified 
(Table 1). For example, Tim-3 and CD44 have been identified as extracellular receptors for 
galectin-945,46 and NF-IL6, a transcription factor, has been implicated as an intracellular binding 
partner47. Up to now, little is known regarding the binding of specific ligands to the different 
galectin-9 isoforms. In addition, the knowledge about the functional consequence of galectin-9 
binding to binding partners is limited and a genome-wide analysis to identify galectin-9 interacting 
proteins would enhance our understanding of the role and function of galectin-9. 
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Galectin-9 expression in cancer 
Galectin-9 expression is widely distributed in tissues involved in the immune system, i.e. spleen, 
thymus and peripheral blood lymphocytes, and in tissues of endodermal origin, i.e. liver, intestine, 
stomach and lung. Conflicting data were reported for skeletal and cardiac muscle, brain and 
kidney25-27 but this most likely reflects differences in the experimental setup and sensitivity of the 
assays used to detect galectin-9 expression. This is exemplified by the observation that gal-9FL - 
long thought to be an intestine specific isoform of galectin-9 - has now also been shown to be 
expressed in several other cell types, like immune cells and endothelial cells35,40.  
Regarding the expression in cancer, one of the groups that first cloned galectin-9 identified 
it as a tumor antigen in Hodgkin’s lymphoma, implicating a role in tumor biology25. Indeed, several 
groups have now shown that galectin-9 levels vary when comparing tumor tissue to normal tissue 
(Table 2). Thus far, most of the studies show a low or decreased expression of galectin-9 in tumor 
cells as compared to their normal counterparts. For example, Lahm et al. performed an mRNA 
profiling study in an extensive panel of human tumor cell lines48. Breast, lung, melanoma, renal, 
adrenal and prostate cancer cell lines all showed low or absent galectin-9 expression. This is in 
line with other studies in which the expression, on both the mRNA and protein level, appears to 
be lost during the transformation to a malignant phenotype49-51. A high or increased galectin-9 
expression has only been reported in leukemia and colon cancer cell lines48. For cell lines derived 
from tumors of the nervous system and the ovaries, the expression of galectin-9 varied depending 
on the particular subtype of the tumor cell line investigated48. 
 Interestingly, galectins are increasingly recognized as prognostic markers for 
malignancies52,53 and galectin-9 is no exception to this (Table 2). When screening a panel of 84 
breast tumors, Irie et al. found galectin-9 to be expressed in half of these tumors. Moreover, 
galectin-9 expression predicted distant metastasis better than lymph node status: 19 out of 21 
metastasis-positive cases were galectin-9 negative while high galectin-9 expression resulted in an 
increased cumulative disease free survival of these patients50. Similar results were obtained in 
melanoma, cervical squamous cell carcinoma and hepatocellular carcinoma51,54,55. Altogether, 
most current data suggest an inverse relation between galectin-9 expression and cancer progression 
for the majority of solid tumors. However, it is important to note that most studies did not take into 
account the extensive galectin-9 splicing. Only Lahm et al. made a distinction between gal-9FL 
and gal-9∆5, indicating that for a minority of cases these splice variants are differentially expressed 
in tumor cell lines48,56. It remains to be determined whether the expression of specific splice 
variants is also different in human tumor tissues. Furthermore, it is still largely unknown how the 
expression of galectin-9 is regulated. So far, interferon-gamma (IFNg) has been shown to induce 
galectin-9 expression in fibroblasts42 and endothelial cells57. In the latter cells, IFNg-dependent 
expression and membrane translocation was under control of HDAC358. Additional modulators of 
galectin-9 include interleukin-1β (IL-1β) and interleukin-5 (IL-5) in respectively astrocytes59 and 
eosinophils60. Again, it remains to be studied whether and how these compounds affect galectin-9 
isoform expression.  
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Table 1. Galectin-9 binding partners 
Binding partner Carbohydrate 
dependent 
Funcional consequence Reference 
Verified 
Branched N-glycan-type 
oligosaccharides 
Yes ND [43] 
Linear b1-3-linked poly-N-
acetyllactosamines 
Yes ND [43] 
Branched N-glycans without 
a2,3-sialylation 
Yes N-terminal CRD specific [107] 
A2,3-sialylated oligosaccharides Yes C-terminal CRD specific [43] 
Lipid rafts ND Induction osteoblast 
differentiation 
[108] 
Latent membrane protein 1 ND ND [109] 
(Galb1-3)n epitopes Yes Leishmania major and host 
interaction 
[110] 
T cell immunoglobulin mucin-3 
(Tim-3) 
Yes Th1 cell apoptosis 
Modulation of numerous immune 
cell types 
[45, 99] 
Thrombin ND Cleavage of gal-9 and decrease of 
eosinophil attraction 
[111] 
Galectin-9 Yes Homo-multimerization and 
increased valency 
[112] 
Galectin-8 Yes Hetero-multimerization and 
increased valency 
[112] 
Galectin-3 Yes Hetero-multimerization and 
increased valency 
[112] 
CD44 Yes Suppression of CD44-hyalunoric 
acid binding 
CD44/BMP receptor complex 
formation 
[46] 
[108] 
IgE Yes Prevention of mast cell 
degranulation 
[113] 
NF-IL6 (C/EBPb) ND Inflammatory cytokine production [47] 
Protein disulfide isomerases Yes Regulation of T-cell migration [88] 
Implicated 
Integrin-a4/b1 (ITGa4ba) ND Suppression of ITGa4b1/VCAM-
1 binding 
[74] 
Vascular cell adhesion molecule-
1 (VCAM-1) 
ND Suppression of ITGa4b1/VCAM-
1 binding 
[74] 
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Table 2. Galectin-9 expression and prognostic value in cancer 
Cancer type Origin (a) Protein/mRNA Prognosis (b) Localization (c) Reference 
Low or decreased galectin-9 expression  
Breast Patient tissue 
MCF7 
Cell lines (9) 
Protein 
Protein 
mRNA 
 
() 
ND 
C 
C 
NS 
[50] 
[50] 
[48] 
Lung Cell lines (10) mRNA ND NS [48] 
Renal ACHN mRNA ND NS [48] 
Adrenal SW13 mRNA ND NS [48] 
Prostate Cell lines (3) mRNA ND NS [48] 
Skin Patient tissue 
Cell lines (3) 
HS294T 
Protein 
Protein/mRNA 
mRNA 
 
() 
ND 
C, N 
C, M 
NS 
[51] 
[51] 
[48] 
Cervical Patient tissue Protein  () C [54] 
Oral Cell lines (3) Protein/mRNA () C [49] 
Brain Cell lines (8) mRNA ND NS [48] 
Ovarian Cell lines (2) mRNA ND NS [48] 
Liver Patients protein ↑ C [55] 
High or increased galectin-9 expression  
Lymphoma Patient tissue Protein/mRNA ND NS [25] 
Leukemia Cell lines (3) mRNA ND NS [48] 
Colon Cell lines (23) mRNA ND NS [48] 
(a) Number of different cell lines tested is indicated between brackets, for additional information see the 
corresponding references. For cell lines, the classification was based the expression level reported in the majority 
of cell lines. (b) ↑ = high expression is correlated with a good prognosis. (↑) = high expression is correlated with 
decreased aggressiveness, i.e. metastasis. ND = Not determined. (c) C = cytoplasm; N = nucleus; M = membrane; 
NS = not specified. 
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Functions of galectin-9 in cancer progression 
 
It is now well established that individual galectins can modulate several processes during 
tumorigenesis simultaneously7. For example, galectin-1 mediates tumor cell transformation by 
anchoring oncogenic H-ras to the membrane, resulting in excessive signaling18. In addition, 
galectin-1 modulates tumor cell adhesion and metastasis61-63, tumor angiogenesis13,64 and tumor 
immune escape24. Similarly, galectin-9 has now also been implicated in several aspects of cancer 
progression. 
 
Apoptosis and cell cycle control 
 Galectins have classically been associated with cell-cycle control and apoptosis20,65. In 
tumor biology this is the most extensively studied property of galectins7. Aside from galectin-1 
and galectin-3, galectin-9 also modulates cell survival. Galectin-9 induces apoptosis when added 
to various cell types, e.g. human melanoma cell lines, T cell lines and different types of leukemia 
cell lines51,60,66-68. This pro-apoptotic effect of galectin-9 is dependent on β-galactoside binding 
activity and signaling seems to occur through NF-kB and the calcium-calpain-caspase-1 pathway 
in T cells67. The receptor for galectin-9-mediated apoptosis on T-cells appears to be TIM-345 
although there are reports indicating that other receptors might be involved69. The observation that 
galectin-9 induces apoptosis of many blood cancer cells appears to contrast with the reports that 
these cells have an increased galectin-9 expression. However, for other galectins differential 
effects on cellular processes like proliferation and apoptosis were found to depend on the 
concentration and localization of the galectin64,70,71. It is likely that these context-dependent effects 
also apply to galectin-9. For example, in endothelial cells IFNg induces both a cell cycle arrest72 
and increased expression of galectin-957. This might indicate an inverse relation between galectin-
9 and cell proliferation. Consequently, loss of galectin-9, as observed in many malignant cells, 
could simultaneously confer resistance to apoptosis and increase the proliferative potential. 
However, the supporting data are largely indirect and further studies are required to establish 
whether such a link exists. 
 
Adhesion, migration and metastasis 
 Initial observations in tumor cell lines pointed towards the involvement of galectin-9 in 
tumor cell adhesion. For example, galectin-9 expressing melanoma cells form colonies while cells 
that lack galectin-9 expression do not51. Similarly, MCF7 breast cancer cells with high galectin-9 
expression form clusters which is not observed for low galectin-9 expressing cells50. In the latter 
study it was shown that restoring galectin-9 expression also restored cell cluster formation. This 
was seen for gal-9FL, gal-9∆5 and gal-9∆5/6. Interestingly, increased expression of only gal-9FL 
and gal-9∆5/6 inhibited the adhesion of MCF7 cells to different extracellular matrix components, 
including collagen, fibronectin, vitronectin and laminin50. On the other hand, low galectin-9 
expressing oral squamous carcinoma cells (OSCC) showed increased adhesion to collagen and 
fibronectin following overexpression of galectin-949. Unfortunately, the latter study did not state 
which galectin-9 variant was overexpressed. Possibly, the adhesion depends on the relative 
abundance of individual galectin-9 splice variants. Thus, while increased levels of gal-9FL and 
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gal-9∆5/6 seem to result in an inhibition of cell adhesion to extracellular matrix components, high 
abundance of gal-9∆5 might promote it. Future studies could provide evidence whether or not such 
variant-dependent regulation of adhesion does occur. Some recent results provided insight that 
such a link might exist. Zhang et al. showed that increased expression of galectin-9 modulates E-
selectin levels in LoVo colon carcinoma cells73. Interestingly, specific galectin-9 splice variants 
showed a diverging effect. Gal-9FL overexpression induces downregulation of E-selectin 
expression in these cells. Gal-9∆5 and gal-9∆5/6 overexpression results in the upregulation of E-
selectin, with concomitant increased adhesion of these cells to endothelial cells. Whether this is a 
mechanism acting in vivo thereby facilitating colon cancer cells to metastasize remains to be 
determined. In addition, while Gal-9FL overexpression did not result in an increased adhesion of 
LoVo cells to endothelial cells it did result in an increased adhesion of these cells to matrigel. This 
further illustrates that the effects of galectin-9 on adhesion depend on which ligands are available 
in a given setting. Since galectin-9 is secreted by various cell types35,42, increased expression of 
this protein in cancer cell lines likely results in an increased secretion accounting for the observed 
effects. Indeed, extracellular galectin-9 has been implicated in the regulation of cell adhesion and 
metastasis. For example, exogenous galectin-9 induces aggregation and apoptosis of MM-RU 
cells51. In addition, intravenous administration of a stable recombinant galectin-9 lacking the linker 
region prevents lung metastasis of B16F10 and Colon26 colon cancer cells74. Interestingly, both 
these cell lines highly express CD44 and integrin family members. Galectin-9 suppressed the 
binding of hyaluronic acid to CD44 in both cell lines and also suppressed the binding of vascular 
cell adhesion molecule-1 (VCAM-1) to integrin-α4β1 (ITGα4β1; very late antigen-4) in B16F10 
cells. In this study, a stable form of recombinant human galectin-9 was used that lacks the linker 
domain. However, experiments performed with mouse gal-9∆5 yielded similar results as those 
performed with the stable form of human galectin-9, suggesting the latter indeed reflects gal-9∆. 
However, further studies to confirm this are required. Of note, modulating cell adhesion by integrin 
binding and regulation is a recurrent theme in galectin biology, with different galectins regulating 
different integrins75,76. In fact, targeting of integrin/galectin axes shows promise as a diagnostic 
and therapeutic tool77,78. 
 As already described, loss of galectin-9 expression is consistently correlated with increased 
tumor aggressiveness. In fact, in both melanoma and breast cancer patients, distant metastasis 
showed a lack of galectin-9 expression in the vast majority of cases50,51 and galectin-9 expression 
in cervical squamous cell carcinoma and hepatocellular carcinoma is inversely correlated with 
malignant potential54,55. Altogether, current data suggest that the most dominant galectin-9 
isoform, i.e. gal-9∆5, might prevent metastasis by maintaining tissue integrity and hampering 
tumor cell migration and extravasation, while other galectin-9 isoforms facilitate metastasis. As a 
result, loss of gal-9∆5 during tumor progression would result in increased aggressiveness. This 
was recently supported by findings of Zhang et al. who showed that loss of galectin-9 in 
hepatocellular carcinoma cells in vitro increased the adhesive and invasiva activity of these cells55.  
 
Immune escape 
 Ever since its initial cloning, galectin-9 has been extensively studied in the context of 
immunity and inflammation4,39. Galectin-9 acts as a cytokine and modulates the activity and 
function of numerous types of immune cells. Surprisingly, a role for galectin-9 in tumor immune 
escape has remained largely unexplored despite the fact that several findings point towards 
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immunosuppressive activity similarly to e.g. galectin-179. First, galectin-9 is well characterized as 
an eosinophil chemoattractant80, with gal-9FL being the most potent splice variant for this effect35. 
Eosinophils have predominantly been associated with anti-tumor activity and consequently, the 
presence of these immune cells is associated to a good prognosis81. Interestingly, eosinophilia is 
often observed in hematological and colon tumors82-84. As discussed previously, these tumors 
frequently display an increased galectin-9 expression compared to normal tissue. At this point, it 
remains to be determined whether tumor-derived galectin-9 indeed mediates infiltration of 
eosinophils into the tumor micro-environment and whether loss of galectin-9, as observed in 
several solid tumor types, indeed allows tumors to escape from an eosinophil-mediated anti-tumor 
response.  
 Galectin-9 has also been shown to modulate the differentiation and expansion of other 
immune cells. For example, galectin-9 administration suppresses the differentiation of Th17 cells 
while promoting the differentiation of CD4+CD25+FoxP3+ regulatory T (Treg) cells in a murine 
model for collagen-induced arthritis85. Interestingly, the galectin-9-Tim-3 axis has been implicated 
in the immune suppression mediated by Tregs86. Galectin-9 has also been shown to induce 
apoptosis in a number of immune cell types like CD4+ type 1 helper T (Th1) cells45 and CD8+ 
cytotoxic T (Tc) cells87. At the same time, galectin-9∆5 promotes the migration of type 2 helper T 
cells through the extracellular matrix without inducing apoptosis88 All this suggests an 
immunosuppressive activity of galectin-9 that might result in tumor immune escape. This 
immunosuppressive effect of galectin-9 was indeed proposed as the mechanism by which Epstein-
Bar-virus-infected nasopharyngeal carcinoma cells escape immune surveillance89. On the other 
hand, galectin-9 administration was also shown to induce the expansion of dendritic cells resulting 
in the potentiation of CD8+ or natural killer (NK) cell-mediated anti-tumor immunity in sarcoma 
and melanoma models respectively90,91. Furthermore, the observation that galectin-9 
predominantly suppresses immune function seems hard to reconcile with the poor outcome in 
patients with low galectin-9 expression. Possibly, galectin-9 expression is lost during the course 
of tumorigenesis, enabling tumor cells to metastasize more easily as soon as multiple other modes 
of immune escape have developed. 
 
Angiogenesis  
 The growth of new blood vessels out of existing capillaries, i.e. angiogenesis, is essential 
for tumor progression. The vascular cells responsible for this process, i.e. the endothelial cell, 
express different galectin family members40 several of which have been shown to regulate tumor 
angiogenesis, including galectin-811, galectin-312,19,92 and galectin-113,64. Multiple galectin-9 splice 
variants have been found to be expressed by endothelial cells36,40. Furthermore, we have shown 
that galectin-9 expression is regulated during endothelial cell activation40 while others have shown 
that galectin-9 expression in endothelial cells appears to involve IFNg57 and HDAC358. Despite 
these findings, the exact role of galectin-9 in endothelial cell biology and angiogenesis remains 
elusive. Although speculative, the protein is possibly involved in attracting eosinophils or 
expanding dendritic cells, which have been shown to release angiogenic growth factors like 
VEGF84,93. In addition, altered galectin-9 levels on the endothelial cell layer might affect 
infiltration of anti-tumor immune effector cells, e.g. Th1 and Tc cells, as well as immune-
suppressive immune cells, e.g. eosinophils and Tregs, thereby interfering with a proper anti-tumor 
immune response.  
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Galectin-9 as a potential target for therapeutic intervention in cancer 
The emerging paradigm is that galectin-9 acts on multiple levels in tumor biology, similarly to 
other galectin family members. So far, galectin-9 has been implicated in tumor cell adhesion and 
metastasis, immune escape and tumor angiogenesis. From these observations a model emerges in 
which a decrease in overall intratumoral galectin-9 levels confers resistance to apoptosis and 
facilitates metastasis while galectin-9 in the tumor vasculature maintains its role in tumor immune 
escape (Figure 2). The observation that galectins can exert diverging functions simultaneously and 
that their expression is often altered in tumors makes these proteins attractive targets for anti-
cancer therapy. For example, agents targeting galectin-113,63,94,95 and galectin-396-98 show 
substantial anti-tumor effects and current data suggest that administration of galectin-9 might be 
similarly beneficial99. In line with this, recombinant stable galectin-9 has been used successfully 
as a therapy in a number of mouse disease models with an overactivated immune system as the 
underlying cause, like graft versus host disease86,87, rheumatoid arthritis85,100 and asthma46. These 
findings have prompted a similar approach for cancers of the immune system. Indeed, in models 
of leukemia and myeloma treatment with galectin-9 hampered progression by inducing 
apoptosis66,101. In addition, administration of galectin-9 also hampered tumor progression in mouse 
models of melanoma and colon cancer by blocking metastasis74. Unexpectedly, galectin-9 was 
found to potentiate the immune response in the melanoma model by expanding dendritic cells and 
potentiating NK cell mediated anti-tumor immunity. As similar effect was reported in murine 
model of lung cancer, in which galectin-9 signaling induces the differentiation of macrophages 
into plasmacytoid dendritic cell-like macrophages102.These initial findings are promising and 
warrant further research into the effect of galectin-9 administration on e.g. metastasis and 
modulation of immune function in other (solid) cancer types. In addition, it will be of interest to 
assess the effect of inhibiting rather than potentiating galectin-9 in the tumor vasculature, given 
that increased endothelial galectin-9 expression might be an important mediator of tumor immune 
escape. Attempts to find compounds specifically targeting individual galectins have been made103-
105. Similarly, some compounds are known to target galectin-9, albeit not specific106. To our 
knowledge, no galectin-9 specific inhibitor has been described yet. Apart from interfering with 
galectin-9 function, the protein itself could also be used to target compounds specifically to e.g. 
the tumor vasculature, similar as described for galectin-177,78. Such a strategy could be employed 
both for therapy and diagnosis of cancer. Finally, no studies have taken the existence of different 
galectin-9 isoforms into account. Given the opposing effects galectin-9 variants can have on e.g. 
cell adhesion, it will be important to determine the effects of targeting or administering specific 
variants in different tumor models.  
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Figure 2. Established and hypothesized roles of galectin-9 in solid tumor biology. Depicted in the picture is a 
tissue as it transgresses from a normal physiological state (left side) to solid tumor tissue (right side). This is generally 
associated with a loss of galectin-9 in the tissue and consequently tissue integrity loss, facilitating metastasis. In 
addition loss of galectin-9 could confer tumor cells with resistance to apoptosis. Conversely, galectin-9 levels on 
endothelial cells are increased in the tumor tissue, possibly facilitating metastasis by mediating tumor cell-endothelial 
cell interactions. Although further experiments are required to test this hypothesis, the high endothelial levels of 
galectin-9 could contribute to an immune-suppressing boundary separating circulating immune cells from tumor cells, 
for example by inducing apoptosis of anti-tumor immune effector cells like Th1 and Tc cells and at the same time 
facilitating immune-suppression by Tregs. In addition, eosinophil attraction near sites of angiogenesis could be 
maintained.  
 
Future perspectives 
A role for galectin-9 as a jack of multiple trades in tumor biology is apparent, although many 
questions remain to be addressed. A better understanding of the molecular mechanisms underlying 
the various effects observed for galectin-9 is required. A genome-wide screening approach to 
identify galectin-9 binding partners would be a logical first step in this endeavor. Also, it is now 
becoming clear that alternative splicing of galectin-9 can have profound effects on the function of 
the protein. As such, future studies should clearly differentiate between galectin-9 splice variants 
when exploring galectin-9 function. Current findings identify galectin-9 as a promising target for 
diagnostic and therapeutic applications. The generation of recombinant galectin-9 isoforms and 
specific inhibitors of these proteins will allow further exploration of the applicability of galectin-
9 in cancer treatment.  
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Abstract 
In mice, the galectin-1 gene LGALS1 encodes for two transcripts which vary in the length of their 
5-prime untranslated region (UTR). Here, we show that different human cells also express two 
transcripts and assert a new role to the longest transcript (gal-1L). In silico analysis showes that the 
5-prime UTR of gal-1L forms a stable loop downstream of which a processing event occurs, 
yielding an RNA fragment of approximately 100 nucleotides. Expression analysis showed that 
both transcripts are differentially regulated during endothelial cell activation. Moreover, the 5-
prime UTR of gal-1L can act as na competing endogenous RNA, i.e. a scavenger RNA for miRNA-
296-5p. As a result, gal-1L can counteract the inhibitory effects of miRNA-296-5p on its target 
genes, including HGS and p21. All this points towards a distinct function of the gal-1L transcript 
and constitutes a novel mechanism in regulation of angiogenesis. 
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Introduction 
Galectin-1 is a carbohydrate binding protein that exerts a number of functions in a wide range of 
cells. Extracellular galectin-1 has been shown to modulate processes like cell adhesion and 
migration 1,2,3,4 and to facilitate signaling by clustering membrane receptors 5. Intracellularly, 
galectin-1 has been linked to RNA splicing 6, and H-ras signal transduction 7, functions that occur 
independent of carbohydrate binding. Because of its broad spectrum of activities on the cellular 
level, galectin-1 is involved in different (patho)physiological processes like immune response 
regulation 8 and tumor biology 9. Regarding the latter, studies indicate that galectin-1 often acts on 
several levels concomitantly, including tumor cell transformation 7, tumor immune escape 10 and 
tumor angiogenesis 11,12. This illustrates the importance of gaining insight in galectin-1 expression 
regulation. Several factors controlling galectin-1 expression have been identified. For example, 
activation of regulatory T cells 13 and endothelial cells 14 as well as irradiation of glioma cells 15 
induce the expression of galectin-1. In addition, several signaling molecules and receptors have 
been shown to affect galectin-1 expression, including epidermal growth factor 16 and transforming 
growth factor-β 17.  
Recently, advances have been made in understanding galectin-1 expression at the genetic level. 
The methylation status of the galectin-1 promotor has been suggested to control galectin-1 
expression, since hypermethylation results in lowered galectin-1 expression in colon cancer 18 and 
demethylation correlates with the level of galectin-1 expression when comparing different tissues 
19,20. Apart from methylation status, several transcription factors have been identified that control 
galectin-1 expression. For example, intronic binding of NF-kB to LGALS1 results in an increased 
transcription in T cells 21,22. In addition, CCAAT/enhancer binding protein-α and hypoxia 
inducible factor 1-α have been shown to act synergistically to increase galectin-1 expression in 
acute myloid leukemic cells 23.  
Interestingly, two distinct and overlapping core promotor elements have been found to 
control galectin-1 expression in mice 24. These two elements, i.e. a TATA-box and an initiator 
element, regulate the transcription of two distinct galectin-1 transcripts that vary in the length of 
their 5’ untranslated region (UTR). The functional relevance of these transcripts remained unclear. 
Here we provide evidence that both transcripts are also expressed by different human cells and 
tissues. In addition, we show that the galectin-1 transcripts are differentially regulated in 
endothelial cells. Finally, we present a possible function of one of the transcripts in endothelial 
cell biology as a scavenger molecule for the pro-angiogenesis miRNA miR-296. 
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Materials and methods  
Isolation of primary endothelial cells and cell culture 
Primary human umbilical vein endothelial cells (HUVECs) were isolated as described previously 
11. To obtain quiescent HUVEC (H0), half of the isolated cells were lysed immediately after 
isolation. Active HUVEC (H+) were obtained by cultering the remaining half of the cells for at 
least 3 days in HUVEC culture medium (RPMI (Gibco) containing 10% fetal calf serum 
(Invitrogen) and 10% human serum, supplemented with L-glutamin (Invitrogen) and 
penicillin/streptomycin (Invitrogen)). HEK293T and MBA-MD231 cells were cultured in DMEM 
supplemented with 10% fetal calf serum (Invitrogen). All cell cultures were maintained in a 
humidified incubator at 37°C/5% CO2. 
Table 1. Primers 
RACE primers 
 Forward (5'-3')  Reverse (5'-3') 
r1*  5'RACE adaptor (Ambion) rA* 3'RACE adaptor (Ambion) 
r1 AGTTAAAAGGGTGGGAGCGT rA GCCTGGTCGAAGGTGATG 
r2 CTCCTGGACTCAATCATGGC rA CTCCAGGTTGAGGCGGTT 
  rA CTTTATTGGGGGCCATGG 
Galectin-1 qPCR primers and walkthrough primers 
q1 AGTTAAAAGGGTGGGAGCGT qA CTCCACCCGAGAGAGATGG 
q2 TGCAACAGCAAGGACGGC qB CGCACCAGCTGTCAGAAGA 
q3 TCTCTCTCGGGTGGAGTC qC AGGATGTTCCCGGGCAG 
q4 ATGGCTTGTGGTCTGGTCG qD GATTGAGTCCAGGAGGATGTT 
  qE CAAGCCATGATTGAGTCCAG 
  qF GAGATTCAGGTTGCTGGCG 
  qG TCGCCTCGCACTCGAAG 
  qH GTTCAGCACGAAGCTCTTAGC 
  qJ CACCTCTGCAACACTTCCA 
 
Rapid Amplification of cDNA Ends (RACE) and sequencing 
RACE was performed with the FirstChoice RLM-RACE kit (Ambion) according to the supplier’s 
protocol. For the 5’RACE experiments, a CIP/TAP treatment followed by adaptor ligation ensured 
only capped RNA was reverse transcribed. In the 3’RACE experiments, the adaptor was ligated to 
the poly-A tail. PCRs were performed both by combining adaptor primers with in-transcript 
primers and by combining primers within the transcript (Table 1). Only adaptor primer-in 
transcript primer combinations were sequenced. Sequence analysis of obtained PCR products was 
performed by BaseClear (Leiden, the Netherlands). 
 
Real time polymerase chain reaction (qPCR) 
RNA was isolated using the miRNeasy kit (QIAgen) according to the supplier’s protocol. On-
column DNaseI digestion (QIAgen) was performed. The purity and concentration of the RNA 
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samples were determined by spectrophotometry (ND-1000, Nanodrop technologies). cDNA 
synthesis was performed on 500 ng total RNA using the iScript cDNA synthesis kit (BioRad) 
according to the supplier’s protocol. The final volume of the cDNA synthesis reaction was adjusted 
to 50 µl. qPCR was performed on the CFX96 real time PCR detection system (BioRad). In short, 
1.5 µl of cDNA was used in a reaction volume of 25 µl containing 1x SYBR mix (BioRad) and 
400 nmol/L of forward and reverse primers (Tables 1 + 2). A 2-step amplification protocol was 
used with Tm = 60°C, followed by a melting curve analysis. Expression was assessed with the ΔCt 
method as described previously 14. 
Table 2. qPCR primers miR296-5p targets 
 Forward (5'-3') Reverse (5'-3') 
HGS GCAAAATATGCTGTGAATTCC TGTTACGGACGTTTACCTCC 
p21 CCCGTGAGCGATGGAACT CGCTCCCAGGCGAAGTC 
SCRIB TGCTCCGGTTCCAGACG TCCTCAGCGTCCTCATCACC 
PUMA GACAAGAGGAGCAGCAGCG TACATGGTGCAGAGAAAGTCC 
HMGA1 ACTGGAGTCTCCTGTGGTGTGT AGTGCTATTTCCCCTCCCTTC 
HWNK4 GTGAAGGCTGCGGAAGACTC CTGGGTCTCCATGTCCTCCTT 
NANOG GAAGACCTGGTTCCAGAACC ATTGTTCCAGGTCTGGTTGC 
 
Galectin expression constructs 
Full length galectin-1 transcripts were obtained by PCR using the following primers: gal-1L 
forward: AATAGGATCCAGTTAAAAGGGTGGGAGC; gal-1S Foward: AATAGGATCCAT-
CTCTCTCGGGTGGAGT; gal-1L/S Reverse: TTTTAAGCTTCTTTATTGGGGGCCATG. 
Subsequently, the amplicons were directionally cloned into pRNAT U6 Hygro using BamHI and 
HindIII digestion and T4DNA ligase according to standard protocols. Succesful cloning was 
confirmed by sequence analysis (Baseclear).  
 
Transfections 
Transfection of expression constructs and miRNAs was performed with Lipofectamine2000 
(Invitrogen) following the supplier’s protocol. The DNA:lipofectamine ratio used was 3:1. For 
transfection, 50nM of premiR-296-5p (Ambion), antagomiR-296-5p (Ambion) or cy3-labeled 
scrambled miRNA (Ambion) were used. Efficient overexpression of all small RNAs and 
constructs was confirmed by stem-loop PCR and qPCR respectively. 
 
Luciferase reporter assay 
For the luciferase reporter assays, pTK Renilla and pmiR-REPORT (Ambion) constructs in which 
the 3’UTR of hgs (luc HGS) or a mutated version of it (luc mutHGS) were cloned were obtained 
from T. Würdinger 25. Luciferin expression was assessed with the Dual Luciferase Reporter Assay 
System (Promega) according to the supplier’s protocol. Renilla luciferase was cotransfected and 
used as an internal control. Two days post transfection, renilla and firefly luciferase activity was 
measured sequentially on a plate reader (Tecan). All samples were analyzed in triplicate. 
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In silico analyses 
The LGALS1 promotor region was analyzed using the Transcriptional Regulatory Element 
Database (http://rulai.cshl.edu/cgi-bin/TRED/tred.cgi?process=home) and TFSearch 
(http://www.cbrc.jp/research/db/TFSEARCH.html). RNA folding was assessed on the mfold web 
server (http://mfold.rna.albany.edu)26. In case multiple folds were possible the one reflecting the 
recurrent theme in folding, e.g. stem-like loops, at the lowest free energy (ΔG) was selected. 
Prediction of miRNA binding was performed with miRWalk (http://www.umm.uni-
heidelberg.de/apps/zmf/mirwalk/index.html)27. 
 
Protein isolation and near-infrared Western Blotting 
For Western blot analysis, cells were lysed in the culture plates using cell lysis buffer (Cell 
Signaling) supplemented with protease inhibitors according to the supplier’s protocol. Protein 
concentrations were determined using the BCA protein assay (Pierce). Subsequently, 30 µg of 
protein was suspended in Laemlli sample buffer (Biorad) supplemented with 1:20 β-mercapto-
ethanol. Samples were boiled and immediately separated by gel electrophoresis on a 15% 
polyacrylamide gel and transferred onto PVDF membranes (Millipore) following standard 
protocols. Membranes were blocked with Oddyssey blocking buffer (LI-COR Biosciences) for 1 
hour and incubated overnight at 4°C with primary antibody: rabbit anti-galectin-1 (1:1000, 
Peprotech), rabbit anti-p21 (1:1000, Cell Signaling) and mouse anti-b-actin (1:10000, MP 
Biomedicals). The membranes were washed with PBS/0.1% tween and subsequently incubated 
with the appropriate secondary IRDye antibodies (1:10000 IRDye 800 anti-rabbit and 1:10000 
IRDye 800 anti-mouse, LI-COR Biosciences) for 1 hour at room temperature. Finally, membranes 
were washed with PBS/0.1% tween and rinsed with PBS. Images were obtained by scanning the 
membranes with the Odyssey infrared imaging system (LI-COR Biosciences). 
 
Results 
LGALS1 encodes for 2 transcripts that vary in the length of the 5’untranslated region 
Previous studies suggested the existence of two LGALS1 transcripts in mouse fibroblasts that 
resulted from two distinct transcription initiation sites in the promoter region (De Gregorio, 2001). 
Since the human and mouse LGALS1 promoter regions show a high degree of conservation and 
contain similar regulatory elements (Figure 1a) we questioned whether endothelial cells also 
express two LGALS1 transcripts. Therefore, 5-prime and 3-prime rapid amplification of cDNA 
ends (RACE) analysis was performed on cDNA from primary isolated human umbilical vein 
endothelial cells (HUVEC). Using different primer combinations (Figure 1b) we identified 2 
galectin-1 transcripts of different length. Cloning and subsequent sequence analysis revealed that 
both transcripts contain the complete galectin-1 ORF and differ only in the length of the 5-prime 
UTR, similar as described for the mouse transcripts. The short transcript (gal-1S) starts 31 bases 
upstream of the long transcript (gal-1L). De Gregorio referred to gal-1S as the +1 transcript and 
gal-1L as the -31 transcript. However, since current genomic databases identify the start of human 
gal-1L at +1 (NCBI: NM_002305; Ensembl: ENST00000215909) we propose to change 
nomenclature of gal-1L as the +1 transcript and gal-1S as the +31 transcript. Interestingly, while 
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both transcripts can be detected using 3-prime RACE, the 5-prime RACE reaction only yields 
products corresponding with gal-1S (Figure 1c). Since our 5-prime RACE protocol only detects 
capped RNAs, this observation suggests that the gal-1L is not capped and thus not involved in 
protein translation. Nevertheless, our data suggest the existence of 2 galectin-1 transcripts in 
human endothelial cells. To exclude this phenomenon was endothelial cell specific we also 
determined the expression of both transcripts in cell lines of different origin. Given the sequence 
homology between both transcripts we used primers that specifically amplify the gal-1L transcript 
or primers that amplify both transcripts. This revealed that gal-1S is the dominant transcript 
although the ratio's between total gal-1 and gal-1L varied considerably (Figure 1d). There was no 
inverse correlation between total and GAL-1L expression levels suggesting cell-type specific 
regulation of expression.  
 
Endothelial cell activation differentially modulates GAL-1S and GAL-1L expression 
Since we are primarily interested in the function of galectin-1 in angiogenesis, we next assessed 
the level of GAL-1S and GAL-1L expression in endothelial cells of different origin. We found that 
the total galectin-1 mRNA expression level is about 50 times higher than the GAL-1L mRNA 
levels in quiescent primary endothelial cells of different isolations (Figure 2a). Previously, we have 
shown that endothelial cell activation increases galectin-1 expression. In line with this, comparison 
of quiescent and activated HUVEC showed an approximately 6-fold increase of total galectin-1 
expression levels. Interestingly, this increase in total galectin-1 expression level was accompanied 
by a 2-fold decrease in gal-1L expression resulting in a ratio of total gal-1 over gal-1L of 45 in 
quiescent HUVEC and 450 in activated HUVEC. Similar ratio's were observed in the actively 
growing endothelial cell lines EC-RF24 and HMEC (Figure 2b).These data indicate that 
endothelial activation differentially affects the expression of the two galectin-1 transcripts.  
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Figure 1 
 
Figure 1. (a) Promotor region of mouse and human LGALS1. The location of 3 promotor elements driving the 
expression are shown, as are the transcription start sites for gal-1L (+1) and gal-1S (+31). (b) Schematic representation 
of the galectin-1 encoding gene LGALS1 and the identified galectin-1 transcripts. LGALS1 codes for two transcripts 
that vary in the length of the 5-prime UTR. One transcript is 31 bases shorter (Gal-1S) compared to the other (Gal-1L). 
The black triangles indicate the location of the different primers used for RACE (see also Table 1). (c) Images of DNA 
gel electrophoresis following RACE PCR using different primer combinations. The absence of amplicons in the most 
left panel indicates that the gal-1L is not capped. The faint bands in the third panel suggest rapid degradation of the 3-
prime UTR of gal-1L. (d) Expression analysis of total gal-1 RNA and gal-1L RNA levels in different cell lines. 
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Figure 2 
 
 
The 5’UTR of GAL-1L can form a loop structure that is processed atypically 
Next, we set out to unravel the functional relevance of the two transcripts. Sequence analysis 
already indicated that both transcripts contain the complete coding sequence of galectin-1. 
However, the observation that the gal-1L transcript lacks a 7mG cap suggests that this transcript 
does not contribute to protein synthesis. De Gregorio et al. suggested that the additional bases in 
mouse gal-1L allowed for folding into stem-loop structures that affect the stability and processing 
of the transcript. To determine whether human gal-1L could also fold into stable stem-loop 
structures we performed an in silico RNA folding analysis. Here, we found that the addition of 31 
bases at the 5’ end allows the formation of a stable hairpin loop structure which does not occur in 
the gal-1S 5’UTR (Figure 3a). Similar RNA folding was observed in other primates but loss of 
sequence homology in other animal species resulted in loss of the hairpin fold (Figure 3b). Since 
the hairpin structure in the primate sequences resembled a pri-miRNA structure, we hypothesized 
that gal-1L might give rise to a miRNA. Indeed, comparing the sequence of the hairpin loop with 
a deep sequencing miRNA library identified a potential miRNA located in the reverse strand of 
the loop, i.e. CUGACAGCUGGUGCGCCUGCC (Figure 3c). However, neither by Northern blot 
analysis nor by stem-loop qPCR we were able to detect this miRNA (data not shown). 
Furthermore, attempts to detect a drosha processing site within the hairpin by stem-loop qPCR 
failed (data not shown) suggesting that the loop does not represent a classic pri-miRNA.  
To determine whether the formation of the loop conferred an alternative form of processing 
to gal-1L we performed a walk-through qPCR with a forward primer at the most upstream 5-prime 
end of the gal-1L transcript combined with a series of reverse primers that bind increasingly distant 
of the 5-prime end of the transcript (Figure 4a and Table 1). This analysis showed a clear drop in 
qPCR signal downstream of reverse primer 4 indicating that gal-1L is processed downstream of 
the loop structure close to the ATG translation start codon (Figure 4b). The drop was not due to 
different PCR efficiencies since a walkthrough qPCR on cloned gal-1L cDNA did show the 
expected increase in signal intensity due to increasing amplicon length (Figure 4c). 
 
Figure 2. (a) Effect of endothelial cell activation 
on total gal-1 (black bars) and gal-1L (white bars) 
mRNA expression levels in primary isolated 
HUVEC (n=8). (b) Comparison of total gal-1 
(black bars) and gal-1L (white bars) mRNA 
expression levels in endothelial cell of different 
origin. 
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Figure 3 
 
Figure 3. (a) Images of the different folding of the first 70 bases in the 5-prime UTRs of gal-1L (left) and gal-1S 
(right). (b) Comparison of the sequence homology of the gal-1 5-prime UTR of different species and the respective 
RNA folding. All primates show complete conservation of the 5-prime UTR and the hair-pin fold. (c) Location of the 
potential miRNA in the gal-1L hairpin structure. 
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Figure 4 
 
 
In addition a similar walk-through qPCR with a forward primer targeting 5'-prime UTR of gal-1S 
did not show a drop suggesting that the processing is confined to gal-1L (Figure 4d). Altogether, 
these data show that the additional 31 nucleotides in gal-1L allow the formation of a stable hairpin 
loop that is processed of the transcript by a yet unknown mechanism.  
 
ce-G1L as a corresponding endogenous RNA 
Since the gal-1L transcript does not contribute to gal-1 protein synthesis (lack of a 7mG cap) and 
the hairpin loop does not represent a pri-miRNA, we assessed whether it could function as an 
competing endogenous RNA (ceRNA), i.e. a scavenger RNA for miRNAs. We thus screened gal-
1L for miRNA binding sites. This analysis revealed that miR-296-5p is an excellent potential prey 
for the gal-1L-hairpin, as it can bind with high complementarity (Figure 5a). In fact, the 
complementarity is 100% in the seeding region of miR-296-5p. Thus, we performed experiments 
to assess whether the gal-1L-hairpin could indeed functionally scavenge miR-296-5p. First, we 
determined the expression of known targets of miR-296-5p in HEK293T cells transfected with 
miR-296-5p alone and in combination with gal-1L or gal-1S (Figure 5b + Table 2). This induced 
different effects on target mRNA expression levels. For example, hWNK4, HGS and Nanog 
mRNA levels clearly decreased in the presence of miR-296-5p. 
 
Figure 4. (a) Schematic 
representation of the gal-1L/S 
transcripts and the 
localization of the different 
qPCR walkthrough primers 
(black triangles). (b) Diagram 
showing a drop in signal 
intensity at the translation 
start site (ATG) after 
walkthrough qPCR with the 
gal-1L forward primer in 
quiescent HUVEC. (c) 
Walkthrough qPCR on 
cloned gal-1L shows signal 
increase in line with 
increasing length of the 
amplicon. (d) Diagram 
confirming drop in gal-1L 
transcript length but not in 
gal-1S transcript length. (e) 
Schematic representation of 
the gal-1L hairpin structure 
with the localization of the 
region where processing by a 
yet unknown mechanims 
occurs. 
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Figure 5 
 
 
Figure 5. (a) Representation of miR-296-5p bound to the 5-prime UTR of gal-1L. The seeding region of miR-296-5p 
is shown in red. (b) Effect of miR-296-5p alone, or in combination with gal-1S or gal-1L on the mRNA expression of 
known targets of miR-296-5p. (c) Luciferase reporter assay (n=3) with wild type 3-prime UTR of HGS (luc HGS) and 
mutated 3-prime UTR of HGS (luc HGSmut) cloned at the 3-prime end of the luciferin reporter. miR-296-5p, gal-1L 
and gal-1S were cotransfected to assess their effect on luciferin expression. (d) Western blot analysis of p21 expression 
in MBA-MD231 cells following transfection with gal-1L, miR-296-5p, an antagomiR for miR-296-5p, or a scrambled 
control miRNA. Beta-actin expression was assessed as an equal loading control.
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Co-transfection with gal-1S or gal-1L did not affect this decrease for HGS or Nanog. On the other 
hand gal-1S did reverse hWNK4 mRNA levels while gal-1L even resulted in increased mRNA 
levels. This increase by gal-1L was also seen for PUMA mRNA levels which were only marginally 
decreased by miR-296-5p alone. The mRNA levels of HMGA1 and p21 were not affected while 
Scrib mRNA levels were increased by miR-296-5p alone or in combination with either gal-1S or 
gal-1L. Since the effects of miRNAs are generally more obvious at the protein level as compared 
to the mRNA levels we also performed a luciferase reporter assay for one miR-296-5p target, i.e. 
hgs. This experiment showed that inhibition of luciferin activity by miR-296-5p could be 
specifically rescued by gal-1L cotransfection (Figure 5c). Finally, Western blot analysis of p21 
levels in MBA-MD231 cells showed that gal-1L counteracted the activity of miR-296-5p to a 
similar extent as an miR-296-5p antagomir (Figure 5d). These data indicate that miR-296-5p 
indeed decreases p21 protein levels, while gal-1L overexpression has the opposite effect. 
Altogether, these data suggest that the gal-1L-hairpin might indeed serve as a competing 
endogenous RNA to regulate miR-296-5p activity. 
 
Discussion 
Several years ago, the existence of two mouse galectin-1 transcripts was reported by De Gregorio 
et al. 24. It was suggested that 2 core promotor elements overlap at the transcription start site 
resulting in the expression of 2 distinct galectin-1 transcripts that differ in the lengths of their 5-
prime UTR. However, the functional consequences of this regulation were not further explored. 
Here, we show that two distinct galectin-1 transcripts can also be detected in a variety of human 
cells. Since only one galectin-1 encoding gene is present in both mouse and human genomes, it 
can be excluded that both transcripts originate from a paralogous gene 28. Like in mice, the two 
galectin-1 transcripts only differ in the length of the non-coding 5-prime UTR, with the short 
transcript, designated gal-1S, starting 31 nucleotides downstream of the long transcript, gal-1L. In 
the current study, both transcripts were detected by 3-prime RACE suggesting that both contain a 
poly-A site at their 3-prime end which is also in accordance with observations in mice 24. However, 
3-prime RACE PCR with different 3-prime reverse primers also revealed that the levels of full 
length gal-1L were low suggesting rapid degradation of the 3-prime end of this transcript. 
Furthermore, gal-1L could not be detected by 5-prime RACE suggesting that this transcript is not 
capped post-transcriptionally. Finally, gal-1L expression levels were relatively low as compared to 
gal-1S in most cell lines. Together, this suggests that gal-1L is not involved in galectin-1 protein 
translation. This is further supported by the observation that the 31 additional bases at the 5-prime 
end of gal-1L allow the formation of a stable loop structure, which has been associated with 
inefficient translation by hampering ribosome entry 29,30. In addition, such structures have been 
shown to regulate translation indirectly, by modulating the activity of additional proteins 31. Thus, 
although it cannot be excluded at this point, it seems unlikely that gal-1S and gal-1L are responsile 
for the translation of different galectin-1 protein isoforms, e.g. those that have been reported by 
Miura et al. 32, especially since there is no alternative start codon in gal-1L. 
Rather than a role in protein translation, our results suggest that gal-1L might be involved 
in another mechanism, i.e. regulation of miRNA activity. Despite the fact that the hairpin fold 
resembles a pri-miRNA hairpin with an appropriate stability 33 and length of lower stem, upper 
stem and terminal loop sequences typically found in these structures 34, we could not detect any 
small RNAs of ~21 bases that might originate from the loop. Instead, we found that the additional 
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nucleotides in the 5-prime end of gal-1L can serve as a potential binding site for miR-296-5p, a 
miRNA which has been implicated in endothelial cell function and angiogenesis 25,34-36. In fact, 
the seed region of miR-296-5p was found to bind with perfect complementarity. In 2011, Salmena 
et al. suggested that non-coding RNAs can sequester miRNAs, preventing the latter to suppress 
protein-coding mRNAs 37. These non-coding where designated as competing endogenous RNAs 
(ceRNAs) since they compete with mRNAs for miRNA binding. Since gal-1L is not involved in 
galectin-1 protein translation it appears more likely that is able to act as a ceRNA for miR-296-5p. 
This is indeed supported by our current data. When assessing the effect of this miRNA on different 
target genes, i.e. HGS 25, PUMA 38, HMGA1 39, p21 40, SCRIB 41, HWNK4 42 and NANOG 43, we 
found that gal-1L but not gal-1S could counteract the inhibitory effects on the mRNA levels of 
PUMA and hWNK4. On a protein level, we observed that the suppression of HGS and p21 levels 
by miR-296-5p could be reversed by gal-1L. Although it still requires further confirmation, this 
regulation might also link the observed changes in gal-1L and gal-1S expression during endothelial 
cell activation to the pro-angiogenesis activity of miR-296-5p. For example, HGS has been 
implicated in the degredative sorting of angiogenic growth factor receptors like PDGFRb 44 and 
VEGFR2 45 while p21 is a cyclin-dependent kinase inhibitor that promotes cell cycle arrest 46 and 
has been implicated in endothelial cell cycle control and angiogenesis 47-49. The decreased 
expression of gal-1L that we found to occur during endothelial cell activation could thus result in 
less scavenging of miR-296-5p causing a better inhibition of HGS and p21. This would allow for 
cell cycle progression and an increase in membrane retention of growth factor receptors.  
Apart from the confirmation of this regulatory mechanism during angiogenesis, two 
additional issues remain to be addressed in the future. One issue concerns the observed processing 
of the gal-1L transcript approximately at position +100. This processing appears to involve the 31 
additional nucleotides since it does not occur for gal-1S. To our knowledge no similar form of 5-
prime UTR processing has been described yet. Natural termination of RNA polymerase III 
transcription can be excluded since there is no stretch of thymidine residues at the processing site 
50. Thus, it remains elusive which mechanism underlies this processing and whether it occurs in 
the 5-prime UTR of other mRNAs as well. Furthermore, the structural requirements for such 
processing, e.g. the presence of a loop and its appearance, should be further explored.  
Another important issue involves the regulation of transcript expression. It has been shown 
in different cell types that galectin-1 expression is increased upon stimulation with cytokines, 
growth factors or hormones 13,14,16,17,51. In addition, several molecular players that regulate galectin 
expression at the genetic level have been identified including NF-kB 21,22, CCAAT/enhancer 
binding protein-α23, hypoxia inducible factor 1α23 and promotor methylation 18-20. However, none 
of these studies distinguished between the two galectin-1 transcripts. De Gregorio et al. suggested 
the involvement of an upstream Sp1 consensus sequence, an Inr and a TATA-Box as core promotor 
elements in mice 24. However, whether this is also the case in human cells appears to be confirmed. 
Unraveling this mechanism appears relevant since we now show that activation of endothelial cells 
differentially affects the expression levels of both transcripts. It is thus important to gain more 
insight in the intracellular factors responsible for the differential regulation of gal-1S and gal-1L. 
In addition, it is important to determine the different functional consequences of this regulation. 
For example, we could still detect the expression of exon 1 in galectin-1 knockout mice 
52(unpublished data). This suggests that while galectin-1 protein expression is absent, additional 
functions of LGALS1 transcripts might still be active. Possibly, deletion of exon one would results 
in a different or more severe phenotype. 
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In summary, we describe the expression of two alternative galectin-1 transcripts in human 
cells, i.e. gal-1L and gal-1S. Both transcript are expressed at different levels and are differentially 
regulated upon endothelial cell activation. Furthermore, the 5-prime UTR of gal-1L folds into a 
stable hairpin structure and is processed by a yet unresolved mechanism. Importantly, the 5-prime 
UTR of gal-1L can serve as a scavenger molecule for the pro-angiogenesis miR-296-5p. This might 
link the differential expression of both transcripts in endothelial cells to the stimulatory activity of 
miR-296-5p during angiogenesis. Further research is required to unravel the mechanisms 
underlying the expression and processing of gal-1L. 
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Abstract 
Tumor angiogenesis facilitates tumor metastasis and allows malignant tissues to grow beyond a 
diffusion limited size. It is a complex process that requires endothelial cells to execute specific 
steps during different phases. miRNAs are small non-coding RNAs that act as molecular 
switches to redirect the expression profile of a cell. Evidence is emerging that miRNAs are 
important players in endothelial cell biology and tumor angiogenesis. In this review we 
summarize the available data of miRNA expression in the endothelium. In addition, we describe 
the current knowledge regarding the function of miRNAs in endothelial cell biology. Finally, we 
discuss the potential applications of miRNA based treatment strategies in angiostatic cancer 
therapy.
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Introduction 
During oncogenesis, tumor cells acquire characteristics that provide them with a growth advantage 
over normal cells. These characteristics, often referred to as the hallmarks of cancer, are shared by 
most, if not all, types of cancer and include infinite and self-sufficient growth, evasion of death 
signals, enhanced tissue invasion and metastasis, and sustained angiogenesis1. While most of these 
characteristics are intrinsic and self-governing, sustained angiogenesis depends on the 
participation of other cells, i.e. endothelial cells. These cells cover the luminal side of all blood 
vessels and they are the primary cells involved in the formation of new blood vessels. Because 
continuous neovascularization allows malignant cells to grow beyond a diffusion limited size, 
tumor angiogenesis has emerged as an attractive therapeutic target2,3.  
To induce angiogenesis, tumor cells have to undergo an angiogenic switch. This involves 
the increased expression and secretion of growth factors like the vascular endothelial growth factor 
(VEGF). When such growth factors bind to receptors on the endothelium in close by vessels, the 
endothelial cells switch from a quiescent to an active state. Subsequently, they embark on a process 
that results in the formation of new blood vessels that nourish the growing tumor mass. Tumor 
angiogenesis is a complex multistep process that requires endothelial cells to carry out specific 
activities at different phases. Proper execution of this process relies on a concerted action of 
multiple proteins. In addition to the classical mechanisms of expression regulation, it has become 
evident that cells also have microRNAs (miRNAs) at their disposal to switch on or off specific 
cellular processes4-8. More recent findings indicate that specific miRNAs might also be responsible 
for regulation of endothelial gene expression during tumor angiogenesis9,10. Here, we review the 
role of miRNAs in angiogenesis with a focus on tumor neovascularization.  
 
Tumor angiogenesis  
Angiogenesis is defined as the growth of endothelial sprouts out of pre-existing post-capillary 
venules. It can be distinguished from vasculogenesis, which refers to neovascularization by 
endothelial precursor cells, and from arteriogenesis, which is the maturation and growth of 
collateral blood vessels11-13. Angiogenesis is the main mechanism by which new blood vessels are 
formed during physiological processes like wound healing, inflammation, and the female 
reproductive cycle. In addition, angiogenesis is involved in various disorders including age-related 
macular degeneration, rheumatoid arthritis, endometriosis, and cancer3,14. Regarding the latter, it 
was observed already a century ago that angiogenesis occurs around tumors and further research 
into this phenomenon led to the hypothesis that tumors produce pro-angiogenesis factors to 
stimulate neovascularization15. In the early seventies, it was proposed that inhibition of 
angiogenesis might provide a means of cancer therapy2. Ever since, tumor angiogenesis research 
has focused on understanding of and interfering with the processes by which tumor cells promote 
the growth of new blood vessels16,17. 
 The process of tumor angiogenesis is primarily activated when a growing tumor mass 
surpasses the maximal volume that can be sustained by diffusion of oxygen and nutrients (Figure 
1)11. The hypoxic environment will cause the tumor cells to undergo an angiogenic switch leading 
to increased production of pro-angiogenesis proteins like the vascular endothelial growth factor 
(VEGF)18-20. These pro-angiogenesis proteins are shed into the environment and activate 
endothelial cells in nearby vessels. At the same time, an increased activity of different proteolytic  
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Figure 1 
 
Figure 1. Tumor angiogenesis. Tumor angiogenesis is initiated when tumor cells grow beyond a mass that can be 
supplied with oxygen and nutrients by diffusion. As a consequence, the tumor cells become hypoxic and undergo an 
angiogenic switch. This results in the production and secretion of growth factors that are sensed by endothelial cells 
in nearby vessels. Vessel dilation and matrix degradation occurs and the endothelial cells start to migrate and 
proliferate into the growth factor gradient. Finally the growing vessels mature providing the growing tumor mass 
with an irregular but functional blood supply. 
 
enzymes results in degradation of the basal membrane and detachment of cell-cell contacts, which 
facilitates vasodilatation and increases vessel permeability11,14. The proteolytic cleavage of the 
extracellular matrix also allows migration of the activated endothelial cells towards chemotactic 
signals that originate from the tumor tissue. These signals are sensed by so-called endothelial tip 
cells and the subsequent migration and proliferation of endothelial cells results in the formation of 
vessel-like structures11,21. The newly-formed premature vessels are fragile and leaky and require 
further stabilization. This maturation process includes inhibition of endothelial cell growth and 
subsequently the formation of capillary tubes by the recruitment of pericytes and smooth muscle 
cells and the deposition of a new extracellular matrix11,21. Eventually, a capillary network is 
formed. Despite its irregular and disorganized structure, this network is capable of providing the 
growing tumor mass with all the required metabolites. In addition, the vascular bed provides the 
tumor cells with the opportunity to enter the circulation and form distant metastases19. 
While different cell types contribute to neovascularization, the endothelial cell is generally 
acknowledged to be the central player in the angiogenesis process. In response to different triggers 
these cells display a variety of functions, including extracellular matrix remodeling, proliferation, 
and migration. All these functions require the expression of specific molecules, and proper 
execution of this complex process relies on the endothelial cell's flexibility to readily adjust the 
transcriptome and proteome to comply with the functional demands. Besides the more classical 
mechanisms, like regulation of gene promoter activity and altered protein turn-over, it has now 
become evident that cells also use small non-coding RNA molecules to govern gene expression. 
One class of these RNA molecules, i.e. microRNAs (miRNAs), act as molecular switches that can 
redirect the expression profile of a cell. Evidence is increasing that these miRNAs fulfill an 
important role in endothelial gene expression regulation during tumor angiogenesis. 
microRNA biogenesis and function 
 MicroRNAs (miRNAs) are non-coding, small single-stranded RNAs of approximately 22 
nucleotides that, together with short interfering RNAs (siRNAs), are key components of the RNA 
interference (RNAi) pathway22,23. RNAi is one of the RNA silencing pathways that cells have at 
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their disposal to specifically modify the expression of targeted genes or of genomic regions22,23. 
miRNA biogenesis is complex24 and for clarity we will only present the basics of miRNA 
biosynthesis and function (Figure 2). In animals, including humans, miRNAs are generally 
transcribed by RNA polymerase II and although the primary transcript, or pri-miRNA, is usually 
non-coding, many miRNA sequences are found to reside in introns of protein-coding transcripts23. 
A characteristic feature of a pri-miRNA is the presence of a single (or multiple) imperfect hairpin 
structure(s) with a stem of approximately 33 base-pairs22. Maturation of these hairpins into 
functional miRNAs is achieved via the sequential activity of two RNase III endonucleases, i.e. 
Drosha and Dicer. In the nucleus, Drosha -in the presence of DGCR8- excises the hairpin structure 
from the pri-miRNA23. The resulting cleavage product, an approximately 70 nucleotide long 
miRNA precursor, or pre-miRNA, is then transported out of the nucleus by an exportin-5 
dependent mechanism. In the cytoplasm, the double-stranded pre-miRNA is further processed by 
Dicer, which removes the hairpin loop to create a mature and functional, double stranded miRNA 
molecule22,23. Proper gene expression regulation by a mature miRNA requires incorporation of the 
double stranded molecule in a multi-protein RNA-induced silencing complex (RISC). Important 
proteins of this complex are Ago's, which constitute a subgroup of the argonaute protein family25. 
Ago's are key players in both siRNAs and miRNAs regulatory pathways since they mediate post-
transcriptional gene silencing by mRNA destabilization or by translational repression25. 
Association of a duplex miRNA strand with an Ago protein results in rapid miRNA unwinding 
after which one strand, the miRNA or guide strand, is retained in the complex and the other strand, 
the so-called miRNA* or passenger strand, is discarded22. At this point, the miRNA can direct the 
miRISC to the appropriate target mRNA and regulate post-transcriptional gene expression.  
 The gene expression regulation by miRNAs is achieved in two ways which are thought to 
depend on the degree of complementarity between the miRNA and the binding sites in the 
(predominantly) 3' UTR of the target mRNA. Perfect complementary binding of a miRNA will 
result in cleavage of the target mRNA while partial complementary binding primarily causes 
repression of protein synthesis26. Recent findings suggest that the latter, i.e. translational 
repression, is actually the default mechanism23,27,28. At which step in the translational process the 
repression occurs is still unresolved but several mechanisms have been proposed, all involving 
interference of the miRISC with the formation of a functional translational complex (for review, 
see Carthew and Sontheimer23).  
An important notion, based partial binding complementarity, is that a single miRNA might 
affect the expression of multiple genes. Indeed, several studies have shown that a single miRNA 
can bind up to hundreds of different gene targets29-31 and it has been suggested that mammalian 
miRNAs might control the expression of one-third of all human mRNAs7. Furthermore, a single 
mRNA can be targeted by multiple different miRNAs32 indicating that miRNAs act as control 
switches that regulate and tune the gene expression pattern of cells during (patho)physiological 
conditions. It is thus likely that miRNA-mediated gene expression regulation also contributes to 
altered cell functions during disease-related processes like tumor angiogenesis. 
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Figure 2 
 
 
 
 
Figure 2. miRNA biogenesis and 
function. miRNA sequences reside in 
intronic regions of protein coding genes or 
in specific miRNA genes. Transcription 
by RNA polymerase II and subsequent 
splicing in case of intronic miRNA results 
in the generation of a pri-miRNA that 
contains a single or multiple hairpin loops 
with a stem of approximately 33 base-
pairs. In the nucleus the hairpin is excised 
by the Drosha/DGCR8 complex, and the 
resulting pre-miRNA is transported to the 
cytoplasm by an exportin-5 dependent 
mechanism. Subsequent cleavage by a 
Dicer/TRBP complex generates a mature 
miRNA duplex which associates with 
Ago proteins to form a RNA-induced 
silencing complex (RISC). Following this 
association one strand of the duplex, i.e. 
miRNA*, is discarded. Although most 
miRNA*'s are degraded, some can form a 
functional RISC and also regulate target 
expression (dotted line). Perfect 
complementary binding of the miRISC 
with a target transcript induces mRNA 
degradation while partial complementary 
binding results in repression of 
translation. 
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Involvement of miRNAs in angiogenesis 
 The first evidence for a regulatory role of miRNAs in angiogenesis came from studies using 
animal models with disrupted miRNA biosynthesis. Both in zebrafish and mice, different 
approaches to interfere with Dicer expression have lead to phenotypes that are associated with 
vascular defects33. However, while highly suggestive, all these studies only provided indirect 
evidence for an involvement of miRNAs in angiogenesis. Considering that blood vessel formation 
is an early developmental process, any alteration during embryogenesis is likely to cause vascular 
defects as a secondary effect.  
 To study the direct effects of impaired miRNA biosynthesis on endothelial cell biology, 
several groups have evaluated the angiogenic activity of endothelial cells after specific knockdown 
of dicer in vitro. Silencing of dicer expression using siRNA resulted in decreased proliferation and 
tube formation of the human endothelial cell line EA.hy.92634. Similar observations were made 
after silencing of dicer expression in human microvascular endothelial cells (HMECs)35. Finally, 
Kuehbacher et al. observed decreased migration, sprouting, and tube formation after transfection 
of human umbilical vein endothelial cells (HUVECs) with dicer siRNA36. The latter group also 
found impaired angiogenesis in vivo using dicer knockdown HUVECs in a matrigel plug assay36. 
Additional in vivo studies were performed by Suarez et al. who generated 2 endothelial cell 
specific dicer knockout mouse models, a conditional Tie2-Cre;dicerfl/fl line and a tamoxifen-
inducible VECad-Cre-ERT2;dicerfl/fl line37. While these mice were viable and displayed no 
apparent (vascular) phenotype, the postnatal response to pro-angiogenesis triggers appeared to be 
hampered. For example, the mice displayed reduced VEGF-driven angiogenesis as assessed by an 
ear angiogenesis model using adenovirus coding for murine VEGF-A16437. In addition, the 
angiogenic response in a hindlimb ischemia model was reduced and cutaneous wound healing was 
delayed after endothelial cell dicer inactivation. Interestingly, tumor growth and microvessel 
density were also significantly reduced in VECad-Cre-ERT2;dicerfl/fl mice when endothelial dicer 
was inactivated prior to tumor implantation, implying a role for endothelial miRNAs in tumor 
angiogenesis37.  
 Surprisingly, gene expression analyses indicated that silencing of dicer increased, rather 
than decreased, the expression of several pro-angiogenesis proteins both in vitro and in vivo34,38. 
Although this appears in line with the general function of miRNAs, i.e. translational repression, 
the elevated expression of pro-angiogenesis factors was not in accordance with the observed 
vascular phenotype. A possible explanation for this paradox might be the concomitant upregulation 
of potent anti-angiogenesis factors. For example, silencing of dicer in HUVECs resulted in an 
increased expression of thrombospondin-1 (Tsp1)36 while elevated expression of tissue inhibitor 
of metalloproteinase 1 (TIMP1) was observed in dicerd/d mice39. Further studies are required to 
determine whether the increased expression of endogenous angiogenesis inhibitors and/or elevated 
activity of inhibitory feedback mechanisms accounts for the anti-angiogenesis phenotypes 
observed in dicer knockdown models.  
While several studies focused on dicer to determine the effects of impaired miRNA 
biosynthesis on endothelial cell biology, the information on disrupting Drosha expression is 
limited. Kuehbacher et al. found that silencing of Drosha in endothelial cells yielded similar results 
as dicer silencing in angiogenesis assays in vitro. However, no significant effects were observed 
when the silenced cells were used in the in vivo matrigel plug assay36. This observation may be 
explained by the existence of miRNA that are independent of Drosha processing, e.g. miRtrons40. 
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On the other hand, this would also imply that most angioregulatory miRNAs would be Drosha 
independent which is highly unlikely. Additional studies using different in vivo models for 
targeted endothelial disruption of Drosha are required to reveal the exact role of this protein in 
miRNA biosynthesis during angiogenesis. 
 
miRNA expression profiling in endothelial cells 
 The studies with disrupted miRNA biogenesis indicated that miRNAs are directly involved 
in regulation of endothelial cell gene expression. To determine the miRNA signature of endothelial 
cells, Poliseno et al. performed the first large scale analysis of miRNA expression in HUVECs41. 
They identified 27 highly expressed miRNAs, 15 of which were predicted to regulate the 
expression of receptors for angiogenic factors41. Additional miRNA profiling studies by other 
groups identified a total of 200 miRNAs that are thought to be expressed by endothelial cells 
(Supplementary Table 1)10,34,36,37,42-44. However, it is difficult to combine all these results since the 
experimental setup of most studies was different with respect to the platform that was used for 
miRNA detection, the experimental setup, and the source of endothelial cells. Overall, there are 
28 miRNAs that were identified in more than half (5 out of 8) of the profiling studies (Table 1). 
These miRNAs are likely an underestimation since the platforms that were used did not always 
include all known human miRNAs. Furthermore, because of the expanding number of miRNAs, 
there is a bias to the earlier denoted miRNAs. Future studies on different endothelial cell sources 
using platforms with a broad miRNA coverage will provide a more comprehensive list of true 
endothelial miRNAs.  
 
Table 1. miRNAs detected in endothelial cells by at least 5 out of 8 profiling studies. 
Name Frequency 
Source* References 
let-7a 6 HUVEC, HCAEC  [38, 40, 41, 43, 45, 46] 
let-7b 7 HUVEC, HBMVEC [10, 38, 40, 41, 43-45] 
let-7c 5 HUVEC, HCAEC [10, 38, 41, 43, 46] 
let-7d 7 HUVEC, HCAEC, HBMVEC [38, 40, 41, 43-46] 
miR-15b 5 HUVEC, HCAEC [38, 40, 41, 45, 46] 
miR-16 6 HUVEC, HCAEC [10, 38, 40, 43, 45, 46] 
miR-20a 7 HUVEC, HCAEC, HBMVEC [10, 40, 41, 43-46] 
miR-21 8 HUVEC, HCAEC, HBMVEC [10, 38, 40, 41, 43-46] 
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miR-23a 7 HUVEC, HCAEC 
[10, 38, 40, 41, 43, 45, 
46] 
miR-23b 7 HUVEC, HBMVEC [10, 38, 40, 41, 43-45] 
miR-24 5 HUVEC, HCAEC, HBMVEC [10, 38, 43, 44, 46] 
miR-27a 5 HUVEC, HCAEC, HBMVEC [38, 40, 44-46] 
miR-29a 7 HUVEC, HCAEC, HBMVEC [38, 40, 41, 43-46] 
miR-30a 5 HUVEC, HCAEC, HBMVEC [10, 38, 44-46] 
miR-30c 6 HUVEC, HCAEC, HBMVEC [10, 38, 41, 44-46] 
miR-31 6 HUVEC, HBMVEC [38, 40, 41, 43-45] 
miR-100 6 HUVEC, HBMVEC [38, 40, 41, 43-45] 
miR-103 6 HUVEC, HCAEC, HBMVEC [10, 38, 43-46] 
miR-106a 6 HUVEC, HCAEC, HBMVEC [38, 40, 43-46] 
miR-125a 6 HUVEC, HCAEC, HBMVEC [10, 38, 43-46] 
miR-125b 6 HUVEC, HCAEC, HBMVEC [10, 38, 43-46] 
miR-126 8 HUVEC, HCAEC, HBMVEC [10, 38, 40, 41, 43-46] 
miR-181a 5 HUVEC, HCAEC, HBMVEC [38, 40, 44-46] 
miR-191 5 HUVEC, HCAEC [38, 40, 41, 45, 46] 
miR-199a 5 HUVEC, HCAEC [10, 38, 40, 45, 46] 
miR-221 6 HUVEC, HCAEC, HBMVEC [38, 40, 43-46] 
miR-222 7 HUVEC, HCAEC, HBMVEC [38, 40, 41, 43-46] 
miR-320 5 HUVEC, HBMVEC [38, 40, 41, 44, 45] 
* HUVEC = Human umbilical vein endothelial cells, HCAEC = human coronary artery 
endothelial cells, HBMVEC = human brain microvascular endothelial cells. 
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Specific miRNA functions in endothelial cell biology 
 As described in the previous section, miRNA expression profiling resulted in the 
identification of numerous miRNAs that are present in endothelial cells. Research into the 
functional role of these miRNAs in endothelial cell biology and their contribution to pathological 
processes like tumor angiogenesis is just emerging. Based on evidence in the literature regarding 
their expression and function in endothelial cells, the endothelial miRNAs can be divided in 4 
classes: 1) Frequently detected miRNAs with a known function, 2) Frequently detected miRNAs 
with an unknown function, 3) Rarely detected miRNAs with a known function, and 4) Rarely 
detected miRNAs with an unknown function. Although the latter class appears superfluous, these 
miRNAs should not be readily discarded for further analysis. Members of the third class, like miR-
296, clearly show that rare miRNAs can have an important function in endothelial cell biology. 
Furthermore, with more and more miRNA expression data becoming available, many of these 
miRNAs may be less rare then initially thought. In the following paragraphs, the function of 
members of the first three classes will be further discussed (For schematic representation see 
Figure 3). 
 
Figure 3 
 
Figure 3. Role of miRNAs in endothelial cell function. Schematic representation of the contribution of miRNAs to 
different steps in the angiogenic cascade.  = stimulation, T = inhibition. Dotted lines indicate regulatory pathways 
described in non-endothelial cells. The box lists pro-angiogenesis miRNAs for which no targets have been described 
in endothelial cells.  
 
 
Frequently detected miRNAs with a known function 
 Off all the miRNAs that are expressed by endothelial cells, miR-126 belongs to the select 
group of those that were identified in every miRNA profiling study performed so far. It is encoded 
by intron 7 of the EGF-like domain 7 (Egfl7) gene and expression appears to be highly enriched 
in endothelial cells45-47. Because of this endothelial specific expression, miR-126 is one of the best 
studied miRNAs in angiogenesis. Knockdown of miR-126 in zebrafish embryos did not affect 
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vascular patterning but compromised vessel integrity as evidenced by vessel collapse and 
increased hemorrhages47. In mice, targeted deletion or disruption of miR-126 also caused a loss of 
vascular integrity which resulted in leaky vessels and hemorrhaging, eventually leading to 
approximately 50% embryonic lethality46,48. Interestingly, the surviving mice did not present 
obvious histological abnormalities46 but displayed impaired angiogenesis activity during both 
physiological and pathophysiological processes46,48,49. This suggests that miR-126 is most 
important for maintaining vascular integrity during ongoing angiogenesis.  
On the cellular level, knockdown of miR-126 caused defects in endothelial cell 
proliferation, migration, tube formation, and sprouting46,47,49. The possible mechanisms underlying 
the angiogenic activity of miR-126 was almost simultaneously presented by different groups. Fish 
et al. employed different algorithms to search for potential target mRNAs of miR-12647. They 
identified and validated three targets that are involved in endothelial cell biology. Two targets, i.e. 
SPRED1 and PIK3R2 are negative regulators of VEGF signaling, while the third target, i.e. 
VCAM1 is involved in leukocyte adhesion to the vessel wall. SPRED1 and VCAM1 were also 
identified by Wang et al. using microarray analysis46 while Kuhnert et al. described a role for miR-
126 in regulation of PIK3R248. Finally, Harris et al. also found regulation of VCAM1 expression 
by miR-12645. Taken together, the current data suggest that elevated miR-126 expression sensitizes 
endothelial cells to VEGF and at the same time decreases the adhesion of leukocytes. While both 
these features are known to occur in tumor activated endothelial cells, the literature on the 
regulation of miR-126 by angiogenesis stimuli is conflicting. Suarez et al. found increased miR-
126 expression after VEGF-A stimulation of HUVEC. However, Wurdinger et al. recently 
published a paper in which they show that miR-126 expression is decreased in human brain 
microvascular endothelial cells (HBMVECs) that were co-cultured with U87 glioma cells42. Most 
likely, this reflects a cell type specific function of miR-126 or activation of alternative regulatory 
pathways by factors secreted by U87 cells. Obviously, further studies are required to unravel miR-
126 regulation in endothelial cells after different angiogenesis stimuli. 
miR-221 and miR-222 are two flanking miRNAs, located within a 1 kb stretch on 
chromosome X11.350,51. Although they have been detected in several endothelial profiling 
studies34,36,37,41,42, their expression is not confined to the endothelium34,52-54. In tumor cells, miR-
221/222 were suggested to act as oncogenes since they target p27Kip1, a member of the cyclin 
dependant kinase inhibitor family that negatively regulates cell cycle progression53,55. Poliseno et 
al. showed that miR-221 and miR-222 directly target the c-kit mRNA in endothelial cells41. c-kit 
is a receptor for stem cell factor (SCF), a growth factor involved in angiogenesis56, and 
overexpression of miR-221/222 in HUVEC resulted in decreased cell migration41. Furthermore, 
Li et al. reported that hyperglycemic conditions induced miR-221 expression in HUVEC, thereby 
reducing their migratory capacity in response to SCF57. miR-221/222 were also shown to partially 
counteract the increased expression of endothelial nitric oxide synthase (eNOS) that occurs after 
dicer knockdown34. Although eNOS is important in endothelial cell function58,59 and vascular 
biology60,61, downregulation of eNOS expression by miR-221/222 did not affect endothelial cell 
proliferation34. Since the 3' UTR of eNOS did not contain a target site for miR-221/222, it was 
suggested that the observed effects were indirect34,44. Interestingly, Tuccoli et al. showed that 
depletion of miR-221/222 alters the overall miRNA signature in HUVEC, indicating  that both 
miRNAs indeed indirectly regulate the miRNA expression in endothelial cells62. A quick analysis 
using miRBase indeed identified three miRNAs that target the eNOS transcript and that were found 
to be regulated by miR-221/222 (unpublished observation, VLT). Furthermore, Chen et al. 
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identified 5 miRNAs that can directly target the eNOS 3'UTR and of which the expression is 
altered after treatment of human coronary artery endothelial cells with TNF-α34,44. Whether and 
how miR-221/222 regulate eNOS expression needs further investigation. Altogether, miRNA-
221/222 appear to confer an angiostatic phenotype on endothelial cells34,41. 
 While miR-221/222 appear to act as a cluster of which the individual miRNAs show 
comparable activity, the role of another miRNA cluster, i.e. miR-17-92, is much more complex. 
This cluster consists of 7 miRNAs, i.e. miR-17(-5p/-3p), -18a, -19a, -20a, -19b-1, -92a-1, that 
originate from 6 tightly grouped stem-loops within a 800bp intronic region on chromosome 13. 
The genomic locus containing this cluster undergoes amplification in several types of cancer and 
miR-17-92 expression is trans-activated by c-myc, a potent oncogene (For review see Medell63). 
In fact, the miR-17-92 cluster targets HIF-1 alpha which could partly account for the observed 
repression of HIF-1 alpha by c-myc64. The miR-17-92 cluster itself also has oncogenic activity, 
affecting cell cycle progression, apoptosis, and tumor angiogenesis63. The latter was illustrated by 
Dews et al., who observed a higher degree of tumor angiogenesis in vivo when overexpressing the 
miR-17-92 cluster in ras-positive tumor cells65. Human endothelial cells were also shown to 
express the miR-17-92 cluster66. Moreover, the expression of different miRNAs within this cluster 
is subject to regulation by angiogenic stimulation10,37. Interestingly, the expression of the 
individual miRNAs within this cluster is clearly different. While miR-20a is frequently found in 
endothelial cells, the other members appear less prominent. In line with this variable expression 
pattern, the effects of the individual miRNAs on endothelial cell function seem to differ. For 
example, Suarez et al. showed that in vitro inhibition of the miR-17-92 cluster results in reduced 
endothelial cell sprouting and tube formation37. Evaluation of single miRNA members revealed 
that the pro-angiogenesis activity was mainly attributable to miR-17-5p, miR-18a and miR-19a37. 
The latter two have been shown to target proteins containing thrombospondin type 1 repeats (TSR) 
which often have angiostatic activity37,65 while miR-17-5p appears to modulate endothelial cell 
migration and proliferation by targeting tissue inhibitor of metalloproteinase 1 (TIMP1)67. All 
these findings, together with the observation that miR-18a is upregulated in endothelial cells in 
response to VEGF treatment37, suggests that the miR-17-92 cluster is involved in the induction of 
a pro-angiogenesis phenotype. In support of this, O'Donnell et al. showed that the miR-17-92 
cluster targets the E2F1 transcript68. This could protect the activated cell from  E2F1 accumulation 
induced apoptosis while maintaining the proliferative phenotype63. On the other hand, miR-17, 
miR-20 and miR-92a do not affect the expression of TSR proteins65. In fact, miR-20a and miR-
92a have been described to display anti-angiogenesis activity54,66. Hua et al. have shown in 
nasopharyngeal carcinoma cells that miR-20a targets the VEGF transcript. They found that 
hypoxia decreases miR-20a expression which could account for the increased VEGF expression 
under hypoxic conditions54. In contrast, endothelial expression of miR-20a was shown to be 
increased rather then decreased in endothelial cells under hypoxic conditions10 or after VEGF 
treatment37. Although the exact role of miR-20a in endothelial cell biology has not been elucidated 
yet, these observation suggest an important function in angiogenesis regulation. In case of miR-
92a, endothelial overexpression results in impaired angiogenesis both in vitro and in vivo whereas 
disruption of miR-92a function induces enhanced blood vessel growth and functional recovery of 
damaged tissue in a murine limb ischemia model66. The pro-angiogenesis protein integrin α5 
(ITGA5) was identified as one of the direct targets of miR-92a66 further exemplifying the anti-
angiogenesis activity of the miRNA. Unfortunately, little is known regarding the response of 
endothelial miR-92a expression to pro- or anti-angiogenesis stimuli. Nevertheless, the data from 
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the miR-17-92 cluster illustrate that it is important to distinguish between the activity of single 
miRNAs when assessing the function of miRNA clusters.  
 
Frequently detected miRNAs with an unknown function 
 A miRNA that is frequently detected in endothelial cells but of which little functional data 
are available is miR-130a. It is located on chromosome 11 and the expression of this miRNA was 
found to be rapidly upregulated under high serum culture conditions69. Furthermore, it was shown 
to target two anti-angiogenesis homeobox genes, i.e. GAX and HOXA5. Overexpression of miR-
130a in HUVEC indeed induces proliferation, migration, and tube formation, supporting the pro-
angiogenesis role of miR-130a69.  
Similar to miR-130a, miR-21 and miR-31 are frequently detected in endothelial cells. 
Recently, some evidence suggested that both miRNAs might be involved in the endothelial 
response to the Kaposi's sarcoma associated herpes virus. This virus induces the invasiveness of 
endothelial cells in vitro by inducing matrix metalloproteinase expression70. Data by Tsai et al. 
suggest that one of the viral proteins induces the migration of endothelial cells through the 
upregulation of miR-21 and miR-3171. While these data suggest a pro-angiogenesis function for 
miR-21 and miR-31 their expression was shown to be downregulated in HBMVECs after 
angiogenic stimulation by co-cultured U87 glioma cells42. Hypoxia hardly affected the endothelial 
expression of both miRNAs43. Thus, whether and how both miRNAs modulate endothelial cell 
function should be further investigated. 
 Upregulation of miR-320 was detected in a miRNA microarray study using myocardial 
microvascular endothelial cells (MMVEC) from type 2 diabetic Goto-Kakizaki (GK) rats72. 
Disruption of miR-320 function results in increased proliferation and migration of diabetic 
MMVECs. Furthermore, miR-320 is predicted to target VEGFR2, IGF-1 and IGF-1R, suggesting 
this miRNA might function as a anti-angiogenesis miRNA72.  
 
Rarely detected miRNAs with a known function 
 While most members of the let-7 family are frequently detected little is known regarding 
their function in endothelial cells. Therefore, most of them are designated class 2 miRNAs. 
However, the one member that has been studied on a functional level, i.e. let-7f, is only rarely 
detected. Together with miR-27b, the expression of let-7f was reduced in HUVEC after disruption 
of either dicer or Drosha. Disruption of these miRNAs resulted in reduced in vitro sprout 
formation, suggesting a pro-angiogenesis function36,73. Although the anti-angiogenesis protein 
Tsp-1 is a predicted target of the let-7 family, disruption of let-7f did not significantly affect Tsp-
1 expression. Additionally, knockdown of Tsp-1 by siRNA did not rescue the observed 
phenotypes, indicating other targets are involved36. 
Human miR-155 is located in a non-coding BIC transcript, located on chromosome 2174,75. 
In fibroblasts, miR-155 was identified as a negative regulator of angiotensin II type I receptor 
(AT1R) expression levels and consequently of angiotensin (Ang II) signaling
76,77. Stimulation of 
AT1R by Ang II has been shown to enhance VEGF-induced proliferation and tube formation of 
bovine retinal microcapillary endothelial cells (BRECs)78, and the observation that miR-155 is 
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expressed in endothelial cells suggests an anti-angiogenesis function of this miRNA9. However, 
stimulation of endothelial cells with VEGF results in increased expression of miR-15537, as does 
exposure to hypoxia10. Thus, the exact role of miR-155 in endothelial cell biology and 
angiogenesis remains to be determined.  
A miRNA that has been identified by only four out of eight profiling studies in endothelial 
cells is miR-210. Interestingly, when comparing hypoxic HUVEC to normoxic controls, miR-210 
showed the strongest upregulation10. This suggests pro-angiogenesis activity of this miRNA. In 
line with this, overexpression of miR-210 was shown to enhance both tubulogenesis and VEGF 
induced migration of HUVEC. Conversely, blockade of miR-210 inhibited endothelial cell tube 
formation and migration in response to VEGF. Moreover, miR-210 knockdown also resulted in an 
inhibition of cell growth and induction of apoptosis in both normoxic and hypoxic conditions43. 
Ephrin-A3 (EFNA3) and neuronal pentraxin-1 (NPTX1) transcripts are targets of miR-210 and the 
pro-angiogenesis effects were attributed to the downregulation of Ephrin-A3 (EFNA3)10,43. 
Although upregulation of miR-210 has also been observed in different cancer types, it was shown 
to be a physiological response to hypoxia, rather than a transforming event in tumorigenesis10,79. 
Considering that miR-210 expression is negligible in normoxic endothelial cells, the present data 
support a role for miR-210 in angiogenesis and endothelial cell survival in response to hypoxia.  
 miR-296 is located on chromosome 20 and has recently been identified as a pro-
angiogenesis miRNA in brain microvascular endothelial cells (HBMVECs)42. When co-cultured 
with angiogenesis stimulating glioma cells, or in the presence of VEGF and EGF, miR-296 
expression was significantly increased. Additionally, miR-296 expression was shown to be 
elevated in tumor endothelial cells derived from human gliomas. Inhibiting miR-296 function 
resulted in decreased tubule length and branching of endothelial cells in vitro. Further analysis 
identified hepatocyte growth factor-regulated tyrosine kinase substrate (hgs), a negative regulator 
of VEGFR2 and PDGFRβ expression levels, as a target of miR-29642, suggesting that endothelial 
activation by pro-angiogenesis factors like VEGF induces a positive feedback loop that increases 
the sensitivity of endothelial cells to additional pro-angiogenic stimuli42. So far, miR-296 has only 
been detected in two other endothelial miRNA profiling studies43.  
 
Therapeutic applications 
In 2004, the US Food and Drug Administration approved a humanized anti-VEGF-A 
monoclonal antibody (bevacizumab) for the treatment of metastasized colorectal cancer in 
combination with a chemotherapy regiment80. Since then, several anti-angiogenesis drugs that 
target the VEGF signaling pathway have been developed. When used in combination with 
conventional therapies81, these drugs can delay disease progression and prolong patient survival 
by a few months. Although promising, this achievement is probably not the major step forward as 
envisioned by the founder of the angiogenesis research field2. Recently, a limitation of targeting 
the VEGF pathway was described by different groups who showed that these drugs may actually 
accelerate metastases formation82,83. These findings support the increasing notion that other targets 
need to be considered84-89. 
The discovery of miRNAs, especially those that are specifically involved in endothelial 
cell biology, has opened an exciting new avenue for targeted anti-angiogenesis cancer therapy. 
With increasing numbers of endothelial miRNAs being identified and characterized, their potential 
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as targets for anti-angiogenesis therapy in cancer is emerging. Already, several studies have shown 
that the expression of miRNAs in the endothelium is altered under angiogenesis-stimulating 
conditions like VEGF-stimulation, hypoxia, or tumor signaling (Figure 4A). Interestingly, the 
expression of many miRNAs appears to increase under pro-angiogenesis stimuli. This suggest that 
miRNAs can act as angioregulatory switches that control endothelial cell function during tumor 
angiogenesis. Moreover, the currently available functional data indicate that the majority of 
miRNAs have angiogenesis stimulatory activity (Figure 4B). Since a single miRNA can potentially 
regulate a plethora of endothelial functions by targeting multiple transcripts, miRNA targeted 
therapy could profoundly influence endothelial cell behavior. However, a potential pitfall of 
miRNA based therapy are the off target effects which are likely to occur because only partial 
complementarity between a miRNA and target mRNA transcripts is required. In addition, miRNAs 
have been shown to induce opposing effects depending on e.g. cell type. This stresses the need for 
specific delivery strategies to direct the miRNA therapy to the site of ongoing tumor angiogenesis. 
This could be achieved using similar strategies and vehicles as developed for siRNA or viral 
therapeutics90-92. In addition, it was recently reported that glioblastoma cells release micro-vesicles 
to deliver proteins and genetic information like miRNAs to neighboring cells93. Targeting such 
micro-vesicles to the tumor endothelium for delivery of miRNA based therapy will be a future 
challenge.  
 
Figure 4 
 
Figure 4. The angioregulatory miRNA-switch. A) Venn diagram showing changes in endothelial miRNA 
expression in response to VEGF treatment, hypoxia, and/or co-culturing with tumor cells. B) The angiogenesis 
miRNA switch showing all miRNAs with an anti-angiogenesis (-) or pro-angiogenesis (+) activity.  
 
Besides multiple methods of delivery there are also different approaches to perform 
miRNA based anti-angiogenesis cancer therapy. One could think of delivering anti-angiogenesis 
miRNAs to sites of tumor angiogenesis. Such miRNAs could directly 'switch of' the expression of 
proteins that are required for the proper execution of the angiogenesis program. Another approach 
could be the delivery of compounds that inhibit the activity of pro-angiogenesis miRNAs, either 
by binding the miRNA itself, e.g. with antagomiRs, or by blocking the binding site on the target 
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transcript94,95. The feasibility of such approaches has been proven by Thum et al. who showed that 
antagomiR mediated silencing of miR-21 inhibits interstitial fibrosis and attenuates cardiac 
dysfunction in a mouse pressure-overload-induced disease model96. In addition, Van Solingen et 
al. showed that injecting mice with antagomiR-126 reduces ischemia-induced angiogenesis49. A 
third approach to interfere with miRNA function might involve the use of RNA-binding proteins 
or mimics that target specific miRNAs, similar to e.g. Dnd1, an RNA-binding protein that 
counteracts miRNA-mediated silencing of several mRNAs97,98.  
As already indicated, a major challenge will be to engineer molecules that target a specific 
miRNA thereby limiting off-target effects. Chemical modifications of either miRNAs or their 
antagonists could greatly enhance their efficiency. For example, conjugation of cholesterol to 
oligonucleotides has been shown to enhance their cellular uptake. Other modifications include the 
use of locked nucleotides (LNA), or the conjugation of 2’-O-methoxyethyl phosporothioate (2’-
MOE). All these strategies have proven successful to reduce plasma cholesterol levels using miR-
122 antagonists94,99,100.  
 Finally, the abundance of miRNAs might be regulated on the transcriptional level. For 
example, interferon-β (IFNβ) and TNF-α have been shown to modulate the expression level of 
numerous miRNAs101 and c-myc is a known regulator of the miR17-92 miRNA cluster68. Getting 
better insight in the mechanisms that regulate endothelial miRNA expression during tumor 
angiogenesis could provide new clues on how to interfere with miRNA function.  
 
Future perspectives 
 By exploring the role of miRNA in tumor angiogenesis two relatively young research fields 
are merging. Besides the exciting new scientific insights this will provide, the previous section 
also illustrates the potential therapeutic opportunities this merger will generate for cancer patients. 
However, as with any new development, many pitfalls will be encountered and many hurdles have 
to be overcome before successful miRNA targeted anti-angiogenesis therapy will reach the clinic. 
A key issue will be to fully unravel the complex biogenesis of miRNAs. A better understanding of 
the mechanisms that regulate endothelial miRNA expression and processing is essential for 
miRNA-based therapy to become feasible. Furthermore, the endothelial expression of miRNAs 
should be mapped, especially, the expression under pro-angiogenesis conditions. This will identify 
the miRNAs that are specifically involved in tumor endothelial cell function. Finally, the 
development of delivery systems and of mechanisms to efficiently target specific miRNAs are a 
major future challenge. All this research will certainly provide opportunities for the development 
of second generation anti-angiogenesis drugs involving miRNAs in the tumor endothelium.  
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Endothelial cells are the prime contractors of angiogenesis, i.e. the sprouting of novel blood vessels 
out of pre-existing ones 1. This process has been implicated in a wide range of pathologies and is 
one of the hallmarks of cancer, since tumors require a functional vasculature when simple diffusion 
no longer suffices to provide these cells with oxygen 2. We previously identified that the expression 
of galectin-1, a prototype galectin, is increased in the tumor endothelium and that it is essential for 
tumor angiogenesis as it has both a mitogenic and a pro-migratory effect on endothelial cells 3,4. 
In addition, a role for galectin-1 -derived from tumor or stromal cells- in tumor immune escape, 
tumor cell transformation, tumor cell adhesion and metastasis has been established 5.  
Aside an increased expression of galectin-1 we also found that overall galectin-9 levels 
decrease upon endothelial cell activation 6. Contrary to galectin-1, not much is known yet about 
the function of galectin-9 in tumor biology although several initial studies point towards a similar 
multi-level role for galectin-9 in tumor progression. Post-transcriptional splicing of the galectin-9 
transcript has been described in a number of studies 7,8 but there is very limited data available on 
the functional consequence of this process or on the differential regulation of the expression of 
these splice variants in different cell types or conditions. The regulation of galectin-1 transcription 
is more actively studied and increasingly understood 9. However, an unresolved and intriguing 
question in galectin-1 biology is whether there are indeed two transcripts originating from 
hLGALS1 and what the functional consequence of this additional layer of complexity might be 10. 
In this thesis, we contributed to a further understanding of galectin-1 and galectin-9 
expression regulation. We developed the tools to exhaustively detect galectin-9 splice variants and 
our data suggests that the expression of these splice variants correlates with disease progression in 
NSCLC and spontaneous abortion. In addition, we provide a novel paradigm for a multi-faceted 
role of galectin-9 in solid tumor biology. We propose that endothelial galectin-9 contributes to the 
formation of an endothelial immune-suppressive barrier between circulating immune cells and the 
tumor mass. Finally, when studying alternative transcription of the hLGALS1 gene, we found a 
transcript that is involved in a new mode of post-transcriptional regulation of miRNA levels. 
 
Galectin-9 splice variant expression in pathological settings 
As described in this thesis, we developed the tools to detect all possible galectin-9 splice variants 
that vary in the inclusion/excision of exons 5, 6 and 10. Such an approach had not been undertaken 
yet in galectin-9 studies, even though our and other data suggest that different splice variants can 
indeed have diverging functions. Splicing of galectin-9 has been recognized soon after its initial 
cloning. At first, it was thought that there was one common galectin-9 variant, i.e. gal-95, and an 
insertional isoform in intestinal tissue, i.e. gal-9FL 8. However, subsequent studies by different 
groups found additional galectin-9 splice variants in a variety of cell types 11-13. The common 
denominator amongst these studies is that galectin-9 transcripts vary in the exclusion of exons 5, 
6 and 10. The former 2 exons encode for the linker region, while exon 10 encodes for the C-
terminal CRD. We found that quiescent endothelial cells express 5 galectin-9 isoforms, i.e. gal-
9FL, gal-95, gal-95/6, gal-95-10 and gal-95/6/10 and upon activation of these cells the 
expression of these isoforms is differently regulated. In fact, gal-95/6/10 is a novel splice variant 
that has not been described yet previously. As in most cell types, gal-95 is the most abundant 
splice variant in endothelial cells and it accounts for the decrease in galectin-9 expression in 
activated compared to quiescent endothelial cells we observed previously. Interestingly, the 
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expression of splice variants lacking exon 6, i.e. gal-95/6 and gal-95/6/10, appears to increase 
upon endothelial cell activation (chapter 4). In addition, we profiled galectin-9 splice variant 
expression in a panel of cell lines and found that different cell types indeed express different 
galectin-9 splice variants and at a different level. Other galectin family members also have splice 
variants whose expression is differently regulated. However, how the alternative splicing pattern 
for galectins, including galectin-9, is regulated is not understood and warrants further research.  
The finding that galectin-9 splicing is alternative regulated between different cell types or upon 
cellular activation state suggests that these isoforms have diverging functions. Although scarce, 
there is data supporting this. As described previously, galectin-9 isoforms appear to affect tumor 
cell adhesion differently. Also, overexpression of galectin-9 isoforms in colon carcinoma cells 
affects the expression of E-selectin differently, i.e. while gal-9FL overexpression decreases E-
selectin levels, gal-95 and gal-95/6 overexpression increases E-selectin expression in these 
cells, with concomitant increased adhesion to endothelial cells 7. In addition, gal-9FL is suggested 
to be a more potent eosinophil chemoattractant than gal-95 12. The function of galectin-9 isoforms 
that lack exon 10 remains to be elucidated. Deletion of this exon results in a frameshift and a 
premature stopcodon and, as a result, a truncated C-terminal CRD. We and others now provide 
evidence that these splice variants are not secreted, suggesting an intracellular role 13. The finding 
of a tandem repeat galectin with a truncated C-terminal CRD suggests that this isoform becomes 
a de facto prototype galectin. Such a “class-switch” from tandem-repeat galectins to prototype 
galectins is a novel concept in galectin biology and raises several questions to be answered. For 
example, it would be interesting to see whether such galectin isoforms dimerize and have a 
different subcellular localization compared to their tandem-repeat alternatives. We employed 
exhaustive galectin-9 profiling to assess whether the expression of galectin-9 splice variants has a 
prognostic or diagnostic value in 2 different pathological settings, i.e. NSCLC and spontaneous 
abortion.  
 In early stage NSCLC patients we identified gal-95 as a prognostic marker for both 
overall survival and disease free survival of these patients (chapter 2). The identification of such 
a marker is of particular importance since NSCLC patients with a poor prognosis would likely 
benefit from adjuvant therapy 14. We detected mRNA expression of galectin-1,-3,-4,-7,-8, and -9 
in human NSCLC tissues, which corroborates with a previous study by Lahn et al. NSCLC cancer 
cell lines HS-24 and SB-3 15. As for galectin-9, the most abundant splice variants was gal-95 and 
the expression of this isoform correlates with a good prognosis for early stage NSCLC patients. 
Interestingly, a previous study found a similar correlation in breast cancer 16. In this tumor type, 
galectin-9 expression predicted distant metastasis better than lymph node status: 19 out of 21 
metastasis-positive cases were galectin-9 negative and high galectin-9 expression resulted in an 
increased cumulative disease free survival of these patients. Of note, no distinction between 
galectin-9 splice variants was made in this study. The finding that gal-95 expression hampers 
tumor progression corroborates with the current literature on the role of galectin-9 in tumor cells 
(as discussed later), as it mediates homo- and heterotypic cell adhesion thereby hampering 
metastasis. However, whether galectin-9 has similar effects on lung cancer cells remains to be 
determined. Although galectin-9 expression correlates with a good prognosis, galectin-1 
expression shows the opposite correlation. Interestingly, when combining the expression of gal-
95 with galectin-1 we were able to further stratify our patient group for overall survival, which 
suggests similar approaches might be valuable for other cancer types. The expression level of 
galectin family members has been regularly recognized as a prognostic marker for cancer 
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progression. In this study, we reported such a role for gal-95 in early stage NSCLC patients. It is 
by splice variant profiling that we found this marker, further underlining the benefit for splice 
variant specific profiling in galectin studies. 
 Our toolset also yielded a collaboration to study the expression of galectin-9 isoforms at 
the feto-maternal interface, i.e. in decidual and placental cells, in both physiological and 
pathological settings (chapter 3). During pregnancy, a strict regulation of the maternal immune 
system induces tolerance of paternal derived antigens displayed by the embryo and still protects 
the mother from infections. Galectin-1 has already been described as an important mediator of 
feto-maternal tolerance 17 and initial studies suggest a similar function for galectin-9, especially 
considering its potent immune-suppressive properties (as discussed later). Endometrial galectin-9 
levels vary throughout the menstrual cycle 18 and are increased during the implantation window, 
suggesting galectin-9 is indeed an important molecule during early pregnancy 19. As a first step in 
assessing galectin-9 function during pregnancy, we analyzed the expression of galectin-9 in a 
murine model and in human samples of normal pregnancy and spontaneous abortion. In mice, we 
performed these analyses in both decidual and placental cells. Decidual overall galectin-9 levels 
increase during normal pregnancy, which corresponds with a shift from Th1 to Th2 cytokines that 
occurs at this stage 20,21, as galectin-9 is able to limit Th1 immunity 
22. Whether galectin-9 is indeed 
responsible for this shift remains to be determined. This increase of overall galectin-9 levels was 
not significant in the spontaneous abortion model, suggesting that a less defined Th1/ Th2 milieu 
might indeed occur here and account for the fetal loss. In placenta, expression of galectin-9 
appeared similar in both models on gd13.5. When looking at galectin-9 splice variants, we detected 
gal-9FL, gal-95 and gal-95/6 expression in the murine models. Since gal-95 was the most 
abundant splice variant its mode of regulation closely resembled that of overall galectin-9 levels. 
Interestingly, the increase of galectin-9 during normal pregnancy appeared to be mainly caused by 
an increase in gal-9FL levels. Unfortunately we could not make this distinction at the protein level 
since there are no antibodies available to specifically detect these galectin-9 isoforms. Increased 
galectin-9 levels were associated with an increase in Tim-3+ cells in decidual tissue during early 
pregnancy. It is tempting to speculate these are NK cells, which secrete IFN in response to 
stimulation with galectin-9 23 and are critical for remodeling of the uterine vasculature 24,25. 
Moreover, IFN itself can induce galectin-9 expression in fibroblasts 26 and endothelial cells 27. 
Finally, in first trimester human samples we did not observe any differences in the expression of 
gal-95 between normal pregnancy and spontaneous abortion samples, which could be due to the 
impossibility to distinguish between decidual and placental tissue in these samples. However, we 
did observe a significant decrease of gal-95/10 expression in samples from spontaneous abortion 
patients, suggesting that this splice variant might serve as a marker for adverse pregnancy outcome. 
Future studies should focus on validating this finding in a larger patient group. In addition, now 
we have demonstrated that galectin-9 expression changes differently in normal pregnancy as 
opposed to spontaneous abortion new research questions arise. In particular exploring the role of 
a galectin-9/IFNγ axis in suppressing the immune system, maintaining a physiological Th1/ Th2 
milieu and ensuring proper decidual vascularization at the feto-maternal interface is warranted.  
 Both profiling studies reported in this thesis add to an ample amount of literature reporting 
the use of galectin expression as a prognostic or diagnostic marker during disease. However, they 
also stress the importance of specifically detecting splice variants of galectins, rather than detecting 
the overall transcription level. In fact, we found that although the overall expression was not 
significantly associated with disease progression, the expression level of specific splice variants 
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like gal-95 or gal-95/10 was. As such, this thesis provides further evidence to urge future 
researchers exploring the potential of galectins as biomarkers to take the existence of different 
isoforms into account.  
 
Tumor immune escape via endothelial galectin-9 
The function of galectin-9 in tumor biology is an emerging field of study to which we provide 
novel insights in this thesis. Galectin-9 is implicated as a critical mediator of tissue integrity in 
different murine cancer models like melanoma 28 and breast cancer 16. In these studies, a decrease 
of galectin-9 levels in the tumor is consistently associated with increased aggressiveness, i.e. 
metastasis. In fact, when combining the data of all studies assessing the influence of galectin-9 
overexpression on tumor cell adhesion 7,16,28,29 it appears this effect is isoform specific, i.e. while 
increased levels of gal-9FL and gal-95/6 seem to result in an inhibition of cell adhesion to 
extracellular matrix components, high abundance of gal-95, the most abundant isoform, seems 
to promote it.  In addition to cell adhesion, galectin-9 is also known to induce apoptosis in a number 
of tumor cells, like melanoma 28 and leukemia cells 30,31, which fits in the model that galectin-9 
levels decrease as tumors progress towards a more aggressive phenotype. An unexplored area up 
to now was the role of endothelial galectin-9 in angiogenesis.  
We found that quiescent endothelial cells express galectin-9 and that its mRNA expression 
decreases upon endothelial cell activation 6. In this thesis (chapter 4), we describe that galectin-9 
protein levels actually significantly increase in the tumor endothelium of breast, lung, kidney and 
liver cancer patients. This apparent contradiction is likely caused by a difference in experimental 
setup. In our former study, supernatant from colon cancer cells was used to achieve endothelial 
cell activation, while in this thesis galectin-9 levels were determined on tissue sections of 4 other 
cancer types. In a study by Lahm et al., colon cancer cell lines were the only ones that consistently 
have high galectin-9 expression, as opposed to other solid tumor cell lines in which galectin-9 
expression was generally lost 8,15. Alternatively this illustrates that mRNA levels do not necessarily 
reflect proteins levels and that other forms of post-transcriptional regulation might be at play.  
Because we found increased levels of galectin-9 on tumor endothelial cells compared to 
quiescent endothelium and because galectin-8, another tandem-repeat galectin, has been 
implicated in angiogenesis 32 we assessed whether galectin-9 modulates angiogenesis as well. 
Overexpression experiments with individual galectin-9 splice variants in HMEC, which have a 
negligible endogenous galectin-9 expression, yielded very weak effects on the proliferation and 
migration of these cells. However, galectin-9 is secreted by various cell types 12,26,33 and we show 
endothelial cells do so too. As for other galectins, the regulation of galectin-9 secretion as well as 
the pathway via which it is secreted remains largely unclear. When studying the effect of 
exogenous gal-95 on endothelial cell proliferation and migration and in the in vivo CAM model 
we found an inhibitory effect of angiogenesis, i.e. endothelial cell proliferation was inhibited and 
total vessel length, branch points and end points were decreased by treatment of the CAM with 
gal-95. Interestingly, exogenous gal-95 appears to have a bimodal effect on endothelial cell 
migration. At low concentration migration is stimulated while at high concentrations it is 
hampered. Taken together, there seems to be a minor inhibitory effect of gal-95 on angiogenesis 
which prompted us to consider an alternative function for the markedly increased levels of 
galectin-9 on the tumor endothelium. 
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 We hypothesized that endothelial galectin-9 has a more prominent role in tumor immune 
escape, rather than tumor angiogenesis. In fact, it was surprising that this possible function of 
galectin-9 is the tumor micro-environment was left largely unexplored for so long considering the 
well-established immune-suppressive capacities of galectin-9. Aside from inducing apoptosis in 
activated Th1 cells 
22 and Tc cells 
34, galectin-9 and its receptor Tim-3 are also implicated in the 
immunoregulatory function of Tregs 
35. Immune escape via exosomes containing galectin-9 has 
been described in EBV-infected nasopharyngeal carcinoma 36,37 and a recent study implicates a 
similar role for the galectin-9/Tim-3 axis in HBV-associated hepatocellular carcinoma 38. We now 
show that when PBMCs are exposed to galectin-9, apoptosis is potently induced in CD4+ and 
CD8+ cells, but not in CD4+CD25hi+ cells, suggesting that endothelial galectin-9 might indeed 
confer a tolerant environment around the tumor vasculature. In this thesis, we propose a novel 
paradigm that we further discussed in a review (chapter 5). We propose a model in solid tumors 
in which galectin-9 levels are decreased in and around the tumor cells, resulting in a loss of tissue 
integrity, leading to invasion and metastasis. Conversely, endothelial galectin-9 levels are 
increased, resulting in the generation of an immune-suppressive barrier between the blood stream, 
i.e. the circulating immune cells, and the rest of the tumor. Future studies are needed to test this 
model and to assess whether other galectin family members modulate tumor progression similarly. 
For example, it will be interesting to see how tumors develop in (endothelial) galectin-9 knockout 
mice 39 and whether there will indeed be stronger immunoreactivity against tumors in these mice. 
Finally, when the role of endothelial galectin-9 in specific cancer types is better understood, we 
can explore how to apply this knowledge for targeted therapeutics. For example, endothelial 
specific inhibition of galectin-9 function, e.g. via endothelial-targeted liposomes 40, might result 
in tumor remission due to a more potent immune response directed against the tumor.  
Although our and other reports suggest diverging roles for galectin-9 isoforms, several 
challenges remain to be tackled to study these variants in tumor biology, e.g. there is a lack of 
availability of recombinant protein of all isoforms except gal-95 and of antibodies that allow 
specific detection of galectin-9 isoforms. 
 
The Gal-1L transcript is processed and scavenges miR-296 
Galectin-1 has a multi-level role in tumor progression, i.e. it modulates tumor cell transformation, 
adhesion and metastasis, tumor immune escape and tumor angiogenesis 5. In addition, galectin-1 
expression is a validated prognostic marker in several cancer types and it is consistently associated 
with increased aggressiveness and poor prognosis 41-43. Thus, understanding galectin-1 expression 
is of critical importance.  
A number of signaling pathways that modulate galectin-1 expression in different cell types 
have been found 9, like EGF 44, TGF 45, estrogen 46 and TSH signaling 47. At the genetic level, 
LGALS1 promotor methylation status 48,49, NF-B 50, HIF-1 and C/EBP51 have been 
implicated. In 2001 de Gregorio et al. found that the murine LGALS1 gene contains 2 core 
promotor elements, an Inr element and a TATA-box and an upstream Sp1 site 10. These elements 
sequentially drive the transcription of 2 distinct transcripts that vary at the 5’ end of the 5’UTR of 
galectin-1. The long transcript, GAL-1L, has 31 additional bases at the 5’ end compared to the 
short transcript, GAL-1S. Although the authors claim a similar observation was made in human 
cells, no such data were published. In this thesis, we confirmed by in silico analysis that the genetic 
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elements driving the expression of these transcripts are conserved in humans and we verified that 
different cell types indeed express both GAL-1L and GAL-1S at different levels (chapter 6). 
Transcription of these transcripts from paraloguous genes can be excluded based on genomic 
mapping 52. Also, since the GAL-1L transcript seems to contain no m7G-cap it is possible that 
another RNA polymerase than RNA polymerase II drives its transcription, which has to be 
assessed in future studies. A possible candidate for this would be RNA polymerase III, which has 
been implicated in the transcription of non-coding RNAs 53. This might also indicate that GAL-1S 
is the protein-coding bonafide mRNA, while GAL-1L has a different function. In addition, which 
pathways control the expression of these 2 variants remains to be studied and will contribute 
greatly to our understanding of galectin-1 biology. 
While the expression of GAL-1S increases upon endothelial cell activation, the expression 
of GAL-1L decreases, which indeed suggests a different function for these transcripts in 
endothelial cells. Next, we assessed whether the addition of 31 bases to the 5’UTR of GAL-1L has 
any consequence for the secondary RNA structure of this transcript and found that these bases 
indeed allow for the formation of a stable loop structure which is not present in the 5’UTR of 
GAL-1S. Such a structure has been associated with inhibition of translation, either directly by 
preventing efficient ribosome entry 54 or indirectly by recruiting other inhibitory proteins 55. 
Although we indeed found GAL-1L is less efficiently translated when overexpressed, this did not 
provide a satisfying answer to the question what the functional relevance of 2 alternative galectin-
1 transcripts is considering their expression is differently regulated upon endothelial cell 
activation. As an alternative hypothesis, the loop reminded us of a pri-miRNA stem-loop, a 
precursor RNA transcript which upon processing by drosha and dicer yields mature miRNAs 56. 
Initial in silico analysis supported this idea, which prompted us to review the literature on 
endothelial miRNAs since several independent groups had performed endothelial miRNA 
profiling studies (chapter 7). None of the various approaches we took to detect small RNAs 
originating from the loop structure in the 5’UTR of GAL-1L, including Northern blot, qPCR 
analysis and stem-loop qPCR analysis, was successful. However, by performing a ‘walkthrough’ 
qPCR, we found that a processing event occurs downstream of the loop structure, resulting in the 
generation of a RNA fragment of ~100 bases, i.e. ceGAL1L. This form of processing has not been 
described yet to our knowledge and it will be interesting to assess whether this occurs more often 
in the 5’UTRs of mRNAs and find the enzymes involved.   
  In 2011 Pandolfi and coworkers proposed an intriguing paradigm shift in miRNA biology 
57. They proposed that mRNAs are competing for miRNA binding and non-coding RNA species 
might in fact scavenge miRNAs and prevent them from binding to protein-coding mRNAs. Thus, 
these competing endogenous RNAs (ceRNAs) effectively control each other’s levels since 
miRNAs are now mainly thought to affect mRNA stability rather than translation 58. They later 
confirmed that PTEN and its pseudogene indeed behave like ceRNAs 59, which lead us to 
hypothesize ceGAL1L might scavenge miRNAs in endothelial cells. Interestingly, we found miR-
296-5p, which has been implicated in endothelial cell biology and angiogenesis 60,61, as a potential 
binding partner of ce-G1L. We then assessed whether overexpression of GAL-1L could scavenge 
miR-296-5p and as a result increase the levels of targets of miR-296-5p. In preliminary 
experiments we indeed obtained data that support our hypothesis for a number of those targets like 
p21 and hgs. To conclude, we propose an important role for ceGAL1L in endothelial cells.  Since 
GAL-1L and consequently ceGAL1L expression decreases in response to endothelial cell 
activation, less miR-296-5p will be sequestered. As a result, more miR-296-5p will be available to 
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bind to the 3’UTRs of p21 and hgs and suppress these mRNAs, allowing for cell cycle progression 
62,63 and an increase in membrane growth factor receptor levels 61. As such, ceGAL1L could act as 
a master switch in endothelial cells that ensures they remain in a quiescent state.  
With this study we contributed to a completely new and exciting field of study, i.e. the 
scavenging of miRNAs by other RNA structures, which adds another regulatory layer that allows 
cells to control their phenotype. Aside experiments to further support our findings, other questions 
immediately arise, the most important of which is whether this type of regulation occurs 
throughout the genome and whether we can demonstrate its importance in vivo.  
Altogether, the studies presented in this thesis show that endothelial cells express transcript 
variants of galectin-1, via an alternative transcription start site, and galectin-9, via alternative 
splicing. This adds another layer of complexity to galectin biology and underlines the need for 
specific detection of these variants for future studies that want to assess the prognostic value or 
function of these galectins. By finding an alternative galectin-1 transcript that can act as a 
scavenger for miRNAs we contributed to the initial steps in a new field that is now waiting to be 
further explored, i.e. the post-transcriptional regulation of miRNA levels.  
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Summary 
Deregulation of angiogenesis has been implicated in many diseases and is in fact a hallmark of 
cancer. When the limited diffusion distance of oxygen causes tumor cells to become hypoxic the 
angiogenic switch will occur. Tumor cells will secrete growth factors that can activate endothelial 
cells and initiate the angiogenesis cascade. We previously showed that an increase of galectin-1 in 
endothelial cells in response to these growth factors is essential for this process and that galectin-
9 levels are also modulated in these cells. Galectin-1 is a prototype galectins, i.e. it contains one 
CRD and can form dimers, while galectin-9 is a tandem-repeat galectin that contains 2 CRDs 
linked by a linker region. Of these two, galectin-1 has been studied the most and has been 
implicated in intracellular processes like pre-mRNA splicing and ras signaling and in extracellular 
processes like VEGFR signaling and cell adhesion and migration. In the latter two processes 
galectin-9 is also thought to play a role. Conversely, very little is known about the intracellular 
role of galectin-9. A complicating factor when studying these galectins is that alternative 
transcripts appear to be transcribed from their respective genes and not much is known about the 
functional role of these yet. Both galectins, derived from tumor cells or stromal cells like 
endothelial cells, have also been shown or suggested to play a role in other hallmarks of cancer, 
which makes them attractive targets for therapy. This is further corroborated by studies who assign 
a prognostic role to galectin-1 and galectin-9 in cancer. In this thesis, we set out to assess the 
function of endothelial galectin-9 in tumor biology and to explore the function of alternative 
transcripts of galectin-1 and galectin-9 as well as evaluate them as prognostic markers. 
 In chapter 5, we reviewed all literature on the role of galectin-9 in tumor biology. Several 
studies support a role for galectin-9 in tumor cell apoptosis and adhesion and metastasis. In 
addition, data suggest a role for galectin-9 in tumor immune escape since it has potent immune-
suppressive properties and in angiogenesis, considering its expression changes upon endothelial 
cell activation. In general, galectin-9 levels appear to decrease in tumors as the progress towards a 
more aggressive phenotype. To provide an answer to the seemingly paradox that occurs when 
trying to reconcile this decrease of galectin-9 levels with a role in tumor immune escape, we 
propose a model in which galectin-9 expression indeed decreased in tumor cells, but increases in 
endothelial cells which then form an immune-suppressive barrier between the circulating immune 
cells and the tumor cells.   
 We indeed provide evidence to support this model in chapter 4. In 4 types of cancer, i.e. 
breast, lung, liver and kidney cancer, we show that endothelial levels of galectin-9 are greatly 
increased in tumors compared to healthy tissue in a large set of patients. We could only find a 
limited role for galectin-9 in angiogenesis in the in vivo CAM model, which led us to explore the 
immune-suppressive functions of this protein. When administered to PBMCs, we show that 
galectin-9 specifically induces apoptosis in CD4+ Th cells and CD8+ Tc cells but not in 
CD4+CD25hi+ Treg cells. The next step in this research is exploring whether endothelial galectin-
9 levels indeed correlate with the infiltration of immune cells in tumor masses and whether 
endothelial knockout of galectin-9 increases tumor rejection. These studies are currently 
ongoing. 
 As mentioned, the galectin-9 transcript is subject to extensive post-transcriptional 
splicing and varies in the exclusion of exons 5 and 6, which encode for the linker region and 
exon 10, which encodes for the C-terminal CRD. At this point only recombinant gal-95, the 
most abundant isoform, is available commercially limiting the functional study of these isoforms. 
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However, by qPCR we can specifically detect all galectin-9 splice variants and found that 
endothelial cells express 5 of them which are differentially regulated upon endothelial cell 
activation. In addition, the development of this technique yielded collaboration with a group that 
studies the cellular changes that occur during pathologies associated with pregnancies, which we 
described in chapter 3. In this study we found that in a model for normal pregnancy galectin-9 
expression in decidual cells increases and that this change was not as clear in a model for 
spontaneous abortion. We propose this abbarant regulation of galectin-9 expression likely affects 
the Th1/Th2 balance as well as the activation of NK cells, resulting in a deregulation of 
angiogenesis in the abortion model. Further studies to confirm this hypothesis are needed.  In 
addition showed that changes in galectin-9 expression in these models are due to changes in the 
expression of specific galectin-9 splice variants and our data suggest that the expression of one 
splice variant, i.e. gal-95/10, might serve as a prognostic marker for adverse pregnancy 
outcome in humans. Specific galectin-9 splice variant expression by qPCR was also applied in a 
profiling study in tissue of NSCLC patients, as described in chapter 2. Here, we showed that 
gal-95 expression levels have prognostic value in NSCLC. In fact, both a gal-95Lo and a 
combined gal-95Lo /gal-1Hi signature are associated with poor prognosis.  
Aside several galectin-9 transcripts, there was also one study published in 2001 providing 
evidence for the existence of 2 distinct mouse galectin-1 transcripts. Rather than being the 
product of alternative pre-mRNA splicing, the occurrence of these transcripts depended on where 
transcription was initiated in the galectin-1 gene. Thus, a long transcript, i.e. GAL-1L, has 31 
additional bases at the 5’ end of the transcript, compared to a short transcript, i.e. GAL-1S. Three 
promotor elements and transcriptional control sites were described in this study and we 
confirmed these are conserved in human. Next, we showed that GAL-1S and GAL-1L are indeed 
expressed in human endothelial cells and that their expression is regulated differently upon 
endothelial cell activation, i.e. while GAL-1S levels increase, GAL-1L levels decrease in 
activated endothelial cells. When exploring the functional consequence of the addition of these 
31 bases we found that the 5’UTR of GAL-1L folds into a stable loop structure that resembles a 
pri-miRNA. As described in chapter 7, this prompted us to review several profiling studies 
assessing the expression or miRNAs in endothelial cells as no exhaustive review on the subject 
was available at that point. Although we could not detect any miRNAs originating from the loop 
structure found in the 5’UTR of GAL-1L, we did find a processing site just downstream of the 
loop structure and designated the 5’ RNA fragment yielded by this processing event ce-G1L, as 
shown in chapter 6. The description of so-called ceRNAs by Pandolfi and coworkers provided 
us with an alternative hypothesis for ce-G1L function, i.e. we hypothesized it could scavenge a 
miRNA that is important for endothelial cell function, thereby regulating the levels of other 
targets of this miRNA. In preliminary experiments we indeed obtained data supporting this 
hypothesis since miR-296, a miRNA with a known function in endothelial cells, is an excellent 
candidate to bind to ce-G1L, although additional experiments are much needed. We propose a 
model in which GAL-1S is the protein-coding transcript while GAL-1L has another role. The 
decreased expression of GAL-1L and consequently ce-G1L in activated versus quiescent 
endothelial cells results in less miR-296 being scavenged by ce-G1L. As a result more miR-296 
is available to bind to mRNA targets like p21 and hgs, proteins which are implicated in a 
quiescent endothelial state. Thus, ce-G1L possibly acts as a master switch to preserve quiescence 
in endothelial cells.  
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 In this thesis, we further increased the knowledge on the role of galectin-9 in tumor 
biology and corroborate the importance of detecting specific transcripts of both galectin-1 and 
galectin-9, as their expression can be differently regulated. In addition, data suggests that these 
transcripts can exert widely different functional roles. This new knowledge increases our 
understanding of the biology and expression patterns of galectin-1 and galectin-9, 2 galectins 
which are promising targets for anti-cancer therapy due to their multi-faceted role in tumor 
progression.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Samenvatting 
 
De rol van galectines in bloedvaten 
 
 
 
 
 
 
 
 
 
 
 
 
  
164 
Samenvatting 
Ontregeling van de groei van nieuwe bloedvaten, een proces dat angiogenese genoemd wordt, 
speelt een rol bij vele ziektes en is een van de kerneigenschappen van kanker. Wanneer de beperkte 
diffusie afstand van zuurstof niet langer volstaat om tumorcellen van zuurstof te voorzien zullen 
deze hypoxisch worden en dit zal leiden tot de zogenaamde angiogene switch, m.a.w. de 
verandering naar een omgeving die de groei van nieuw bloedvaten stimuleert. Tumorcellen zullen 
groeifactoren uitscheiden die endotheelcellen activeren en dit zal aanzet geven tot angiogenese. In 
eerdere studies hebben we aangetoond dat een toename in de expressie van galectine-1 in 
endotheelcellen noodzakelijk is voor dit proces en dat galectine-9 hoeveelheden ook veranderen 
in endotheelcellen die gestimuleerd worden met groeifactoren. Galectine-1 is een zogenaamde 
prototype galectine, wat wil zeggen dat het 1 suiker-bindend domein bevat terwijl galectine-9 een 
tandem-repeat galectin wordt genoemd omdat het 2 suiker bindende domeinen heeft die met elkaar 
verbonden zijn door een linker domein. Galectine-1 is het meeste bestudeerd en studies tonen aan 
dat het een rol speelt in processen in de cel, zoals het verwerken van pre-mRNAs en het medieren 
van ras-signaalstransductie maar ook in processen die plaatsvinden buiten de cel, zoals het 
aanzetten van de VEGF receptor en het medieren van de aanhechting en het migreren van cellen. 
Galectine-9 speelt ook een rol in de laatste 2 processen maar er is niet veel geweten over de rol 
van galectine-9 in de cel. Een gegeven dat het ingewikkeld maakt om deze galectines te bestuderen 
is dat er alternatieve transcripten lijken te bestaan en dat er bijna niets geweten is over de 
functionele consequenties hiervan. Beide galectines, die zich zowel in tumorcellen als in cellen 
rond de tumor zoals endotheelcellen kunnen bevinden, spelen ook een rol in andere 
kerneigenschappen van kanker of zo’n rol is voorgesteld door onderzoekers. Dit gegeven van een 
rol op meerde niveaus in tumoren leidt ertoe dat galectines worden gezien als aantrekkelijke 
doelwitten voor anti-kanker therapie, wat nog verder ondersteund wordt door studies die aantonen 
dat galectine-1 and galectine-9 expressie gebruikt kan worden als een prognostische test. In deze 
thesis wilden we de rol van galectine-9 in endotheelcellen dichtbij tumoren verder onderzoeken. 
Daarnaast wilden we ook de functie van alternatieve transcripten van zowel galectine-1 als 
galectine-9 verkennen en nagaan of de expressie van deze transcripten gebruikt kan worden voor 
prognostische doeleinden.  
 In hoofdstuk 5 hebben we alle literatuur samengevat over de rol van galectine-9 in de 
biologie van tumoren. Vershillende studies tonen aan dat galectine-9 een rol speelt in 
geprogrammeerde celdood van tumorcellen en ook in de aanhechting en metastase van deze cellen. 
Daarnaast zijn er ook studies die aantonen dat galectine-9 krachtig het immuunsysteem kan 
onderdrukken, wat suggereert dat galectine-9 een rol zou kunnen spelen in het onderdrukken van 
de immuunrespons tegen tumoren. Ook in angiogenese zou galectine-9 een rol kunnen hebben 
omdat de expressie ervan verandert in endotheelcellen als deze geactiveerd worden. Over het 
algemeen neemt de hoeveelheid galectine-9 in tumoren af als deze verder evolueren naar een 
aggressievere vorm. Deze vinding lijkt moeilijk te verzoenen met een rol in het onderdrukken van 
de immuunrespons. Wij stellen een model voor waarbij de hoeveelheid galectine-9 in tumorcellen 
inderdaad daalt, maar de hoeveelheid in endotheelcellen stijgt. Zo kan er als het ware een immuun-
onderdrukkende barriere gevormd worden door deze endotheelcellen tussen de immuuncellen in 
het bloed en de tumor cellen.   
 Uit hoofstuk 4 blijkt dat dit model zou kunnen kloppen want in 4 verschillende 
kankertypes, namelijk borst, long, lever en nierkanker, tonen wij aan dat de hoeveel galectine-9 in 
endotheelcellen rond tumoren inderdaad veel hoger is dan op andere plekken in het lichaam van 
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kankerpatienten. We konden maar een beperkte rol voor galectine-9 in angiogenese aantonen in 
een zogenaamd ‘levend’ CAM model, wat ons ertoe aanzette om de immuunsysteem-
onderdrukkende eigenschappen van galectine-9 te onderzoeken. Wanneer we galectine-9 
toevoegen aan mononucleaire bloedcellen leidt dat tot geprogrammeerde celdood van 
immuuncellen die tumoren kunnen aanvallen, namelijk helper T cellen en cytotoxische T cellen, 
maar niet van cellen die het immuunsysteem temperen zoals regulatoire T cellen. Of de 
hoeveelheid galectine-9 in endotheelcellen rond de tumor inderdaad overeenkomt met de infiltratie 
van immuuncellen in deze tumoren wordt nagegaan in volgende studies, alsook of er meer 
afstoting van tumoren optreedt in muizen die geen galectine-9 in hun endotheelcellen hebben.  
 Zoals we reeds vermelden zijn er alternatieve transcripten van galectine-9, wat wil zeggen 
dat na transcriptie exonen 5, 6 en 10 uit het transcript geknipt kunnen worden door gespecializeerde 
enzymen wat leidt tot verschillende galectine-9 varianten. Exon 5 en 6 coderen voor het linker 
domein, terwijl exon 10 codeerdt voor het tweede suiker-bindende domein van galectine-9. Tot nu 
toe is er enkel galectine-95, de meest voorkomde variant, beschikbaar om aan te kopen, wat 
studies naar de functie van deze varianten moeilijk maakt. Een techniek genaamd qPCR laat ons 
wel toe om specifiek galectine-9 varianten te detecteren en via deze techniek hebben we 
aangetoond dat endotheelcellen 5 galectine-9 varianten aanmaken die verschillend veranderen 
wanneer endotheelcellen geactiveerd worden. Deze techniek heeft ook geleidt tot een 
samenwerken met een groep die onderzoek doet naar de cellulaire veranderingen die plaatvinden 
bij problemen omtrent zwangerschap. In hoofdstuk 3 laten we zien dat de expressie van galectine-
9 toeneemt in deciduale cellen in een muismodel voor normale zwangerschap. Deze toename was 
echter niet zo duidelijk in een muismodel voor spontane abortie, waardoor wij voorstellen dat in 
dit model de balans tussen T helper cellen van het type 1 en het type 2 verstoord is alsook de 
activatie van NK cellen. Mits verdere studies, zou dit de verstoorde angiogenese bij spontane 
abortie kunnen verklaren. We konden ook aantonen dat de verandering van de hoeveelheid 
galectine-9 komt door de verandering van de hoeveelheid van specifieke varianten van galectine-
9. Het lijkt er zelfs op dat de hoeveelheid van galectine-95/10 als prognostische test kan gebruikt 
worden om te voorspellen of er problemen met de zwangerschap zullen optreden. De techniek om 
specifiek galectine-9 varianten aan te tonen d.m.v. qPCR werd ook gebruikt in een studie 
beschreven in hoofdstuk 2, waarbij we keken naar de expressie van deze varianten in weefsels 
van NSCLC patienten. We konden aantonen dat het niveau van gal-95 expressie prognostisch is 
in NSCLC. Zowel een lage expressie van gal-95 als een combinatie van een lage gal-95 
expressie met een hoge galectine-1 expressie  duiden op een slechte prognose bij deze kanker.  
 Naast studies die alternatieve transcripten van galectine-9 beschrijven is er in 2001 ook 1 
studie gepubliceerd waarin aangetoond wordt dat er 2 verschillende galectine-1 transcripten zijn 
in de muis. In tegenstelling tot bij galectine-9 worden deze transcripten niet aangemaakt voor het 
uitknippen van exonen maar door een verschil in startplaats van transcriptie van het galectine-1 
gen waardoor er een lang transcript is, GAL-1L, dat 31 extra bases heeft aan het 5’ uiteinde van 
het transcript vergeleken met het korte transcript, GAL-1S. Drie elementen die het galectine-1 gen 
aansturen werden beschreven in deze studie en wij tonen aan dat deze elementen inderdaad ook 
voorkomen in het menselelijke genoom. We laten ook zien dat er inderdaad expressie van GAL-
1S en GAL-1L plaatvindt in menselijke endotheelcellen en dat deze expressie verschillend 
veranderd wanneer endotheelcellen geactiveerd worden. De hoeveelheid van GAL-1S transcripten 
neemt dan namelijk toe, terwijl de hoeveelheid van GAL-1L transcripten afneemt. Daarna 
probeerden we te achterhalen welke gevolgen de toevoeging van 31 bases aan het 5’ uiteinde heeft 
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en vonden dat de 5’UTR van GAL-1L stabiel vouwt in de vorm van een lus welke ons meteen 
deed denken aan een pri-miRNA, een voorloper RNA voor miRNAs. Dit zette ons ertoe aan om 
een overzicht te publiceren, in hoofdstuk 7, over welke miRNAs voorkomen in endotheelcellen. 
We konden echter geen miRNAs aantonen die uit de lus in de 5’UTR van GAL-1L ontstaan. Wel 
laten we in hoofdstuk 6 zien dat er na de lus-structuur een knip plaatsvindt, waardoor er een RNA 
fragment ontstaat dat we ce-G1L genoemd hebben. De beschrijving van zogenaamde ceRNAs 
door de groep van Pandolfi inspireerde ons om een andere functie voor ce-G1L te bedenken, 
namelijk het wegvangen van een miRNA dat belangrijk is voor de functie van endotheelcellen, 
waardoor de hoeveelheid van andere doelwitten van dit miRNA verandert. Een aantal initiele 
experimenten suggeren dat deze hypothese wel eens zou kunnen kloppen omdat miR-296, een 
miRNA dat belangrijk is voor de functie van endotheelcellen, een excellente kandidaat is om door 
ce-G1L weggevangen te worden, maar verdere studies zijn nodig. We stellen een model voor 
waarin GAL-1S het transcript is dat codeert voor het galectine-1 proteine terwijl GAL-1L een 
andere functie heeft. De afname van de hoeveelheid van GAL-1L transcripten en dus ook ce-G1L 
RNA fragmenten in endotheelcellen die geactiveerd worden, zou ertoe kunnen leiden dat er minder 
miRNA-296 weggevangen wordt door ce-G1L. Hierdoor zal er dus meer miR-296 kunnen binden 
aan andere mRNA doelwitten zoals p21 en hgs, waarvan gekend is dat ze belangrijk zijn om 
endotheelcellen in een rustende fase te houden. Het zou dus kunnen dat ce-G1L een soort 
deurwachter in de cel is die ervoor zorgt dat endotheelcellen niet foutief geactiveerd worden.  
 In deze thesis hebben we de kennis over de rol van galectine-9 in de biologie van tumoren 
verder uitgebreid en laten zien dat het belangrijk is om rekening te houden met het bestaan van 
verschillende transcripten van galectine-1 en galectine-9. Zowel de expressie als de functie van 
deze alternatieve transcripten kan namelijk erg verschillen. Deze thesis draagt bij aan een beter 
begrip van de biologie en de expressie-patronen van galectine-1 en galectine-9, 2 galectines die 
veelbelovende doelwitten voor kankertherapie zijn omdat ze verschillende rollen vervullen 
naarmate tumoren groeien en aggressiever worden.  
 
 
 
 
 
 
 
 
 
 
  
Dankwoord 
Interesse voor wetenschap in het algemeen en biologie in het bijzonder was er al vroeg. Ik herinner 
me mijn grote wereld-, dieren- en dinosaurusatlassen. Gewone leesboeken waren niet aan mij 
besteed, gaf mij maar een populair wetenschappelijk boek met veel plaatjes. Eigenlijk is er niets 
veranderd dus.   
Fast forward naar het jaar 2000, toen werd het menens, celbiologie! Mijn enthousiaste 
leraar biologie mr. Buntinx zorgde ervoor dat ik het toen al wist: biologie is wat ik later zou 
studeren. Vreemd om me nu te realiseren dat het humaan genoom project toen nog in volle gang 
was, maar dat terzijde. Het was een bijzonder jaar, want in 2000 werd mijn klasgenootje Vinciane 
ook mijn vriendin. Het begon met elkaars handen niet mogen vasthouden op de speelplaats en nu 
lopen we al hand in hand met onze dochter Froukje.  Vinciane, mijn grootste geluk is samen met 
ons gezin door het leven te rennen, springen, vliegen, duiken, vallen, opstaan en weer doorgaan. 
Jij bent het N-acetyllactosamine voor mijn carbohydrate recognition domain. Nu moet je mijn 
proefschrift toch maar helemaal lezen… 
In 2002 trok ik naar Leuven om er biomedische wetenschappen te gaan studeren. Goedele, 
bedankt voor de leuke tijd en voor al je nota’s van de lessen, ook niet onbelangrijk. De blok-
paniek-sessies zal ik nooit vergeten. Ik wil graag prof.dr. Danny Huylebroeck, prof.dr. An Zwijsen 
en de andere leden van het Celgen labo, waar ik het onderzoek voor mijn master thesis gedaan 
heb, bedanken en in het bijzonder mijn begeleider Freddy. Ik vond het heel jammer destijds om 
afscheid te moeten nemen van zo’n geweldige groep na het mislopen van een doctoraatsbeurs.  
Maar, kort daarna viel mijn oog op een vacature aan de Universiteit Maastricht voor een 
doctoraatsstudent met als project: “Unraveling the role of endothelial galectins in vascular 
development and cancer”. Ik mailde al snel met dr.ir. Victor LJL Thijssen. Twee titels! Dat sprak 
wel aan. Victor, jij hebt van mij een wetenschapper gemaakt. Je bent ook veel meer geworden dan 
mijn begeleider: vriend, privé-chauffeur, imitator van populaire volkszangers, quizmaster en 
drinkbroeder. Maar niets van dat woog op tegen onze bijna dagelijkse brainstorm-hoogmis. Wat 
mis ik dat! Ik ga het galectin onderzoek nu verder zetten in Luik, dus je bent voorlopig nog niet 
van mij verlost. Het spreekt voor zich dat ik ook veel geleerd heb van mijn promotor prof.dr. Arjan 
Griffioen. Arjan, tijdens mijn eerste sollicitatiegesprek vertelde je me dat mijn collegas als familie 
zouden worden en dat kan ik alleen maar beamen. Ik wist snel dat het goed zat tijdens een van de 
de eerste lunchen: “On Old Olympus' Towering Top, A Finn And German Viewed Some Hops”. 
Je ontmoet niet iedere dag een niet-arts die een opsomming van de craniale zenuwen naar waarde 
weet te schatten! Bedankt voor al je wetenschappelijke input en goede raad en voor de leuke tijden 
op het lab.  
In Maastricht belandde ik op de kamer bij Judy en Victor en dat is nooit meer veranderd. 
Judy, thanks voor je nuttige input tijdens de labmeetings en ook voor de leuke sfeer op onze kamer 
en op het lab. Ik mis je licht meegrunten met minder volkse zangers nog niet maar misschien is 
daar nog wat voortschrijdend inzicht voor nodig. Ook wil ik graag Edith, Petra en de groep van 
prof.dr. Manon van Engeland bedanken en in het bijzonder Veerle en Joep, dank jullie voor de 
goede sfeer. Na enkele maanden leerde ik in Maastricht ook een nieuwe doctoraatsstudent, Yvette, 
kennen. Yvette, dank je voor de leuke tijden en discussies en veel succes met je nieuwe baan als 
lerares. Aan de VU is het niet gebruikelijk dat er stellingen toegevoegd worden aan het 
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proefschrift, maar in dit dankwoord kan het wel: Er is in onze samenleving meer nood aan goede 
wetenschappers die in het onderwijs stappen. Een quote van Carl Sagan zegt in deze context alles: 
“We live in a society exquisitely dependent on science and technology, in which hardly anyone 
knows anything about science and technology.”  
Na mijn eerste sollicitatiegesprek volgde er onverwacht een tweede versie: Arjan en Victor 
vertelde me dat ze naar Amsterdam verhuisden, net buiten het bereik van een volle tank met mijn 
scooter. Dus, na met veel geluk een kamer gevonden te hebben, werkte ik plots op het CCA. Hier 
begon Iris ook haar PhD studies. Iris, jij was de ideale reisgezel op onze tocht door de galectin 
jungle. Het begon allemaal met het samen opzetten van het ondertussen legendarische cCAFE. 
Zeker voordat we de leveringsdienst van de Albert Heijn ontdekten was het altijd weer een groot 
avontuur iedere laatste donderdag van de maand om voldoende bier, wijn en chips aan te slepen. 
Ook het salsa dansen was super, no fear de dansvloer op en ellebogen ontwijken! Over enkele 
maanden ben jij ook klaar en kunnen we samen als eregasten uitgenodigd worden op de jaarlijkse 
cCAFE Pubquiz. Saskia, jij verving na enkele maanden een andere secretaresse (nou ja) op het 
CCA en het klikte meteen. Iris en jij zullen mij bijstaan als paranimfen op mijn promotie. Dank 
jullie voor de vriendschap, humor, steun en gezelligheid. De lijst van herinneringen is lang (Sugar 
Factory, museumplein, lift “buiten gebruik”, pubquizzes, cCAFEs, …) en ik hoop dat er nog veel 
bijkomen te beginnen op 11 november.  
Ik herinner me nog de eerste meeting met de groep onderzoekers met wie wij zuiderlingen 
fuseerden op het CCA. Daar zaten Mariëtte, Maaike, Maudy, Kristy, Henk D en Henk B en Henk 
V, Richard en Laura. Bedankt voor de hartelijke ontvangst, jullie deden mij meteen thuis voelen. 
Eerlijk gezegd dacht ik tijdens die meeting dat het wel ging klikken met die relaxte post-doc 
tegenover me. Achteraf vertelde Victor me dat dat prof.dr. Henk Verheul was, tevens hoofd van 
de medische oncologie van het VUmc en nu lid van mijn leescommissie. Een onderschatting van 
zowel kennis als leeftijd dus, voorlopig zonder gevolgen. Henk, die week meelopen in de kliniek 
zal me als onderzoeker altijd bij blijven, wat een goed initiatief! Later werd ons lab nog aangevuld 
met Esther, Koen, Maarten, Maria, Ed, Tse, Saskia, Laurens, Jennifer, Kitty en Rajshri en 
tussendoor kwamen daar nog vele studenten bij zoals Martijn en Nga-Jien onder mijn hoede. Jullie 
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